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IgA is the dominant antibody isotype found at mucosal surfaces during homeostasis.  However, 
genetic variation in Fcγ receptors (FcγRs), a family of receptors that mediate immune cell 
activation by IgG, influences susceptibility to inflammatory bowel disease (IBD), suggesting 
that IgG may be important during gut inflammation.  IBD is a chronic relapsing condition with 
two major subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), both driven by aberrant 
immune responses to commensals.  In the first part of this thesis, we sought to investigate 
anti-commensal IgG responses in patients with UC and to determine the mechanism by which 
local IgG might contribute to intestinal inflammation.   
We found that UC and murine dextran sodium sulfate (DSS)-induced colitis are associated 
with a significant increase in anti-commensal IgG and local enrichment of FcγR signalling 
pathway genes.  The genes most robustly correlated with FCGR2A, an activating FcγR 
associated with UC susceptibility, were IL1B and CXCL8.  Ex vivo stimulation of human and 
murine lamina propria mononuclear cells with IgG immune complexes (IC) resulted in an 
increase in these cytokines/chemokines.  In vivo manipulation of the macrophage FcγR A/I 
ratio in transgenic mice determined IL-1β and Th17 cell induction.  Finally, IL-1β blockade in 
mice with a high FcγR A/I ratio reduced IL-17 and IL-22-producing T cells and the severity of 
colitis.  Our data reveal that commensal-specific IgG contributes to intestinal inflammation via 
FcγR-dependent, IL-1β-mediated Th17 activation. 
In this thesis, we have also addressed the interplay between IgG and group 3 innate lymphoid 
cells (ILC3s).  ILC3s are closely related to natural killer cells, which are known to express 
FcγRs, and are characterised by their production of Th17 cytokines.  Here, we have shown 
that ILC3s express FcγRs, that ICs drive IL-22 production and MHC class II expression by 
ILC3s, and FcγR signalling induces a transcriptional programme that reinforces ILC3 
maintenance and functionality.  These results represent a new paradigm for ILC activation, 
with direct regulation by the adaptive immune response. 
Finally, we have begun to address the role played by ILC3-derived cytokines in the regulation 
of local tissue-resident immune cells.  We have demonstrated that ILC depletion significantly 
alters the activation state of intestinal macrophages, resulting in detrimental bacterial 
outgrowth following C. rodentium infection but protection from overwhelming DSS-induced 
inflammation.  We have shown that GM-CSF promotes macrophage IL-1β and IL-23 
production, which in turn act to reinforce ILC3-derived GM-CSF and IL-22 secretion in vitro, 
respectively.  Therefore, ILC3s are essential coordinators of the local inflammatory response 
within the gut through activation and possible recruitment of immune cells, and their modulation 
may be beneficial in the treatment of IBD. 
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1. Introduction 
1.1. The immune system 
1.1.1. Overview 
The immune system is essential for protective responses against potentially pathogenic 
microorganisms and for the elimination of tumours.  Furthermore, a growing body of literature 
demonstrates fundamental roles for immune cells in the maintenance of homeostatic 
physiology and host-commensal mutualism at barrier sites throughout the body.  However, 
dysregulated immunity has detrimental consequences and may give rise to autoimmune 
diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), as well 
as inflammatory disorders, including inflammatory bowel disease (IBD), amongst others [1]. 
The immune response can be divided into two major categories: innate and adaptive (Fig. 1.1).  
Innate immunity comprises rapid nonspecific defences, sufficient for initial protection against 
most microorganisms.  These are driven by the recognition of conserved pathogen-associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs) expressed on innate 
immune cells, such as macrophages, dendritic cells (DCs), and neutrophils.  Adaptive 
immunity is driven by two major cell populations, T cells and B cells, that express somatically-
recombined antigen-specific receptors.  Driven by antigen encounter and signals derived from 
the innate arm, the activation of adaptive immunity results in highly targeted and augmented 
immune responses and the generation of immunological memory.  Presented here is a brief 
overview of the cells that make up these two arms. 
1.1.2. Innate immunity 
The epithelium at barrier sites, such as the gastrointestinal (GI) tract, provides the first defence 
against the invasion of microorganisms.  As well as a physical barrier, epithelial cells can 
directly sense microorganisms through PRRs and instruct local immune cells through the 
production of inflammatory mediators, including cytokines and chemokines [2].  Following 
breach of the epithelium, tissue-resident innate cells are the first to sense PAMPs or danger-
associated molecular patterns (DAMPs) released by damaged cells.   
Haematopoietic innate immunity consists of a variety of myeloid and lymphoid cells (Fig. 1.1A).  
Tissue-resident macrophages act as sentinels and display voracious phagocytic capabilities 
for the elimination of microorganisms.  These cells also orchestrate the initiation, progression, 
and resolution of inflammatory responses through their production of cytokines and 
chemokines [3].  Macrophage function is complemented by granulocytes, such as neutrophils 
and eosinophils.  Neutrophils are myeloid cells rapidly recruited to sites of inflammation that 
express an array of cell surface receptors.  They respond rapidly and potently to a wide range 
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of pathogenic stimuli and display essential microbicidal activities, such as the production of 
reactive oxygen species (ROS) and inflammatory mediators [4].  
DCs sit at the interface of innate and adaptive immunity.  Their primary function is to transport 
antigen from peripheral sites to draining lymph nodes in a CCR7-dependent manner for major 
histocompatibility complex (MHC)-dependent presentation to T cells [5], [6].  Additionally, DC-
derived cytokines play key roles in shaping immune responses.  This includes the 
differentiation of T cell subsets or the induction of B cell class-switch recombination (CSR), as 
shall be discussed shortly [7]–[10]. 
Finally, distinct lymphocyte subsets also form part of innate immunity.  Natural killer (NK) cells 
are a class of cytotoxic lymphocyte characterised by the production of perforin, granzymes, 
and interferon gamma (IFNγ) in response to ligation of an array of cell surface receptors.  
These include cytokine receptors, as well as those for cellular antigens exposed on stressed 
and infected cells [11].  In addition, the recently describe helper innate lymphoid cells (ILCs) 
are enriched at mucosal sites, where they receive inflammatory stimulation from local 
macrophages and DCs, and produce large amounts of T cell-associated cytokines [12].  A 
growing body of literature has identified pleiotropic roles for this novel class of cell in 
homeostasis and inflammation, as shall be discussed in more depth in later sections. 
1.1.3. Adaptive immunity 
Adaptive immunity consists of two major lymphocyte populations, B cells and T cells, derived 
from the common lymphoid progenitor (CLP) in the bone marrow (Fig. 1.1B). 
B cells mature in the bone marrow and migrate to the periphery, where their primary function 
is to develop into antibody-secreting cells – rare terminally-differentiated plasmablasts and 
plasma cells – upon antigen encounter.  All mature B cells express functional antigen-specific 
B cell receptors (BCRs) that recognise unprocessed antigens and drive B cell activation.  
These BCRs are identical to the immunoglobulin (Ig) antibody subsequently secreted by the 
cell.  Three classes of mature B cells exist: follicular B cells that reside primarily within the 
eponymous B cell follicles of secondary lymphoid organs (SLOs), marginal zone (MZ) B cells 
located in the marginal sinus of the spleen, and B1 cells, enriched in peritoneal and pleural 
cavities, as well as at mucosal sites [13].   
Follicular B cells typically undergo T cell-dependent (TD) responses in response to protein 
antigens.  Primary signalling through the BCR can elicit the generation of short-lived 
plasmablasts in an extrafollicular responses that results in antibody of limited affinity [14].  
Activated B cells can re-enter the B cell follicle and proliferate extensively, under the influence 
of local T follicular helper (Tfh) cells, to form a germinal centre (GC).  Following several rounds 
of positive selection, GCs ultimately yield high-affinity, long-lived plasma cells that contribute 
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to sustained high-level antibody production, as well as memory cells [15].  In the presence of 
T cell-independent (TI) antigens, such as bacterial polysaccharides, plasmablast formation 
occurs in the absence of GC formation. 
T cells are characterised by their expression of the eponymous T cell receptor (TCR), which 
recognises protein epitopes presented in the context of MHC class I (MHC-I) or MHC class II 
(MHC-II) on antigen presenting cells (APCs).  Two major populations of T cells exist based on 
their functional characteristics and can be divided based on expression of CD4 and CD8.  CD8+ 
T cells are a cytotoxic subset that kill infected or tumour cells presenting antigen in the context 
of MHC-I.  In contrast, following MHC-II-dependent TCR ligation in SLOs, naïve CD4+ T cells 
can differentiate into a range of T helper (Th) cells, depending on secondary signals and TCR 
signal strength.  Th subsets differ in their cytokine profile, location, and transcription factor (TF) 
dependence, and include type 1 (Th1), type 2 (Th2), type 17 (Th17), Tfh, and regulatory (Treg) 
subsets [16].   
Therefore, innate and adaptive immunity exert unique functions that contribute to the protection 
of the host from invading pathogens and transformed cells.  Extensive cross-talk between 
these two arms is achieved through contact-dependent mechanisms, such as antigen 
presentation by DCs and engagement of co-stimulatory molecule pairs, as well as through 
soluble effectors, such as cytokines, and is required for the development of appropriate 
inflammatory responses.  In the following section, focus will switch primarily to the effector 
functions of the immunoglobulin antibodies produced by activated B cells. 
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Figure 1.1.  Major cellular components of the immune system.  Major haematopoietic and 




Ig antibodies have taken centre stage in immunological research since the end of the 19th 
century, when von Behring and Kitasato discovered humoral antitoxins to diphtheria and 
tetanus.  In 1892, von Behring and Wernicke further demonstrated the passive transfer of 
immunity in animals, with the former receiving the first Nobel Prize in physiology of medicine 
for these seminal studies and their subsequent use in the treatment of previously intractable 
diseases.  These humoral antitoxins were shown to be directly capable of bacterial lysis, 
clashing with the cellularist theory of immunity championed by Metchnikoff, which postulated 
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that phagocytes were responsible to immunity to pathogens [17].  Almonth Wright mediated 
somewhat this dispute through the discovery of the phenomenon of opsonisation.  Opsonins 
were described as “… what you butter the disease germs with to make your white blood 
corpuscles eat them.”, demonstrating cooperation between cellular and humoral immunity [18].   
 
 
Figure 1.2.  Paul Ehrlich’s hypothesis of antibody generation.  Specific immune cells 
express receptors that interact with antigens (1).  Upon ligation of the receptor (2, 3), cells 
secrete antibodies resembling the engaged cell surface receptor (4).  From Silverstein et al., 
2003. 
 
Paul Ehrlich, one of the founding fathers of immunology, conceptualised Ig function into 
something resembling the modern paradigms of antibody biology, and was the first to coin the 
term “antibody” (Antikorper).  He proposed a strictly specific relationship between toxin and 
antitoxin, with the formation of chemical bonds that eliminate toxin function.  Furthermore, he 
hypothesised the “lock-and-key” model for antibody production: an identical cell receptor, 
known as a “side-chain”, would interact specifically with toxins and induce the production of 
antibodies/antitoxins (Fig. 1.2) [19].  These theories were subsequently confirmed by the 
demonstration of the shape-dependent specificity of antibodies by Linus Pauling in the 1940s 
[20], and the identification of plasma B cells as the source of antibody generation by Astrid 
Fagraeus in 1947 [21]. 
We now know antibodies as glycoproteins secreted by plasma cells as part of the humoral 
immune response, with a diverse range of effector functions (Fig. 1.3).  These include their 
ability to activate complement via the binding and activation of C1q, the activation of immune 
cells via Fc receptors, and the direct neutralisation of toxins and microbes [22].  Indeed, 
engagement of distant immune cells through Fc receptors allows for the development of 
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targeted innate immune responses by cells otherwise lacking somatically-recombined 
receptors, underlying the observations made by Wright.  It is estimated that humans generate 
approximately 10 billion different antibodies, each capable of binding to distinct antigen 
epitopes.  Their critical importance is starkly exemplified in primary antibody deficiencies, such 
as X-linked agammaglobulinemia, whereby individuals are susceptible to recurrent bacterial 
and viral infections, often requiring intravenous immunoglobulin (IVIG) therapy throughout life 
[23].   
Unsurprisingly, given their pleiotropic roles in immunity, detrimental Ig-driven immune 
responses are associated with several inflammatory and autoimmune disorders, including 
SLE, Goodpasture’s syndrome, and RA.  As such, antibodies are a key class of effector 
molecule that both contribute to anti-microbial immunity, as well as drive susceptibility to 
autoimmunity, as shall be discussed.  
 
 
Figure 1.3.  Immunoglobulin antibody effector functions.  Ig isotypes and subclasses can 
differentially mediate numerous effector functions, such as toxin/microbe neutralisation and 
agglutination, Fc receptor engagement, and activation of complement via binding of C1q 
(green). 
1.2.2. Structure 
Igs are heterodimeric glycoproteins composed of two heavy (H) and two light (L) chains, with 
the eponymous Ig domain forming the building block of both chains (Fig. 1.4A).  Each chain 
contains a single variable (V) amino-terminal domain and one, three or four carboxy-terminal 















only one.  The high sequence variability of the V domain allows for the generation of antigen 
binding sites with astounding resolution: discrimination between antigens can occur at the 
single atom level.  Each V domain contains three regions of sequence variability, called 
complementarity determining regions (CDRs).  The three H CDRs and three V CDRs pair to 
form an unique antigen binding site [24]. 
 
 
Figure 1.4.  Structure of Ig isotypes.  (A) Detailed diagram of IgG structure.  Overview of 
oligomeric structure of pentameric IgM (B) and dimeric secretory IgA (C). 
 
Beyond the V domains, the first C domain of the H chain (CH1) associates with the single C 
domain of the L chain to form a stable platform for VH and VL pairing, together forming the Fab 
domain.  The remaining CH2 and CH3 (for antibodies with a hinge region) or CH3 and CH4 (for 
antibodies with an extra CH2 domain) form the Fc domain and, together with the hinge region, 
dictate effector functions of the antibody [25].  The length and flexibility of the hinge region 
varies extensively among isotypes and subclasses, imparting unique characteristics.  The C-
terminal domain also encodes a secretory tail that allows the antibodies to exit the cell.  
Alternatively, the secretory tail is replaced by differential splicing with two 
membrane/cytoplasmic tail domains, M1 and M2, that control the embedding of Ig into the 
membrane.  This membrane-embedded Ig forms the BCR, the “side-chain” of B cells that 
dictates their activation. 
1.2.3. Isotypes 
Antibody isotype is determined by the CH region, and encodes the effector functions of the 


























IgE, each differing in their antigen specificity, tissue distribution and ability to engage cell 
surface Fc receptors and complement [25].  IgG and IgA will be the main subjects of this thesis, 
with a brief introduction to IgM.  
1.2.3.1. IgM 
IgM is the first antibody to be produced during an immune response, and is also the oldest, 
found in all vertebrate species.  While surface IgM forms the naïve BCR, secretory IgM forms 
a pentameric complex via disulphide bonds between the CH4 domains that allows it to interact 
avidly with several antigens and bind C1q with 1000-fold greater affinity than IgG (Fig. 1.4B) 
[24], [26].   
Natural polyreactive IgM, found in germ-free (GF) mice, binds to conserved bacterial and host 
structures, making it particularly effective in promoting the engulfment of apoptotic cells and in 
early defence against infection.  Pertioneal B1 cells are major producers of natural IgM [27], 
[28].  In contrast, immune IgM, i.e. in response directly to immune challenge, originates from 
B2 cells and can be both innate-like, TI IgM, such as from MZ B cells [29], and TD, for example 
in follicular B cells prior to class-switching to other isotypes, as well as MZ B cells.   
Due to its large size, IgM cannot enter extravascular spaces, while monomeric IgG, IgE and 
dimeric IgA can be distributed systemically.  Therefore, IgM primarily plays a key role in 
bridging the temporal gap between antigen exposure and the development of class-switched 
high-affinity IgA and IgG antibodies for antigen eradication and the generation of memory. 
1.2.3.2. IgG 
IgG is the major antibody isotype in human serum and extravascular compartments, 
accounting for 10-20 % of all plasma protein and 70-75 % of total Ig [25].  IgG can be 
subdivided into four subclasses in humans (IgG1-4), named in order of their relative serum 
concentration, while four major subclasses exist in mice (IgG1, IgG2a, IgG2b, and IgG3).  
Despite an estimated 90 % sequence similarity across IgG subclasses, there are differences 
in structure, function and half-life ascribed to each subclass, as outlined below.  Differences in 
the hinge region appear to be particularly important in this regard.  Generally, however, IgG 
antibodies are known for their high antigen affinity, driven by somatic hypermutation (SHM), 
and are key molecules involved in immunological memory, serving a variety of inflammatory 
effector functions, including complement activation via the classical pathway and binding of 
Fcγ receptors (FcγRs). 
IgG1 is the most abundant IgG subclass in humans and is generally associated with soluble 
protein antigens and membrane proteins.  Along with IgG3, IgG1 can potently activate 
numerous effector mechanisms, including complement activation and FcγR ligation, and is 
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largely TD [30].  As such, IgG1 is frequently exploited in pharmaceutical settings for the 
generation of therapeutic monoclonal antibodies [31].  Specific resides on IgG1 CH2 are 
responsible for interaction with C1q, with each IgG having two binding sites for C1q on the Fc 
domain.  Artificial substitution of similar residues in IgG2 is sufficient to impart complement-
fixing activity on this subclass [32], [33].   
IgG2 responses are almost completely restricted to TI bacterial capsular carbohydrates, 
although anti-carbohydrate IgG antibodies of other subclasses do exist [34].  IgG2 and IgG4 
antibodies have a short rigid hinge region compared to IgG1 and 3, resulting in impaired 
antibody flexibility, and dictates to a certain extent the affinity of these molecules for FcγRs 
and C1q.  While thought to possess little capacity for complement activation, high epitope 
densities are associated with IgG2-mediated complement activation [35]. 
IgG3 antibodies are the most effective subclass in activating effector functions, with enhanced 
binding to C1q, increased affinity for FcγR binding, and a shorter half-life.  This reduced half-
life is ascribed to an R435 residue that replaces a histidine in all other subclasses [36].  R435 
reduces affinity for the neonatal Fc receptor (FcRn), which normally binds IgG in acidic early 
endosomes and redirects it away from lysosomal degradation [37], [38].  Furthermore, IgG3 
has a very long hinge region and increased molecular flexibility.  While a potent pro-
inflammatory antibody, IgG3-dominated responses appear to be rare: viral responses can 
induce IgG1 and IgG3 subclasses, with IgG3 antibodies appearing first during infection. 
IgG4 is associated with induction by allergens following repeated or long-term exposure to 
antigen in a non-infectious setting, as well as in immune responses to parasitic infections [25].  
Of interest is the ability of IgG4 to suppress immune responses.  Due to a proline-to-serine 
substitution, studies have shown that IgG4 can spontaneously dissociated into half-molecules, 
forming novel bispecific IgG antibodies that can no longer cross-link epitopes and potentially 
exhibit anti-inflammatory characteristics [39].  Furthermore, IgG4 can capture allergens before 
IgE binding, preventing the activation of mast cells.  Finally, IgG4 displays relatively high affinity 
for the inhibitory Fc receptor, FcγRIIB, resulting in the inhibition of effector cell responses [40].  
Therefore, immunotherapy has aimed at driving IgG1/3/E-dominated immune responses 
towards IgG4 as a means to dampen autoimmunity and inflammation [41]. 
1.2.3.3. IgA 
While only constituting 10-15 % of total serum Ig, IgA is the major Ig isotype at mucosal 
surfaces.  Secretory IgA (S-IgA) consists of IgA dimers covalently linked by the joining (J) chain 
and one secretory component (SC) chain, the extracellular portion of the polymeric Ig receptor 
(pIgR) (Fig. 1.4C).  pIgR is expressed in mucosal epithelial cells and transfers polymeric IgA 
or IgM from basolateral to apical surfaces [42]. 
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Two IgA subclasses exist in humans: IgA1 comprises 80 % of IgA in serum, while IgA2 is the 
major form in certain mucosal secretions, including in the large intestinal (LI) mucosa, the latter 
thought to be driven by the enhanced resistance of IgA2 to proteolysis resulting from its shorter 
hinge region. 
While considered to be a largely non-inflammatory isotype, given the relative scarcity of Fcα 
receptors and an impaired ability to activate complement, S-IgA participates in shaping the 
mucosal microbiota, immune maturation, and the resistance to pathogens through several 
mechanisms, collectively referred to as immune exclusion.  This will be discussed in more 
detail in subsequent sections.   
1.2.4. Class-switch recombination 
The emergence of specific Ig isotypes is tightly regulated to suit the requirements of the 
immune response.  Following BCR activation, Ig isotype switching occurs by an intra-
chromosomal deletion recombination event known as CSR, the replacement of the default 
expressed Cμ exon cluster in naïve B cells with Cγ, Cϵ, or Cα, for IgG, IgE, and IgA, respectively 
[43].  The regulation of CSR, rather than the mechanism itself, will be discussed here.   
1.2.4.1. Primary signals 
Primary signals in CSR are involved in the induction of activation-induced cytidine deaminase 
(AID) and other CSR factors [43].  B cell CD40 engagement by CD40L found on Tfh cells 
occurs within GCs and is essential for the induction of AID [44].  Other than CD40L, Tfh cells 
also express co-stimulatory molecules, such as PD-1 and OX40, and the B cell-activating 
cytokines interleukin (IL)-4 and IL-21 [45].  As a consequence, GCs, memory and plasma B 
cell formation, and Ig production are severely impaired in the absence of Tfh cells or CD40 
ligation [46].   
In the absence of CD40 ligation, B cell-activating factor (BAFF) and a proliferation-inducing 
ligand (APRIL) can provide a primary signal in TI class-switching by extrafollicular B cells [47].  
These tumour necrosis factor (TNF) ligand superfamily members engage BAFF receptor, B 
cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI) to 
stimulate AID expression [48].  BAFF and APRIL are released in response to Toll-like receptor 
(TLR) stimulation by several cell subsets, including neutrophils, eosinophils, ILCs, DCs, 
follicular dendritic cells (FDCs), and epithelial cells [47], [49]–[53]. 
Murine IgG3 levels are relatively unaffected by the absence of CD40 or T cells [54].  TLR 
signalling is involved in polysaccharide-specific IgG generation and immune responses to 
encapsulated bacteria.  TLR1-2, TLR4, TLR7 and TLR8 can synergise with the BCR to induce 
class-switching to IgG3 and other isotypes in the absence of T cell help [48], [54], [55].  
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Lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria is the only 
known microbial product that can directly induce CSR through simultaneous TLR4 ligation and 
BCR cross-linking in murine B cells.  It should be noted that BCR activation is not sufficient to 
induce AID expression, and likely reflects a regulatory checkpoint prior to class-switching. 
1.2.4.2. Secondary signals 
Secondary T cell- and DC-derived cytokines determine the fate of CSR by regulating 
transcription from the S regions, short tandem repeats located upstream of each CH region.  
IL-4 supports class-switching to IgG1 and IgE in the presence of CD40 ligation via signal 
transducer and activator of transcription (STAT)-6, while IFNγ and transforming growth factor 
beta 1 (TGFβ1) support class-switching to IgG2a and IgA via SMAD3 and SMAD4 or Runt-
related transcription factor (RUNX) proteins, respectively [56], [57].  Indeed, IFNγ secretion by 
CD8+ T cells supports murine IgG2a/b production in vivo [58].  Furthermore, recent data has 
demonstrated that Th17 cells support IgG generation in vivo.  While IL-17A promoted IgG2a 
and IgG3, IL-21 drove class-switching to IgG2b and IgG1 class-switching in mice [59].  IL-21 
secretion by Tfh cells is also essential for antibody responses by stimulating B cell proliferation 
and expression of AICDA, BLIMP1, and XBP1 [60]. 
Recently, Tfh cells were found to progressively secrete IL-21 and IL-4 for the induction of high-
affinity BCR clones and the development of Blimp-1-dependent plasma cells, respectively [61].  
Therefore, Tfh cells can provide both primary and secondary signals over the course of the 
GC reaction. 
In summary, efficient TD antibody responses require primary CD40 ligation by Tfh cells and 
secondary cytokine signals and dictate CSR.  However, in the absence of T cells, TI antibody 
production can arise following BAFF/APRIL- or TLR-mediated primary signals that induce the 
expression of AID. 
1.3. Fcγ receptors 
1.3.1. Overview 
FcγRs are cell surface glycoproteins that bind to the Fc portion of IgG antibodies [62]. They 
are responsible for mediating numerous cellular effects of IgG, including immune cell 
maturation and migration, the production of inflammatory mediators, and the elimination of 
opsonised microbes. 
There are several activating FcγRs and a single inhibitory receptor, FcγRIIB, in both mice and 
humans (Fig. 1.5).  Other than FcγRI (and FcγRIV in mice), most FcγRs are low-to-medium 
affinity for IgG, requiring cross-linking of several receptors into signalling synapses on the cell 
surface to initiate productive signalling.  This is achieved through the formation of high avidity 
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antigen:antibody immune complexes (IC), aggregated IgG, or by IgG-opsonised cells and 
surfaces.  The absence of signalling upon ligation of monomeric IgG prevents inappropriate 
immune cell activation, which is critical given the abundance of circulating monomeric IgG.  
The inhibitory receptor, FcγRIIB, acts as an additional regulatory mechanism to suppress IgG-
mediated inflammation [62], [63].  
As well as IgG, certain murine FcγRs (FcγRIIB, FcγRIII, and FcγRIV) are able to bind IgE.  
While IgE affinity is approximately 2 log lower, this should be borne in mind when ascribing Ig 
function [64]. 
1.3.2. Signalling 
Crosslinking of activating FcγRs results in the phosphorylation of immunoreceptor tyrosine-
based activating motifs (ITAMs) located on the intracellular domain of FcγRs or on the 
associated common γ-chain (also known as FcϵRIγ/FcRγ) [65], [66].  ITAM phosphorylation 
activates signalling cascades via SRC family kinases and spleen tyrosine kinase (SYK), 
resulting in the downstream activation of phosphatidylinositol3-kinase (PI3-K) and 
phospholipase-Cγ.  This subsequently triggers protein kinase C and a calcium flux [62], [64], 
[66].  Importantly, binding of monomeric IgG to high affinity FcγRs has not been shown to 





Figure 1.5.  Human and murine Fcγ receptors and affinity for IgG subclasses.  (A) Human 
FcγRs and affinity to IgG subclasses (KA (M-1)), divided into activating (left) and inhibitory (right) 
receptors.  (B) Murine FcγRs depicted in the same way.  γ2 = common γ-chain.  Adapted from 
Bruhns & Jonsson, 2015. 
 
The inhibitory FcγRIIB contains an intracellular immunoreceptor tyrosine-based inhibitory motif 
(ITIM).  Cross-linking of FcγRIIB with activating FcγRs leads to ITIM phosphorylation by SRC 
kinases and the recruitment of inositol phosphatases, most notably phosphatidylinositol-3,4,5-
trisphosphate 5-phosphatase 1 (SHIP1).  These phosphatases act to neutralise activating 
signals and dampen IgG-mediated responses [62], [67].  Unsurprisingly, therefore, activating 
and inhibitory FcγRs are co-expressed on many immune cells, with their relative expression 
level and activity setting the cellular activation threshold upon encounter of ICs and opsonised 
cells. 
1.3.3. Functions 
FcγRs are widely expressed on immune cells, including neutrophils, monocytes, 
macrophages, DCs, mast cells, NK cells and B cells.  However, the FcγR repertoire differs 
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between immune cells.  Furthermore, the immune cell phenotype dictates the effect of IgG-
mediated FcγR cross-linking, as shall be discussed.  These effects are summarised in Figure 
1.6. 
1.3.3.1. Macrophages 
Both ex vivo-isolated and in vitro-generated macrophages express elevated levels of both 
activating and inhibitory FcγRs, with the ratio skewed in favour of activating signalling.  Indeed, 
FcγRI (CD64) is often used as a specific marker to discriminate between tissue-resident 
macrophages (FcγRI+) and DCs (FcγRI-) [68].  As well as FcγRI, human and murine 
macrophages express the full complement of canonical FcγRs, except for FcγRIIIB in humans. 
The role of FcγRs in macrophage activation is widespread and has recently been excellently 
reviewed [69], [70].  Internalisation of opsonised material or ICs is a common function shared 
among all FcγRs, although the fate of internalised cargo differs depending on the class of Fc 
receptor.  ITAM-bearing activating receptors favour a degradative route for antigen processing 
and presentation.  In contrast, the ITIM-bearing FcγRIIB has been proposed to favour a non-
degradative route of internalisation for transfer of intact antigen to B cells [69], [71]. 
FcγRs also regulate the production of inflammatory mediators by macrophages.  Historically, 
macrophages can be classified as so-called M1 and M2 macrophages [72].  IFNγ-activated 
M1 macrophages are proposed to represent inflammatory tissue macrophages that produce 
IL-12, IL-1, and TNF in response to LPS.  In contrast, M2 macrophages are generated in vitro 
through IL-4 stimulation and are characterised by production of anti-inflammatory molecules, 
such as arginase and IL-10.  In vitro studies with human monocyte-derived macrophages 
(MDMs) and murine bone marrow-derived macrophages (BMDMs) polarised in this way have 
allowed the elucidation of FcγR-induced activation.   
FcγR-mediated human monocyte and macrophage activation induces pro-inflammatory 
cytokine production characterised by production of IL-1β, IL-6, IL-10, IL-12 and TNF-α, as well 
as chemokines including CXCL8 [73].  Interestingly, several studies have highlighted a link 
between TLR and FcγR co-stimulation and the induction of a Th17-inducible macrophage 
phenotype.  Co-stimulation of human M2 macrophages with IgG-opsonised bacteria resulted 
in potent production of IL-1β [74].  A similar phenotype is also seen in human monocyte-derived 
DCs (MDDCs) [75], [76], while IgG opsonisation of Plasmodium falciparum-infected 
erythrocytes increased inflammasome-dependent IL-1β production by human macrophages 
[77], [78].  Strikingly, M1-polarised MDMs did not respond in this way, suggesting that FcγR-
mediated Th17 induction is a feature unique to “anti-inflammatory” macrophages.  In murine 
BMDMs, LPS and IC co-stimulation results in the inhibition of LPS-induced IL-1β and TNF 
production, at least partly dependent on production of prostaglandin E2 (PGE2) [79], [80].   
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While helpful in dissecting the mechanistic roles of FcγR signalling, the in vitro-defined subsets 
of macrophages, in many circumstances, poorly mimic the complex macrophage phenotypes 
observed in vivo.  For example, macrophages induced following mycobacterial infection 
resemble a mixed M1/M2 phenotype, with high levels of IL-1β, TNFα, IL-10, and IL-12 [81].  
Strikingly, these cells resemble IC-elicited M2 macrophages and could similarly skew T cell 
responses towards IL-17A and IL-22 production.  Similarly, intestinal macrophages are 
characterised by high levels of IL-10 and TNFα, and their reprogramming to potent IL-1β-
producing cells during intestinal inflammation that can support Th17 differentiation [82], [83]. 
1.3.3.2. Dendritic cells 
An essential function of DCs is the transportation of antigen via the CCR7-CCL19/21 axis from 
tissues to local draining lymph nodes for antigen presentation to T cells.  
While DCs express FcγRI and FcγRIIA in humans, and FcγRIII in mice, FcγR expression is 
skewed towards FcγRIIB in immature DCs.  DC FcγR expression is tightly regulated, with 
maturation signals, such as LPS or IFN-γ, down-regulating FcγRIIB to allow for IgG-induced 
cell activation via activating FcγR ligation [84].  DCs efficiently process FcγR-internalised 
antigen and upregulate MHC and co-stimulatory molecules for robust antigen presentation to 
T cells [85]–[87].  A recent study demonstrated that FcγR cross-linking induces CCR7 and 
matrix metalloprotease (MMP) expression that facilitates DC migration from inflamed 
peripheral sites to local draining lymph nodes [88].  Therefore, FcγRs play a critical role in 
antigen presentation to T cells through a variety of mechanisms. 
As previously mentioned, studies have demonstrated cytokine and chemokine production by 
DCs in response to FcγR signalling, both directly and through synergism with TLR signalling 
[75], [76].  FcγRIIB blockade leads to spontaneous DC maturation and the induction of a 
cytokine programme characterised by TNF-α, IL-6, CXCL8, and IL-12p70 production, similarly 
to macrophages [73], [84], [89]. 
1.3.3.3. Neutrophils 
Human neutrophils constitutively express FcγRIIA, FcγRIIC and FcγRIIIB, as well as low levels 
of FcγRIIB, which is relative refractory to in vitro cell stimulation [90], [91]. Murine neutrophils 
predominantly express FcγRIII and FcγRIV, with similarly low levels of FcγRIIB expression at 
rest [92], [93]. Cross-linking of activating FcγRs has profound effects on neutrophil function, as 
one might expect of cells poised to acutely respond to a variety of stresses.  FcγR-inducible 
mechanisms include intracellular calcium fluxing [94], antigen phagocytosis [95], [96], the 
generation of a respiratory burst [97], neutrophil adhesion to endothelial cells [98], neutrophil 
extracellular trap formation [99], [100], and cytokine production, including TNF-α, IL-1β and 
oncostatin M (OSM) [96], [101].  
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1.3.3.4. Natural killer cells 
NK cells express activating FcγRIIC and FcγRIIIA in humans, and FcγRIII in mice, but not 
FcγRIIB [102], [103].  Indeed, CD16 (FcγRIII) is often used to discriminate between cytotoxic 
CD56dim NK cells (CD16+) and CD56bright NK cells (CD16-).  FcγR signalling on NK cells 
stimulates the targeted release of cytotoxic molecules to kill opsonised cells, a process known 
as antibody-dependent cell-mediated cytotoxicity (ADCC).  As well as ADCC, NK cells undergo 
IFN-γ and TNF-α release following FcγR cross-linking [104], [105]. 
1.3.3.5. B cells 
FcγRIIB is the only FcγR expressed by B cells, where it cross-links to the BCR to increase the 
cellular activation threshold and suppress antibody production [62].  Furthermore, direct cross-
linking of FcγRIIB on the surface of mature B cells and bone marrow-resident plasma cells can 
directly mediate apoptosis, thereby limiting the peripheral pool of antibody-producing cells 
[106], [107].  As such, FcγRIIB has a critical role in maintaining humoral tolerance. 
1.3.3.6. Non-haematopoietic cells  
In addition to the well-described roles for FcγR signalling on immune cells, evidence suggests 
that non-haematopoietic cells can also undergo cellular activation in response to IgG binding. 
FDCs are stromal cells located within B cell follicles in SLOs [108].  FcγRIIB is highly expressed 
on GC FDCs and involved in immune complexed antigen capture, with impaired antibody and 
memory B-cell responses in its absence [109], [110]. 
A significant body of literature has demonstrated effects of IgG on endothelial cells, both 
through FcγR-dependent and independent mechanisms.  In antibody-mediated rejection 
(ABMR) following transplantation, donor-specific IgG antibodies (DSAs) can directly mediate 
endothelial cell activation via binding to surface MHC [111]–[113], while FcγRs on cultured 
human aortic endothelial cells were shown to induce phagocytosis, cytokine production, and 
the upregulation of adhesion molecules in response to C-reactive protein (CRP) [114].  TNF-α 
and IFNγ have been shown to further enhance FcγR expression by human endothelial cells in 
vitro, and this may have added importance during tissue inflammation [115].  Finally, FcγRIIB 
was implicated in protection against obesity-induced hypertension through IgG-mediated 
attenuation of endothelial nitric oxide (NO) synthase activity in mice [116].  
Therefore, activating FcγRs are widely expressed on cells of the innate immune system, as 
well as B cells and non-haematopoietic cells, where they mediate cell maturation, antigen 
presentation, cytokine production, and target-cell destruction in response to IgG ligation.  




Figure 1.6.  Effect of FcγR cross-linking on major immune cell populations.  FcγR 
expression across cell types is depicted.  Green = canonical activating FcγRs; red = canonical 


















































































1.3.4. Innate signals and FcγRs 
FcγRs not only serve to bind IgG, but can also signal in response to ligation by other soluble 
effectors.  Furthermore, FcγRIIB can influence non-FcγR signalling pathways, such as TLRs, 
as shall be discussed (Fig. 1.7).  
 
 
Figure 1.7.  Canonical and non-canonical functions of FcγRs.  Activating FcγRs can bind 
both IgG and pentraxins, both inhibited by FcγRIIB (panel 1).  FcγRIIB can cross-link to TLRs 
(panel 1), complement receptors and C-type lectin receptors (panel 2).  FcγRIIB is known to 
inhibit signalling from the BCR by SHIP1-mediated dephosphorylation of BCR-associated 




















FcγRs can bind to pentraxins, including CRP and serum amyloid P (SAP), demonstrating a 
link between FcγRs and innate humoral immunity [117], [118].  SAP was shown to bind to 
FcγRI, IIA, and IIIB on human polymorphonuclear leukocytes (PMNs), while CRP 
predominantly binds to FcγRIIA on human monocytes and neutrophils.  CRP, a commonly 
used biomarker in inflammatory disease, binds to phosphorylcholine moieties on microbes and 
necrotic cells, as well as chromatin and histones, allowing for FcγR-mediated internalisation 
and disposal of damaged cells and self-antigens, while also potentially activating inflammatory 
responses in FcγR-expressing cells [63], [119], [120]. 
1.3.4.2. FcγRIIB and innate immune receptors 
FcγRIIB can inhibit activating signals from non-FcγR cell-surface receptors via the recruitment 
of SHIP1 to signalling synapses.  This so-called trans-inhibition was demonstrated for Kit-
dependent mast cell activation [121], [122], and TLR4 and Ca5R signalling in innate cells [79], 
[123].  In the latter, this was in part dependent on the association of FcγRIIB with dectin-1 
mediated by IgG galactosylation.  
1.3.5. Modulating FcγR function 
The regulation of FcγR expression by immune cells influences their ability to respond to IgG-
ICs.  The so-called activating-to-inhibitory (A/I) ratio, i.e. the relative expression or activity of 
activating to inhibitory receptors, has important implications for immune cell activation in the 
context of an inflammatory response, as well as in tissue-specific immunity, whereby the 
unique homeostatic milieu can regulate cellular IgG responsiveness [124].  Furthermore, 
differences in the IgG glycome, FcγR gene polymorphisms, and gene copy number variation 
(CNV) can also influence the A/I ratio, with implications for inflammatory disease (Fig. 1.8). 
1.3.5.1. Expression 
IFNγ is associated with an increase in the A/I ratio of several cells: cultured monocytes and 
MDDCs downregulate expression of FcγRIIB is response to IFNγ [84], as well as upregulating 
activating FcγRIIA expression [115], [125].  PGE2 also upregulated FcγRIIA expression on 
MDDCs in vitro [84].  In contrast, Th2 cytokines, such as IL-4, have the opposite effect, 
upregulating FcγRIIB and downregulating activating FcγR expression, to decrease monocyte 
A/I ratios [125]. 
1.3.5.2. Glycosylation 
Glycosylation is a post-translational modification that alters the structure and activity of 
glycoproteins.  Each IgG heavy chain carries a single covalently attached biantennary N-
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glycan at the highly conserved asparagine 297 residue in each of the Fc fragment Cγ2 
domains, with over 900 IgG glycoforms possible [126].  Biantennary complexes can contain 
additional bisecting N-acetylglucosamine (GlcNAc), core fucose, galactose and sialic acid 
residues [127].  IgG glycosylation is required for IgG stability and effector function [128], with 
differences in IgG glycosylation altering affinity for activating versus inhibitory FcγRs and, 
therefore, modulating the strength of FcγR signalling within cells [129]–[132].  
The presence of fucose on core glycans alters binding to FcγRIIIA, with defucosylation 
resulting in increased binding affinity through increased Fc interaction with the Asn-162 glycan 
on the receptor [133].  Agalactosylated IgG, with two oligosaccharide chains ending in GlcNAc 
rather than galactose/sialic acid, is termed G0 (no galactose) [63].  G0 IgG can activate 
complement via binding to mannose-binding lectin, and can bind the mannose receptor on 
phagocytes [134], [135].  In contrast, sialylation promotes anti-inflammatory functions of IgG 
by reducing FcγR affinity and promoting binding to the C-type lectin receptor, SIGN-R1 (DC-
SIGN in humans) [136]–[138].  Indeed, sialylation is required for the protective functions of 
IVIG.  Furthermore, binding to C-type lectin receptors causes structural changes in IgG that 
reduce binding to classical FcγRs [139]. 
1.3.5.3. Single nucleotide polymorphisms 
Single nucleotide polymorphisms (SNPs) are found in FCGR genes that alter receptor 
expression and function, while CNV also determines the levels of FcγR expression on different 
cell types. 
FCGR2A - A polymorphism in FcγRIIA encoding a histidine or arginine at position 131 
(H/R131) within the second Ig-like domain results in altered ligand affinity [140], [141].  H131 
results in higher affinity for IgG1 and IgG2 compared to R131, with little change in affinity for 
IgG3 and IgG4 [30], [142].  Furthermore, a splice variant of FcγRIIA (FcγRIIA-exon 6*) is 
associated with increased neutrophil response to IgG [143]. 
FCGR2B - SNPs in FcγRIIB are well-studied, with one SNP in human FCGR2B gene 
(FcγRIIBT232; rs1050501) found at high frequency in the population.  This polymorphism 
encodes an isoleucine-to-threonine substitution in the transmembrane domain that results in 
receptor loss-of-function, mediated by impaired lateral mobility and receptor exclusion from 
lipid rafts [144]–[146].  Two further SNPs (386(G/c) and 120(T/a)) collectively constitute the 
2B.4 promoter haplotype.  The c/a haplotype results in increased promoter activity and FcγRIIB 
expression on a variety of immune cells [62], [147]. 
FCGR2C – A glutamine at position 13 (Q13) allows for functional receptor expression in 20 % 
of individuals.  In the remaining 80 %, a stop codon is present (stop13) and FCGR2C 
21 
represents a pseudogene.  As a result, NK cells expressing FcγRIIC exhibit enhanced IgG-
mediated cytotoxicity [102]. 
FCGR3A – The FcγRIIIA-V158 variant, encoding a valine rather than a phenylalanine at 
position 158, exhibits enhanced affinity for all IgG subclasses [30].  CNV is associated with 
efficacy of NK-mediated cytotoxicity [148]. 
FCGR3B – Three variants of FcγRIIIB exist: NA1, NA2 and SH.  However, differences in IgG 
binding affinity were not detected across variants [30].  NA1 is associated with enhanced 
neutrophil uptake of IgG-opsonised erythrocytes [149], while SH enhances FcγRIIIB surface 
expression [150].  CNV of FCGR3B is also correlated with cell-surface receptor expression 
levels, IC uptake, and soluble serum FcγRIIIB levels [91]. 
 
Figure 1.8.  Modulation of FcγR activating-to-inhibitory ratio.  FcγR signalling can be 
modulated by cytokine signals that alter cellular FcγR expression, genetic variants that alter 
receptor expression and/or function, and glycosylation of IgG, a modification that alters FcγR-











































































































1.4. Fcγ receptors and disease 
Given their roles in mediating numerous inflammatory mechanisms in vivo, it is unsurprising 
that FcγR-mediated signalling and immune cell activation is associated with several 
autoimmune disorders associated with IgG, as well as in differential susceptibility to infection. 
1.4.1. FCGR SNPs in autoimmunity and infection 
Genetic polymorphisms in human FCGR genes are frequently associated with differential 
susceptibility to infection, autoimmunity, and monoclonal antibody responses [62], [144], [151].  
However, these associations are complex.  Increased IgG affinity can promote detrimental 
autoimmune progression, while promoting responses to therapeutic antibodies.  In contrast, 
reduced IgG affinity is associated with impaired IC clearance, which is a risk factor for SLE 
[152]. 
FCGR2A – The high-affinity H131 polymorphism is associated with enhanced detrimental 
immunity in patients with Kawasaki disease, systemic vasculitis treated with IVIG [153], and 
IBD [154]–[156].  Furthermore, H131 increases response to rituximab (anti-CD20 IgG) therapy 
in B-cell lymphomas [157],  while the low-affinity R131 variant is associated with susceptibility 
to SLE and graft rejection [158]–[160]. 
FCGR2B – FcγRIIB-T232, encoding the dysfunctional inhibitory receptor, is associated with 
susceptibility to SLE, an autoimmune disorder characterised by IgG deposition within different 
organs, particularly the kidney [161], [162].  Indeed, macrophages and DCs isolated from 
T/T232 homozygous individuals exhibit an exacerbated pro-inflammatory response to IgG-IC 
[163].  Conversely, however, FcγRIIB dysfunction is associated with enhanced protection 
against infectious diseases in humans, with complementary demonstrations in mice.  In African 
and South East Asian populations, FcγRIIB-T232 homozygosity can exceed 10 % and is 
associated with protection against malaria (odds ratio (OR) = 0.56; P = 7.1 x 10-5) [162].  
Curiously, the 2B.4 promoter haplotype is also overrepresented in SLE, implicating FcγRIIB in 
pathogenesis [147]. 
FCGR2C – FcγRIIC expression and CNV are associated with Kawasaki disease, consistent 
with detrimental high-affinity FCGR2A SNP associations with this disease [164]. 
FCGR3A – The V158 variant, with enhanced IgG affinity, is associated with susceptibility to 
rheumatoid arthritis [165], [166] and immune-mediated thrombocytopenic purpura (ITP) – a 
disorder characterised by platelet destruction [167] – but a better clinical response to rituximab 
in B-cell lymphomas [157], [168], a lower risk of recurrent periodontitis [169], and improved 
outcome in bone marrow transplantation [170].  Furthermore, CNV is associated with anti-
glomerular basement membrane disease [171].  In contrast, the low-affinity F158 variant is 
associated with SLE, consistent with impaired IC clearance [152]. 
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FCGR3B – Low FcγRIIIB expression, as a result of reduced CNV, and the FcγRIIIB-NA2 
variant are associated with susceptibility to SLE, consistent with a role for FcγRs in IC 
clearance [91], [172], [173].   
It is clear, therefore, that polymorphisms affecting FcγR expression, IgG affinity, and function 
has wide-ranging consequences in human disease and responses to therapeutic intervention. 
1.4.2. Glycosylation in disease 
Abnormalities in the IgG glycome have been identified in patients several autoimmune 
disorders, as well as in individuals with impaired responses to infectious agents, such as 
Mycobacterium tuberculosis.  Agalactosylation is observed in patients with RA, as well as in 
SLE, which may favour binding to activating FcγRs, while reductions in sialylation are also 
observed in SLE [126], [174], [175].  A reduction in IgG galactosylation has also been observed 
in IBD, while decreased IgG sialylation was detected in Crohn’s disease (CD), specifically 
[127], [176]. 
Seminal work by Alter and colleagues has allowed large-scale profiling of IgG glycomes in 
disease [78], [177].  Via a “systems serology” approach, they have demonstrated distinct IgG 
glycosylation patterns, correlated with IgG functionality and immune reactivity, in patients with 
M. tuberculosis and in human immunodeficiency virus (HIV) vaccine trails.  Specifically, 
successful pathogen management was associated with reduced fucose, G0, and increased 
sialic acid, resulting in enhanced FcγRIIA binding, ADCC, and inflammasome activation. 
In further support of the contribution of altered glycosylation patterns in disease development, 
SNPs in glycosyltransferases are associated with several autoimmune disorders [126].  The 
induction of these genes is dynamically regulated by the immune system.  An elegant recent 
study demonstrated that in response to IL-23, Th17 cells produced IL-22 and IL-21 to alter the 
glycosylation profile of B cells in a murine model of RA.  Specifically, IL-23 was required for 
the desialylation of IgG, mirroring RA-associated glycosylation patterns, and augmented 
inflammatory FcγR signalling by macrophages [178].  Therefore, as well as IgG class-
switching, Th17 cytokines can also inflammatory profile of IgG produced by B cells. 
1.4.3. Murine models 
Murine transgenic models have been essential for elucidating the role of FcγR signalling in 
vivo during homeostasis and inflammatory responses, with several transgenic strains 
available, from single- and pan-FcγR knockout (KO) mice, lines with transgenic FcγR 
overexpression, and humanised FcγR models.  However, single FcγR deficiencies may affect 
the expression of other FcγRs, such that interpretation may require caution [64]. 
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1.4.3.1. Autoimmunity and inflammation 
Fcgr2b-deficient mice have been crucial for establishing the key role of this receptor in the 
suppression of IgG-mediated immunity.  FcγRIIB is essential for the maintenance of tolerance:  
KO mice develop increased autoantibody IgG titres with age [151], a phenotype shared with 
humanised mice containing the SLE-associated FcγRIIB-T232 polymorphism [179], and are 
susceptible to spontaneous autoimmune disease.  This is most commonly associated with fatal 
glomerulonephritis [180]–[182].  Autoimmunity appears to be mediated by enhanced IL-17A 
production and could be abrogated through genetic deletion of the IL-17R adaptor protein 
CIKS, establishing a link between FcγR signalling and enhanced Th17 immunity in vivo [183].   
As well as spontaneous autoimmune disease associated with FcγRIIB deficiency, passive 
transfer of IgG-containing immune serum or antigen immunisation leads to FcγR-mediated 
inflammation.   
Fcgr2b-deficient mice are susceptible to collagen-induced (CIA) and antigen-methylated 
bovine serum albumin (BSA)-induced arthritis [184], [185].  Mice develop dysregulated B cell 
responses, elevated antigen-specific IgG titres, joint destruction, and leukocytic infiltration and 
activation [185]–[188].  Similarly, immunisation of Fcgr2b-deficient mice with bovine collagen 
type IV also resulted in pulmonary haemorrhage and glomerulonephritis in a murine model of 
Goodpasture’s syndrome, a disorder characterised by IgG deposition on basement 
membranes [189].  FcγRIIB imparts protection from experimental autoimmune 
encephalomyelitis (EAE).  EAE is a murine model of multiple sclerosis (MS) induced by 
immunisation with myelin oligodendrocyte glycoprotein in complete Freund’s adjuvant [190].  
In this model, Fcgr2b-deficient mice demonstrated by an increase in CNS demyelination [191]. 
These observations are often associated with the role of FcγRIIB on BCR activation.  Strikingly, 
however, transfer of serum from arthritis patients was sufficient to induce arthritis in Fcgr2b-
deficient mice, neatly demonstrating not only the pathogenic potential of IgG antibodies in RA, 
but also the B cell-independent roles for FcγR signalling in disease [192].  In the lung, passive 
transfer of ICs induces severe alveolitis in Fcgr2b-deficient mice, with increased haemorrhage, 
edema, neutrophil infiltration, and TNF production [193].   
Fcgr2b-deficient mice were originally bred from back-crossing Fcgr2b-deficient mice on the 
129-background with C57BL/6 mice, leading to transfer of additional susceptibility loci in the 
Sle16 locus.  Fcgr2b-deficient mice generated by gene targeting in B6-derived embryonic stem 
cells display similar enhanced susceptibility to autoimmunity, although with a less severe 
phenotype [194].  Therefore, FcγRIIB is essential for the maintenance of tolerance in vivo. 
In contrast to Fcgr2b-deficient mice, mice deficient in activating FcγRs exhibited resistance to 
several models of arthritis [187], [195]–[198].  Furthermore, Fcgr1- and Fcgr3-deficient mice 
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show an impaired Arthus reaction, a vasculitis induced by injection of local antigen and 
systemic antigen-specific antibody  [199]–[201].  Similarly, these mice are protected from 
rheumatoid factor-driven vasculitis, ascribed to impaired mast cell TNF production [202].  In 
contrast, Fcgr4-deficient mice are protected from a murine model of nephrotoxic nephritis, and 
are suggested to be the major conduit for IgG2b-mediated pathology in this model [197]. 
Transgenic mouse models allowing the cell-type specific modulation of FcγRIIB expression 
have allowed for the dissection of differential contributions of cell-mediated immune 
mechanisms towards IgG-mediated disease.  FcγRIIB deletion at the germinal/post-germinal 
centre stage through Cg1Cre-mediated targeting demonstrate the important role of this 
receptor in inhibiting the development of spontaneous antibodies [203].  Furthermore, while B 
cell and DC-targeted FcγRIIB deletion enhanced susceptibility to CIA, only DC-specific 
FcγRIIB deficiency is relevant to K/BxN serum-induced arthritis, as expected [203].  Similarly, 
while B cell overexpression of FcγRIIB reduced IgG-mediated T cell responses and severity in 
CIA and SLE-like pathology [204], macrophage-specific FcγRIIB overexpression, in so-called 
macrophage-transgenic mice (M-TG), did not affect disease progression [205]. 
1.4.3.2. Infection 
In addition to their ability to drive detrimental autoimmune disorders, FcγRs are essential 
mediators of immunity against a wide range of pathogens.  Fcgr2b-deficient mice exhibit 
enhanced resistance to malaria and S. pneumoniae, with increased protective IgG responses, 
enhanced pathogen phagocytosis, and increased TNF and IL-6 production in vivo [163], [206].  
Conversely, M-TG mice are more susceptible to S. pneumoniae infection and mortality [205].  
Fcgr1 and Fcgr3-deficient mice also show impaired responses to pathogen challenge, with 
increased bacterial burden and reduced cytokine production both in vitro and in vivo [207]–
[209].  Therefore, the activity of both activating and inhibitory receptors is essential in mounting 
appropriate anti-pathogen responses.   
One detrimental side effect of FcγR signalling in infection is illustrated in murine models of 
sepsis.  While Fcgr2b-deficient mice are protected from lower levels of bacterial challenge, 
high bacterial burdens induce rapid mortality in Fcgr2b-deficient mice, attributed to an 
overwhelming inflammatory response [206]. 
1.4.3.3. Antibody-based therapy 
FcγRs are essential for the in vivo efficacy of therapeutic monoclonal antibodies, for example 
in anti-tumour immunity and IVIG therapy, with many descriptions in the literature arising from 
the use of FcγR-transgenic mice. 
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In a murine model of syngeneic B16 melanoma, the efficacy of IgG2a monoclonal antibody 
therapy was increased in Fcgr2b-deficient mice, while several studies demonstrated reduced 
protection in the absence of individual activating FcγRs, although the specific contribution of 
each receptor varied between studies [124], [210]–[212].  Similarly, following anti-CD20 
immunotherapy, murine lymphoma depletion was enhanced in the absence of FcγRIIB, and 
inhibited through combined deficiency of FcγRI, RIII, and RIV [213].   
The protection of IVIG is intimately associated with FcγR function.  Deletion of FcγRIIB 
reversed the therapeutic effect of IVIG in mice.  This effect is thought to be driven by the 
upregulation of FcγRIIB expression in macrophages following IL-4 secretion by IL-33-activated 
basophils [196], [214]–[216].  While IVIG also downregulated FcγRIV expression, this was not 
sufficient to protect mice from nephrotoxic nephritis in the absence of FcγRIIB [217]. 
FcγRIII has also been demonstrated to mediate anti-inflammatory effects of IVIG.  While 
FcγRIIB was required on host cells for IVIG protection, IVIG-primed donor DCs were 
dependent on FcγRIII for the suppression in a murine model of ITP [218].  Furthermore, 
FcγRIII-mediated IVIG signalling can downregulate IFNGR2 expression on host cells and 
inhibit NKT cells [219], [220]. 
Therefore, murine models demonstrate a role for FcγRs in the onset and progression of 
autoimmunity, and have allowed the mechanistic dissection of these effects otherwise 
impossible in human studies.  Furthermore, studies have demonstrated that protective anti-
microbial immunity and the response to therapeutic antibodies, from monoclonal antibodies to 
IVIG, are critically dependent on FcγR signalling in vivo. 
1.4.4. Targeting IgG and FcγR signalling therapeutically 
1.4.4.1. Targeting IgG and B cells 
Strategies aimed at blocking or removing pathogenic IgG are commonly used in several 
inflammatory disorders.  Plasmapheresis, the removal, treatment or exchange of blood 
plasma, is common in IgG-mediated disorders, such as ABMR [221].  IVIG is also used in 
ABMR to bind and remove pathogenic DSAs and prevent binding to target cells [222].  
Enforced sialylation has been hypothesised as a mechanism by which to convert pathogenic 
IgG into an anti-inflammatory mediator similar to IVIG [137], and has been demonstrated to be 
effective in murine models of CIA [223].  However, the technical challenges for the translation 
of this method for the treatment of human disease are not clear. 
As well as targeting IgG itself, rituximab, an anti-CD20 monoclonal antibody, is used to induce 
transient B cell depletion in autoimmunity, with B cell recovery typically within 6-9 months [222].  
It is used effectively in the treatment of RA and off-label in SLE, as randomised controlled trials 
failed to show a benefit [224].  However, pan-B cell depletion can give rise to autoimmunity as 
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a result of regulatory B cell depletion.  In contrast, BAFF inhibitors, such as belimumab, can 
deplete long-lived plasma cells and are used successfully in the treatment of SLE [225]. 
1.4.4.1. Targeting FcγRs 
Strategies aimed at targeting FcγR-mediated inflammatory pathways have yielded success in 
the treatment of human autoimmune disease. 
Small molecule SYK inhibitors were shown to be beneficial in RA patients [226].  However, 
given the widespread function and expression pattern of SYK, off-target side-effects are 
common and more targeted approaches are under development [227].  Modulation of FcγRIIB 
activity is central to many novel therapies.  Enforced co-localisation of FcγRIIB with CD19 on 
B cells using an engineered anti-CD19 monoclonal antibody successfully suppressed humoral 
immunity in peripheral blood mononuclear cell (PBMC)-engrafted SCID mice [228].  
Furthermore, small preliminary studies have demonstrated efficacy of soluble human FcγRIIB 
in the treatment of ITP and SLE [227]. 
Therefore, targeting IgG, B cells, and FcγRs have shown promise in the treatment of 















1.5. The gastrointestinal tract and inflammatory bowel disease 
1.5.1. Overview and host-microbe interactions 
The GI tract comprises a series of organs whose primary functions are digestion, absorption, 
excretion, and protection.  The stomach and small intestine (SI) contribute to physical and 
chemical digestion and absorption, while the LI is primarily involved in the desiccation and 
compaction of waste [229]. 
The GI tract is colonized by trillions of microorganisms that together form the microbiome, 
including at least 1000 species of bacteria, the major component of the commensal microflora.  
Bacterial colonisation increases progressively along the GI tract: while the stomach and 
proximal SI contains relatively low microbial densities (103-105 organisms per gram of luminal 
contents), the ileum (108 per gram) and colon (1010-1012 per gram) are densely colonised, with 
greater species diversity.  In particular, in the lower GI tract of healthy individuals, anaerobes 
dominate, including Bacteroides, bifidobacteria, fusobacteria, and peptostreptococci, while 
aerobes, such as enterobacteria, are present at lower densities [230]. 
During homeostatic conditions, a state of mutualism exists between the host and the 
commensal microbiota, whereby bacteria benefit from the energy-rich sources of food, and the 
host salvages essential compounds from indigestible nutrients, such as dietary 
polysaccharides [230].  Unsurprisingly, in such a scenario, the host immune system is skewed 
towards anti-inflammatory mechanisms that support ongoing symbiosis, with dynamic cross-
talk between intestinal epithelial cells (IECs), microbes, and local immune cells preventing 
opportunistic invasion by commensal species [50], [231].  This includes the production of anti-
microbial peptides and mucus by IECs, secretion and transport of IgA into the lumen, and an 
IL-10/TGFβ-dominated milieu that suppresses damaging inflammatory responses (Fig. 1.9).  
Conversely, immune education by intestinal microbes has been shown to be essential for 




Figure 1.9.  Homeostatic immune mechanisms that promote host-commensal 
mutualism in the GI tract.  Several mechanisms contribute to the anti-inflammatory milieu in 
the GI tract.  Tissue-resident plasma cells produce IgA to suppress bacterial immunogenicity 
and opportunistic invasion, ILC3-derived IL-22 promotes epithelial barrier function, and tissue-
resident macrophages and DCs sample luminal contents, produce anti-inflammatory 
mediators, and induce GI-resident T cells.  Bacteria influence immune cell phenotype through 
secretion of immunomodulators, such as short chain fatty acids (SCFAs). 
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1.5.2. Crohn’s disease and ulcerative colitis 
1.5.2.1. Overview 
Inflammatory bowel disease is a chronic remittent or progressive inflammatory disorder of the 
GI tract that causes considerable morbidity and increased risk of colorectal cancer.  There are 
two main subtypes, CD and ulcerative colitis (UC), that differ in their clinical and pathological 
presentations [232].  CD may affect any part of the GI tract and is associated with transmural 
inflammation affecting the entire mucosa and the formation of granulomas.  In contrast, in UC, 
lesions are localized to the large bowel, resulting in continuous superficial mucosal 
inflammation and ulceration of the intestinal wall, with micro-abscess formation and neutrophil 
infiltration within the lamina propria (LP) common [233], [234].   
While a strong genetic component exists, particularly in CD, the  discordance among 
monozygotic twins (50-75 % concordance in CD; 10-20 % concordance in UC) and the 
increasing incidence of IBD in Western nations highlights the importance of environmental 
factors in disease development and progression [235], [236].  Strikingly, genome wide 
association (GWA) studies have demonstrated relatively modest risk associated with individual 
SNPs, suggesting that hundreds of polymorphisms may contribute to the onset of IBD [232].   
1.5.2.1. Microbiota 
Several circumstantial observations point towards the microbiota as being the target of the 
pathogenic immune response in IBD.  As well as the association between several immune-
sensing genes, such as NOD2, and disease susceptibility, IgG antibodies in IBD are commonly 
directed against components of the microbiota [237]–[242].  Furthermore, study of the 
microbiome has demonstrated that IBD itself is associated with decreased microbial diversity, 
the outgrowth of enterobacteria, and a reduction in anaerobes, such as Clostridia and 
Veillonellaceae [243]–[245].   
How intestinal dysbiosis may initiate or propagate inflammation is the subject of intense 
research, not only within the intestine itself, but also for various systemic inflammatory 
disorders, and has benefited greatly from the use of sophisticated murine models, as shall be 
discussed. 
1.5.2.2. Genetic associations 
GWA studies have contributed significantly towards the understanding of the pathogenesis of 
IBD.  Susceptibility is driven by a genetic predisposition to aberrant mucosal immune 
responses to commensals microbes, with unique and shared genetic traits between CD and 
UC (Fig. 1.10).  Furthermore, inflammatory mechanisms in IBD are thought to be shared with 
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other extra-intestinal diseases, including ankylosing spondylitis and psoriasis, given the 
overlap of associations between these disorders [154], [246]. 
Prominent associations in CD include polymorphisms in NOD2 and ATG16L1 [234], [247]–
[250].  NOD2 is an intracellular receptor for bacterial peptidoglycan [251].  Three uncommon 
SNPs in NOD2, located within the binding domain, result in reduced NOD2 function, with 
studies demonstrating that NOD2 signalling is required for the maintenance of tolerance and 
prevention of bacterial outgrowth within the GI tract [252], [253].  A SNP in the autophagy gene 
ATG16L1 enhances its degradation and reduces autophagy [249].  This results in exacerbated 
endoplasmic reticulum (ER) stress within IECs, Paneth cell dysfunction, and exacerbated 
cytokine production [254]–[258].  These findings implicate an impaired capacity to sense 
bacteria and deal with ER stress as drivers of inflammation in CD. 
UC, by contrast, is associated with defects in epithelial barrier integrity (HNF4A and LAMB1), 
IL-10 signalling, and the MHC locus [155], [259], [260].  Other than the MHC locus, one of the 
robust associations with UC is the FcγRIIA-H/R131 variant [155], [156], [261] (Fig. 1.10; bold 
italic).  Homozygous R/R131 individuals are protected from the onset of UC (OR = 0.63; P = 
1.56 x 10-12; [156]).  This is in contrast to its association with SLE, in which R/R131 increases 
disease susceptibility and suggests that high-affinity variant H131 may contribute to disease 
progression through exacerbated inflammatory responses to IgG.  
One of the key pathways implicated in both UC and CD is the IL-23/IL-17 cytokine axis [262].  
An uncommon Arg381Gln substitution in the cytoplasmic domain of IL-23R confers significant 
protection against IBD, while alternatively spliced isoforms of IL23R transcripts are also linked 
to differential susceptibility.  This has spawned an era of investigation into the role of IL-23 and 
other Th17-activating cytokines in GI inflammation and the development of novel therapeutics, 
as shall be discussed later. 
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Figure 1.10.  Genetic associations in IBD.  IBD is prominently associated with defects in 
Th17 immunity.  CD is specifically associated with defects in microbial sensing, such as NOD2, 
while UC is characterised by defects in barrier immunity and association with FcγR 
polymorphisms.  Adapted from Lees et al. 2011 [263]. 
1.5.3. Murine models 
Several murine models exist for the investigation of IBD, each with certain advantages and 
disadvantages.  These include chemically-induced models of inflammation, including dextran 
sodium sulfate (DSS)- and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis, infection 
models, such as Citrobacter rodentium and Helicobacter hepaticus, T cell-transfer models, and 
immune-activator models, such as anti-CD40 administration. 
1.5.3.1. Chemically-induced colitis 
Given its similarities in aetiology and pathology with human IBD, as well as its reproducibility 
and ease of use, DSS-induced colitis is perhaps the most prominent model of chemically-
induced colitis.  DSS is a colitogen with anticoagulant properties that erodes the epithelial 
monolayer of the colon when added to drinking water and can be administered for the study of 
both acute and chronic inflammation [264].  Clinical features include weight loss, shortening 
and thickening of the colon, blood in stools, and enlargement of spleen and mesenteric lymph 





















































































The duration of DSS administration dictates to a certain degree the clinical and immune profile 
associated with inflammation.  Acute administration (5-7 days) is typically associated with 
epithelial destruction and ulceration, mucin and goblet cell depletion, and neutrophilic 
infiltration of the intestinal LP and crypts, features similar to human UC [266].  Furthermore, 
Th1 and Th17 cytokines are increased significantly [267].  In contrast, chronic DSS 
administration (2 or more cycles of 5-7 days) results in the infiltration of alternative pro-
inflammatory immune cells, an increased prevalence of transmural inflammation and lymphoid 
follicle formation, characteristics of CD.  While still prevalent, Th1 and Th17 cytokines are 
generally reduced relative to acute DSS, with an increase in IL-10 [267]. 
DSS administration for the study of intestinal inflammation is widespread, and has provided 
key translational insights into human disease, including the role of epithelial cells in barrier 
immunity [258], [268]–[273], the role of microbiota-derived metabolites [274], [275], intestinal 
humoral immunity [276], [277], and mechanistic insights into GWA study hits, such as those 
associated with the activation of Th17 immunity [82], [278]–[280]. 
TNBS-induced colitis is not as widely used, although has proved useful in the dissection of 
Th1-associated pathology.  Used in combination with ethanol to disrupt the intestinal epithelial 
barrier, TNBS acts as a hapten by binding to proteins of high molecular weight, rendering them 
immunogenic [281].  TNBS induces transmural inflammation, reflective of CD-associated 
pathology, and high levels of IL-12 and IFN-γ production within the inflamed mucosa [267].  
1.5.3.2. Infection models 
Numerous infection models have contributed to our understanding of basic immunology within 
the GI tract and its translation to chronic inflammatory disease. 
Citrobacter rodentium is a murine model of human attaching-effacing Escherichia coli infection 
[282].  Infection primarily targets the colon, with 109 organisms day 7-14 post-infection, and 
clearance of infection by day 21.  Both B and T cells are essential, with IgG and IgM, not S-
IgA, being required for sterilising immunity and the prevention of systemic bacterial spread 
[283], [284].  Furthermore, C. rodentium infection has gained popularity due to the requirement 
for Th17 immunity in its control, allowing for the study of IBD-associated mechanisms within 
the gut [285]–[291]. 
Helicobacter hepaticus has also proved useful in the investigation of intestinal Th17 immunity 
[292]–[297].  Although found in wild-type mice without any colitis, this enteropathogen can 
induce chronic proliferative typhlitis, colitis, and rectal prolapse in immunodeficient strains 
[298].  Indeed, H. hepaticus administration is usually carried out in immunodeficient 129SSvEv 
Rag2-/- mice or in combination with anti-IL-10R administration.  As such, its inability to 
successfully induce colitis in wild type (WT) mice restricts somewhat its applicability to bona 
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fide pathobionts in humans, but may more accurately reflect complications associated with 
dysbiosis and outgrowth of commensals during inflammation. 
1.5.3.3. T cell transfer colitis 
A widely used and cited experimental model of IBD is the adoptive transfer of naïve CD4+ T 
cells (CD4+ CD45RBhi T cells) into syngeneic immunodeficient mouse strains, such as SCID 
or Rag1-/- mice [299].  Following adoptive transfer, mice develop wasting disease and colonic 
inflammation after approximately 5-10 weeks.  Histopathological analysis of inflamed colons 
demonstrates transmural inflammation, similar to CD, PMN and mononuclear leukocyte 
infiltration, crypt abscesses and epithelial erosions [300]. 
Transfer of mature CD45RBlo T cells does not induce colitis, an observation ascribed to the 
presence of Tregs.  Indeed, not only was this model key in demonstrating the pathogenic role 
of T cells in colitis [301], but also the essential function of Tregs in suppression of intestinal 
inflammation [302].  As with other models, T cell-driven colitis is also dependent on the 
microbiota. 
1.5.3.4. Anti-CD40 innate colitis 
Another model making use of the absence of host adaptive immunity is the anti-CD40 innate 
model of colitis.  In this model, Rag1-/- or SCID mice are injected with an agonistic anti-CD40 
monoclonal antibody that induces an intestinal innate inflammatory response.  CD40 is 
expressed by innate immune cells, such as DCs and monocytes, whereby it induces antigen 
presentation machinery, pro-inflammatory cytokine production, and proliferation [303].  Indeed, 
CD40-induced colitis is associated with elevated IL-23 production, making it useful for the study 
of the IL-23/IL-17A axis in relation to ILC-mediated pathology [304]. 
However, care must be taken in the observations made in immunocompromised mouse 
strains.  The absence of local Tregs and IgA production likely has profound impacts on the 
microbiota and immune homeostasis within the gut, and probably contributes to the 
effectiveness of anti-CD40- or T cell-induced colitis. 
1.5.4. Murine models and the microbiota 
Studies in murine models of colitis have supported the notion that the microbiota has a 
predominant influence on intestinal disease development.  GF mice are protected from several 
murine models of colitis, including DSS, while commensal-specific T cells can induce intestinal 
inflammation [237]–[242].   
DSS and C. rodentium-induced colitis, as well as antibiotic treatment, causes dysbiosis that 
reduces the microbiota’s ability to provide colonisation resistance.  The subsequent outgrowth 
35 
of Enterobacteriaceae and enteropathogens can trigger inflammation, as well as supporting 
tumour development in mice [305]–[308].  Dietary fibre intake has also been shown to suppress 
outgrowth of mucolytic bacteria [309].  Finally, several examples exist demonstrating the ability 
of the microbiome to educate the intestinal immune system.  Commensal-derived SCFAs 
induce colonic Tregs and promote IEC function, bacterially-induced Th17 cells regulate EAE 
susceptibility, while faecal transplantation alters murine susceptibility to colitis and obesity 
[274], [277], [310]–[316]. 
Therefore, while host-microbe interactions are a key facet of intestinal pathology, it is clear the 
majority of commensal microbes are likely to be host protective, and the distribution and 
composition of the microbiome skewed in disease [317].  
1.6. Immunopathology in inflammatory bowel disease 
1.6.1. Overview 
The host mechanisms that drive intestinal inflammation are under intense investigation given 
the clear involvement of the immune system in disease.  In addition to the association with IL-
23/Th17 axis, both CD and UC are characterised by the altered production of inflammatory 
cytokines [318].  For example, CD is associated with the production of IFNγ and Th1 cytokines, 
driven by IL-12 signalling, while in UC, LP cells produce elevated levels of IL-5 and IL-13, 
classically Th2-associated cytokines [319], [320].  However, these rigid classifications of IBD-
associated inflammatory networks are oversimplifications of a broader network of immune 
dysfunction.  Furthermore, the functional relevance of certain observations has proved 
enigmatic with regards to translation to the clinic.  Here, we discuss some of the major 
pathways implicated in IBD pathology, how murine models have informed our understanding 
of disease, and attempts to target them therapeutically. 
1.6.2. Antigen-presenting cell-derived cytokines 
Dysregulated cytokine production by myeloid cells, in particular APCs such as macrophages 
and DCs, is observed in patients with IBD.  Indeed, APC-derived cytokines currently represent 
the most successful therapeutic targets in this disease.  Here, our current understanding of the 
mechanisms of action of these cytokines and the implications for murine and human disease 
pathology are discussed.  
1.6.2.1. Tumour necrosis factor and TNF ligand-related molecule 1A 
TNF is a pleiotropic heterotrimeric cytokine.  It is first produced as a transmembrane protein 
before being cleaved by the metalloproteinase TNF-converting enzyme.  TNF exerts its 
functions through two receptors: TNF receptor 1 (TNFR1) is ubiquitously expressed and drives 
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pro-inflammatory responses, while TNF receptor 2 (TNFR2) expression is more restricted and 
associated with homeostasis [321].   
TNF induces various inflammatory mechanisms, such as augmentation of angiogenesis, 
cellular apoptosis and necroptosis, with the concomitant release of intracellular contents [322], 
MMP production, and immune cell activation [318], [323].  However, the role of TNF is 
complicated given its involvement in homeostasis.  For example, TNF can desensitise 
macrophages [324], induce IL-10 production, and promote inflammatory cell senescence and 
death [325].  Furthermore, TNF is required for appropriate formation of B cell follicles and GCs 
[326].  Therefore, therapeutic targeting of TNFR1 may help to refine anti-TNF therapy to avoid 
undesirable complications [321]. 
In IBD, aberrant TNF production is observed in the colonic mucosa.  CD-like models of colitis 
support a role for TNF in driving inflammation: overexpression of TNF in mice results in 
spontaneous transmural inflammation, dependent on TNFR1, IL-12p40 and IFN-γ production 
by T cells [327], [328].  Similar observations are seen in the T-bet-/- x Rag-/- ulcerative colitis 
(TRUC) model – communicable colitis in TRUC mice is associated with exacerbated TNF 
production by DCs [329], [330].  Furthermore, macrophage and IEC-derived TNF drives 
intestinal inflammation in the CD45RBhi transfer model of colitis [331].  In relation to its 
regulating cell death, two studies demonstrated that TNF-driven IEC apoptosis and necroptosis 
is a key driver of colonic inflammation [332], [333].  Recently, TNF was shown to synergise 
with OSM, a cytokine recently identified as a driver of infliximab-resistant IBD, for the induction 
of pro-inflammatory chemokines and cytokines [334]. 
In contrast, in DSS-induced colitis, TNF-deficient mice are more susceptible to disease.  Given 
the similarities of DSS-induced colitis to UC, this may represent a differential role of TNF in 
different models of colitis [335].  Alternatively, this may reflect a requirement for homeostatic 
TNF levels within the gut, with exacerbated TNF production remaining pathological.  
Regardless, anti-TNF monoclonal antibodies are currently the most efficacious treatment for 
IBD, with infliximab administration a cornerstone of IBD therapy [232].  Infliximab is an IgG1 
chimeric antibody that binds to both soluble and membrane TNF.  In contrast, etanercept, a 
soluble TNFR fused to IgG1 Fc, has little therapeutic effect in IBD, activity ascribed to its 
inability to block membrane TNF and kill LP-resident T cells [336].  Studies have demonstrated 
that the in vivo efficacy of infliximab is dependent on FcγR binding [337], and the ability of TNF-
infliximab interactions to from anti-inflammatory ICs that dampen disease locally, given the 
heterotrimeric nature of TNF (van den Brink; unpublished communication).  This may explain 
which etanercept, which cannot form ICs, is less effective. 
TNF ligand-related molecule 1A (TL1A) is also increased in CD and associated with DSS-
induced colitis [338]–[340].  Functionally, TL1A is derived from DCs and macrophages and 
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promotes IFN-γ production by T and NK cells, while recent studies have also implicated TL1A 
in ILC activation in the gut [291].  This once more reinforces the notion of Th1 characteristics 
in CD.  However, targeting of TL1A in human disease has yet to be carried out. 
Therefore, elevated TNF responses appear to contribute to intestinal disease development, 
particularly in murine models resembling CD-like pathology, in which Th1 responses are 
exacerbated.  Furthermore, targeting this pathway is currently the gold standard approach to 
treating IBD, although the specific targeting of TNF may prove to be somewhat circumstantial. 
1.6.2.2. IL-1β 
IL-1β is a prototypical inflammatory cytokine with wide-ranging effects on virtually all cells and 
organs [341].  Unsurprisingly, therefore, it is a major pathogenic mediator of inflammation.   
Unlike the alarmin IL-1α, which is constitutively produced by many non-haematopoietic cells, 
IL-1β is produced by haemtopoietic cells is response to PAMP/DAMP, activated complement, 
or cytokine stimulation.  It requires cleavage from an inactive pro-form by caspase 1 for 
extracellular release.  Pro-caspase-1 itself also requires activation, which occurs via the 
assembly of inflammasome complexes within cells.  A key component of inflammasomes is 
nucleotide-binding oligomerisation domain, leucine-rich repeat and pyrin domain containing 3 
(NLRP3) [341], [342].  However, non-canonical inflammasome-mediated activation via 
caspase 11 is also possible, as well as extracellular activation of pro-IL-1β by neutrophil 
enzymes.  Metabolic changes in activated immune cells can also support IL-1β production.  
For example, accumulation of succinate in macrophages stabilises hypoxia-inducible factor 1 
alpha (HIF-1α), which induces pro-IL-1β [343]. 
IL-1β plays pleiotropic roles in inflammation.  It acts as the classic endogenous pyrogen to 
induce fever and promotes IL-6 expression for induction of the acute phase response in the 
liver [344].  IL-1β also influences neutrophil inflammatory responses, driving immune cell 
activation, the upregulation of adhesion molecules on endothelial cells, and prolonging the 
lifespan of leukocytes within inflamed tissues [341], [345].  Finally, IL-1β has important roles in 
type 17 immunity, as shall be discussed in the next section.   
Elucidation of the role of IL-1β in IBD has lagged behind IL-23.  However, promising results 
demonstrate this may represent a novel target for therapeutic intervention.  Enhanced IL-1β 
production is associated with IBD pathogenesis, with IL-1β expression increased in the 
inflamed colonic mucosa relative to levels of IL-1 receptor antagonist (IL-1Ra) [346].  
Furthermore, IL-1β levels are enriched in colonic biopsies from patients with infliximab-
refractory IBD [334].  Encouragingly, targeting IL-1β signalling has proved fruitful in several 
murine models of colitis.  NLRP3 inflammasome-dependent IL-1β production is induced by 
distinct commensal microbes and its blockade has proved beneficial in DSS-induced colitis 
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and H. hepaticus infection  [279], [296].  Furthermore, caspase-1-deficient mice are protected 
from DSS-induced inflammation [347].   
Therefore, given its pleiotropic roles in inflammation, and recent demonstrations of 
dysregulated IL-1β responses in human and murine colitis, IL-1β targeting likely represents 
one of the major novel avenues to be exploited for IBD therapeutic intervention.  Indeed, trials 
of IL-1Ra in UC are currently underway (Arthur Kaser, unpublished communication). 
1.6.2.3. IL-23 
IL-23 is a heterodimeric cytokine composed of the IL-12p40 subunit, shared with IL-12, and IL-
23p19 (otherwise known as IL-23A).  Since its discovery in the early 2000s, particular attention 
has focused on its role in the activation of immune cells that dually express IL-23R and RORγt, 
including Th17 cells, group 3 ILCs (ILC3s), and γδ T cells.  In response to IL-23, these cells 
potently produce signature type 17 cytokines, including IL-17A, IL-22, and granulocyte 
macrophage-colony stimulating factor (GM-CSF), that contribute to local tissue inflammation 
[348]. 
In many circumstances, IL-1β and IL-23 act in concert for the activation of type 17 immunity.  
Our current understanding of Th17 biology suggests that while IL-23 can promote Th17 
differentiation and survival from naïve CD4+ T cells along with TGFβ and IL-6 [349], IL-1β 
promotes the expansion and maintenance of Th17 cells in inflamed tissues following IL-6-
induced IL-1R1 upregulation [350].  Mechanistically, signalling via IL-1R1 induces expression 
of transcription factor interferon-regulatory factor 4 (IRF4) via phosphorylation of mammalian 
target of rapamycin (MTOR), which in turn reinforces expression of RORγt [351].  Strikingly, 
O’Shea and colleagues demonstrated that combined stimulation of naïve T cells with IL-23, IL-
1β, and IL-6, in the absence of TGFβ, was sufficient to induce a pathogenic subset of Th17 
cells, characterised by expression of RORγt, T-bet, and IL-33 [352].  Therefore, cooperation 
between IL-23 and IL-1β likely exacerbates type 17 immune responses. 
As well as Th17 cells, IL-1β and IL-23 support innate cytokine production by γδ T cells and 
ILC3s, likely bridging the temporal gap prior to the onset of adaptive immune responses [353]–
[358]. 
Several studies, in both WT and Rag2-deficient mice, have supported a pathogenic role for IL-
23 in intestinal inflammation.  IL-23 was shown to drive pathology in two models of H. 
hepaticus-induced T cell-dependent colitis independently of IL-12, whereby IL-17A and IFNγ 
synergized to promote tissue destruction.  Monoclonal anti-IL-23p19 IgG administration was 
sufficient to control colitis in this case.  Furthermore, several studies have shown that IL-23 
can drive innate type 17 cytokine production and IFNγ in both adult and neonatal intestines 
that are sufficient to promote microbiota-dependent colitis [292], [294], [295], [359]–[362].  In 
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contrast, IL-23 exerts a protective role in TNBS-induced colitis by blocking IL-12 secretion 
[363]. 
Excitingly, anti-IL-12p40 and anti-IL-23p19 monoclonal antibody therapy significantly 
increased clinical remission rates in moderate-to-severe CD patients that were resistance to 
infliximab [364], [365], and nicely illustrates how murine models have helped to inform human 
pathology. 
Therefore, the concerted action of IL-23 and IL-1β supports intestinal pathology through the 
activation of type 17 cytokine responses and IFNγ production, with clinical intervention of these 
pathways proving to be promising in both human disease and murine colitis. 
1.6.3. T and innate lymphoid cell-derived cytokines 
Type 17 responses are of major interest in the field of IBD research, given the abundance of 
studies demonstrating the therapeutic benefit of IL-23 and IL-1β blockade in both mice and 
humans.  However, the specific roles of these cytokines, particularly IL-17A, IL-22, and GM-
CSF, remain enigmatic.  Indeed, little or no therapeutic benefit has been demonstrated from 
targeting these cytokines individually. 
1.6.3.1. IL-17A and IFNγ  
Since the discovery of Th17 cells and their association with several inflammatory disorders, 
studies probing the biology of IL-17A have been widespread.  IL-17A seems to be of particular 
significance at epithelial barrier sites, where Th17 cells, γδ T cells, and ILC3s reside in 
abundance.  Here, IL-17R signalling is thought to drive tissue destruction through its ability to 
promote cytokine production and cellular recruitment via the activation of local non-
haematopoietic cells [366].   
Mechanistically, IL-17A can induce cytokine production from both haematopoietic and non-
haematopoietic cells, including IL-1β, IL-6, GM-CSF, PGE2 and TNF [366]–[369].  IL-17 also 
has a critical role in neutrophil recruitment to tissues via the induction of chemokines, including 
CXCL1, CXCL2 and CXCL8, while GM-CSF and MMP induction can sustain neutrophil survival 
and activation within tissues [370]–[372].  At mucosal sites, IL-17 can also induce expression 
of anti-microbial peptides critical for barrier immunity [373], [374]. 
In many instances, IL-17A also acts cooperatively with other cytokines, particularly TNF.  IL-
17A can induce expression of TNFR1 and acts in synergy to drive production of anti-microbial 
peptides, chemokines, IL-1β and MMPs [375], [376].  Furthermore, both cytokines induce 
endothelial cell expression of selectins, CXCL1 and CXCL2 for sustained neutrophil 
recruitment to inflamed sites.  
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The involvement of Th17 cells in inflammation appears to be widespread, from anti-microbial 
immunity [367] to autoimmune and inflammatory disorders, such as psoriasis [377], RA [378], 
MS [379], asthma [380], SLE [381], and IBD [262].   Furthermore, γδ T cell-derived IL-17A has 
been shown to promote neutrophil infiltration following E. coli infection [382], and to augment 
the severity of EAE [354].  γδ T cell-derived IL-17A can also sustain IL-23-driven dermal 
inflammation in Imiquimod models of psoriasis [383].   
Within the GI tract, IL-17A has been shown to be necessary for defence against intestinal 
pathogens, such as C. rodentium [384].  However, the role of IL-17A in driving colitis remains 
enigmatic: IL-17A neutralisation exacerbates DSS-induced colitis [385] and monoclonal anti-
IL-17A antibodies enhance IBD severity [386].  This has been hypothesised to be due to the 
roles of IL-17A in the preservation of the intestinal epithelial barrier.  Lee et al. found that γδ-T 
cell production of IL-17A was independent of IL-23 and associated with a reinforced epithelial 
barrier [387], while Maxwell et al. demonstrated that IL-17RA blockade, although reducing 
neutrophil recruitment during colitis, resulted in an exacerbation of colitis and reduced epithelial 
barrier function [388].  Finally, Song et al. demonstrated a role for IL-17A in epithelial wound 
healing following DSS-induced colitis [389].  Therefore, while IL-17A is clearly associated with 
colitis and is involved in neutrophil recruitment to the inflamed GI tract, these studies argue for 
IL-17A-independent roles for IL-23 in the exacerbation of disease.  
IL-23 can induce IFNγ secretion by inflamed colonic LP cells, and argues against a strict Th17 
role for IL-23 [390].  IFNγ contributes to inflammation through the activation of tissue-resident 
macrophages, apoptosis of IECs, and augmentation of antigen processing [318].  Elevated 
IFNγ expression is historically characteristic of LP-resident CD4+ T cells [335].  In CD patients, 
IFNγ production vastly outnumbers IL-17A production, and is strongly linked to disease activity 
[391].  Initial studies in the CD4+ T cell-transfer model of colitis demonstrated that blockade of 
IFNγ or T-bet deficiency (a transcription factor required for IFNγ production) was sufficient to 
suppress inflammation [301], [392].  Similarly, IFNγ-deficient mice are protected from DSS-
induced colitis [393].  Given the observation of T-bet-expressing Th17 cells, it may be possible 
that these pathogenic T cells contribute to inflammation through dual IL-17/IFNγ production.   
Strikingly, a study by Feng et al. demonstrated that transfer of flagellin-specific CBir Th17 cells 
into T cell-deficient mice resulted in IL-17-dependent innate IL-12 and IL-23 production and 
the emergence of pathogenic IFNγ-producing Th17 cells [394].  In this model, blockade of IL-
17A was effective in the suppression of colitis.  Therefore, it is possible that IL-23-dependent 
mixed Th1/Th17 responses cooperate in the induction and progression of colitis.  However, 
common to IL-17A, the IFNγ-specific monoclonal antibody fontolizumab has not proved 
effective in CD therapy [318], [395].   
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Therefore, despite associations between upstream innate cytokines and the activation of Th1 
and Th17 immunity in the GI tract, as well as the clear roles played by T cells in driving colitis, 
targeting single Th-associated cytokines has not proved effective in the treatment of IBD.   
1.6.3.2. IL-22 
IL-22 is a recently described cytokine of the IL-10 family that is produced by a variety of cells, 
including DCs, NKT cells, γδ T cells, Th17 cells, and the newly identified ILC3s [396]. 
IL-22 receptor expression is largely confined to non-haematopoietic cells, particularly epithelial 
and stromal cells, where it signals via STAT3 to induce a programme of cellular proliferation, 
tissue regeneration, and reinforced barrier function [397].  Therefore, unsurprisingly, IL-22 
plays a key role at mucosal interfaces, with a wealth of growing data as to its role in the GI 
tract. 
In vivo, IL-22 production by T cells and ILC3s is heavily dependent on IL-23, with increased 
numbers of IL-22-producing ILC3s observed in patients with IBD [398].  However, despite its 
link to IL-23, the roles of IL-22 in driving colitis are unclear.  In chronic CD45RBhi CD4+ T cell 
transfer and DSS-induced models of colitis, IL-22 was protective [361], [399]–[402].  However, 
blockade of IL-22 in acute CD40-induced colitis was beneficial, although the mechanism by 
which this was achieved was unclear [361].  Indeed, Powrie and colleagues initially ascribed 
the pathogenic role of CD90.2hi SCA-1+ ILCs in this model of colitis to their production of IL-
17A and IFN-γ, rather than IL-22 [292]. 
While its role in driving colitis is disputed, IL-22 may be involved in IBD-associated colorectal 
cancers through its ability to stimulate epithelial cell turnover.  Indeed, murine models have 
demonstrated sustained H helicobacter + azoxymethane (AOM)-driven colorectal cancer 
through an IL-22-dependent mechanism [403].  IL-22 activity in vivo can be antagonised by IL-
22 binding protein (IL-22BP), highly expressed by intestinal DCs and dynamically regulated 
during immune responses.  In support of a tumorigenic role for IL-22, IL-18-dependent 
downregulation of IL-22BP is associated with enhanced tumorigenesis in the DSS/AOM model 
of colorectal cancer [404]. 
In summary, IL-22 appears to exert a homeostatic function in the repair and maintenance of 
the intestinal epithelium, with little direct association with IBD pathology.  However, 
dysregulated IL-22 activity may contribute to IBD-associated colorectal cancer.  The regulation 
and function of IL-22 will be discussed in more detail in the section on innate lymphoid cells. 
1.6.3.3. Granulocyte-macrophage colony-stimulating factor  
GM-CSF is a member of the CSF superfamily that signals through a heterodimeric receptor 
composed of the GM-CSF-specific α chain (CSF2RA) and the signal transducing β subunit 
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(CSF2RB).  GM-CSF is produced in response to danger signals by many cell types, including 
DCs, T cells, B cells, ILCs, and non-haematopoietic cells [405], [406].  As well as its well 
established roles in the myelopoiesis, recent reports have demonstrated key inflammatory 
roles for GM-CSF in mediating tissue destruction, with implications for IL-23- and IL-1β-driven 
inflammation [407].  
GM-CSF has been identified as an M1-inducing stimulus that can induce inflammatory 
reprogramming of macrophages that may drive local inflammation and immune defence [72], 
[408], [409].  GM-CSF can promote LPS-induced inflammatory cytokine production by BMDMs 
in vitro, including IL-1β, a feature associated with enhanced glycolytic flux and expression of 
the GTPase Rab39a [410], [411].  Indeed, GM-CSF has been shown to drive EAE via the 
licensing of pathogenic IL-1β production by CCR2+ monocytes [412].  Furthermore, GM-CSF 
can sustain neutrophil survival and activation in the periphery, as previously mentioned. 
Higher levels of GM-CSF are identified in mucosal lesions in CD and UC compared to healthy 
controls.  Furthermore, colonic GM-CSF expression is increased following DSS exposure 
[413]. 
In the murine H. hepaticus colitis model of IL-23-driven colitis, GM-CSF can drive dysregulated 
haematopoiesis and local granulocyte activation to promote colitis [414], [415].  Furthermore, 
GM-CSF-deficient mice are more susceptible to C. rodentium infection.  Conversely, however, 
GM-CSF depletion exacerbates DSS-induced colitis, ascribed to defects in DC and 
macrophage survival and activation [413], [416], [417].   
Therefore, GM-CSF clearly has roles in the maintenance and activation of myeloid cells within 
the GI tract, although the relative contributions to homeostatic and inflammatory programmes 
likely differ between models.  It is noteworthy that anti-GM-CSF antibodies are identified in a 
subset of patients with IBD (particularly CD), and associated with enhanced disease severity, 
intestinal epithelium permeability and reduced neutrophil responsiveness [418]–[420].  In this 
setting, it is tempting to speculate this may contribute to colitis as a result of dysbiosis and 
opportunistic invasion by commensal microbes, in a manner similar to NOD2 polymorphisms. 
1.6.4. IL-10 
IL-10 is the prototypical anti-inflammatory cytokine.  Most classically associated with Foxp3+ 
Tregs, IL-10 functions to suppress lymphocyte and myeloid immunity through a variety of 
mechanisms, such as the inhibition of inflammatory cytokine production [421].  
Within the GI tract, IL-10 is also produced by macrophages, regulatory B cells (Bregs), and 
epithelial cells [5], [422]–[424].  Here, the critical role of this cytokine is acutely illustrated by 
associations between IL10R SNPs and UC, as well as the widespread use of the H. hepaticus 
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infection model: the presence or absence of IL-10R signalling dictates whether an otherwise 
innocuous bacterium induces colitis [259], [260], [298]. 
A recent study by Medzhitov and colleagues demonstrated that IL-10R signalling in BMDMs 
was essential for the inhibition of glycolysis and the clearance of damaged mitochondria by 
mitophagy.  In the absence of IL-10R signalling, macrophages accumulated damaged 
mitochondria in a murine model of colitis and in patients with IBD, resulting in exacerbated 
NLRP3-dependent IL-1β production [425].  A complementary study also demonstrated that IL-
10Rα signalling in intestinal macrophages was required for the suppression of intrinsic IL-1β 
production via transcriptional suppression of the Il10 locus and caspase-1-dependent pro-IL-
1β processing [426].   
Mauri and colleagues demonstrated that microbiota-dependent IL-6 and IL-1β production was 
sufficient to induce IL-10-producing Bregs within MLNs that contain systemic inflammation 
[423], while adoptive transfer of these cells is sufficient to suppress intestinal inflammation 
[422]. 
Therefore, through its roles in the suppression of intestinal macrophage function, IL-10 is 
critical for the maintenance of a tolerogenic milieu within the GI tract. 
1.6.5. IgG and FcγRs in IBD 
Given the prevalent inflammatory characteristics of IgG, it is unsurprising that de novo IgG 
generation is associated with chronic intestinal inflammation in IBD patients [240], [427].  This 
IgG response is directed against components of the commensal microbiome, with a prominent 
example of an IBD-associated antigen being flagellin [241], [428], [429].   It has been 
demonstrated that CXCR4+ IgG plasmablasts are enriched in the inflamed colonic LP of 
patients with IBD [430], while additional inflammatory mechanisms have been ascribed to LP-
infiltrating plasma cells, such as granzyme B production [431]. 
UC patients are also characterised by the development of auto-antibodies, resulting in its 
classification as a partially autoimmune disorder.  Circulating antibodies against colon 
epithelial goblet cells are common [432], while perinuclear anti-neutrophil cytoplasmic 
antibodies (pANCA) are observed in two thirds of UC patients [433]–[435]. 
However, despite the robust association between FcγRIIA SNPs and IBD, a systematic 
characterisation of IBD-associated IgG is severely lacking.  Furthermore, the pathological 
implications of this local antibody production remain largely unknown.  
Recently, aberrant IgG glycosylation was demonstrated in IBD patients, with agalactosyl IgG 
associated with both UC and CD [436].  Indeed, 5 genes known to regulate IgG glycosylation 
show robust association with IBD (IKZF1, LAMB1, MGAT3, IL6ST, and BACH2) [127], 
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including genes encoding galactosyltransferases [126].  Given the association between 
pathological IL-23R signalling and IBD, and the observation that IL-23-derived Th17 immunity 
promotes IgG class-switching and inflammatory glycosyl patterns, these pathways may 
reinforce one another for the augmentation of pathology in the GI tract. 
Drugs targeted at reducing IgG-mediated inflammation have received little attention in the 
treatment of IBD.  No randomised control trials exist for IVIG but a meta-analysis identified a 
handful of case reports which indicated that IVIG can induce a rapid improvement in steroid 
resistant CD [437], [438], and there are reports of utility in UC [439].   
A single randomised controlled trial exists for the anti-CD20 antibody rituximab in UC [440].  
Of 16 patients who failed to respond to standard therapies, half demonstrated a response at 4 
weeks compared to 2 of 8 placebo-treated patients.  This response was not maintained to 12 
weeks in a further half of patients, however.  The small size of this study, however, is in stark 
contrast to the cohort size required to demonstrate efficacy of other IBD therapeutics [365], 
and was substantially underpowered.  Furthermore, given the likely depletion of regulatory B 
cells with rituximab, pan-B cell depletion can result in exacerbation of allo- and auto-immunity, 
and my not be the optimal therapeutic strategy.  Therefore, the question of whether B cell 
manipulation may be of benefit in UC has not been adequately addressed.  
These observations challenge the dogma that IgA is the predominant method of humoral 
protection at mucosal surfaces.  Additionally, FcγR signalling at mucosal sites in response to 
local IgG could drive disease pathology in IBD.  Given its induction in vitro following FcγR 
ligation, this may proceed through the activation of type 17 immune responses within the 
inflamed mucosa.  This shall be discussed in more detail below. 
1.7. Intestinal B cells 
Intestinal plasma cells are an essential component of mucosal immunity, with the majority of 
plasma cells producing IgA under homeostatic conditions [42].  Secretory IgM-producing 
plasma cells are also present in the human gut [441], and can survive for decades within the 
GI tract itself, as well as in the bone marrow [442], [443].  During inflammatory disorders, such 
as IBD, IgG-producing plasma cells are markedly increased, demonstrating a skewing of the 
humoral response from an anti- to a pro-inflammatory phenotype [430].  However, the 
mechanistic underpinning and consequences of this switch are not well understood. 
Here we shall discuss the mechanisms of Ig within the GI tract, as well as their generation 
during homeostasis and inflammation. 
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1.7.1. IgA in homeostasis 
S-IgA participates in the maintenance of mutualism in the GI tract through a variety of 
mechanisms collectively known as immune exclusion.   
S-IgA can neutralise toxins and pathogens without causing inflammation because of its inability 
to fix complement [444].  In addition, S-IgA anchors microbes to the mucus, preventing invasion 
of the underlying epithelium.  S-IgA can suppress inflammatory responses to bacterial 
products: it downregulates expression of inflammatory epitopes [445] and can neutralise 
intracellular LPS within IECs [446].  Via its ability to agglutinate bacteria through carbohydrates 
in the Fc domain, S-IgA induces the formation of a biofilm that inhibits the growth of pathogens 
[447].  Recently, high affinity IgA was shown to mediate enchainment of bacterial daughter 
cells as they divide, limiting colonisation, bacterial evolution, and promoting elimination from 
the body [448].  This function of high-affinity TD IgA may allow for the retention of beneficial 
commensals, which do not elicit such a potent response under homeostatic conditions.  Finally, 
natural or low-affinity IgA can deliver antigens to M cells for transport into Peyer’s patches (PP) 
for the induction of adaptive immune responses [449]. 
The importance of IgA is demonstrated by species of commensal microbes that mediate IgA 
degradation, which promote GI inflammation [276]. 
1.7.2. CSR in the GI tract 
Gut-draining MLNs, gut-associated lymphoid tissues (GALT), including PP and isolated 
lymphoid follicles (ILFs), and the intestinal LP have been proposed to be sites for IgA 
generation, with the mode of IgA generation differing across tissues [450].  Local IgA 
production within the LP and ILFs is thought to be largely TI, given the absence of abundant T 
cell zones, whereas MLNs, the caecal patch, and PPs can support both TD and TI IgA 
induction [42], [451], [452].   
Generally, IgA generation in T cell-deficient mice is less efficient and less effective than in WT 
mice [45].  Furthermore, while T-B cell interactions do not appear to be required for CSR, the 
vast majority of LP-resident plasma cells are heavily mutated, suggesting a germinal centre 
origin, T cell help, and SHM [453]. 
1.7.2.1. IgA generation in GALT 
PPs are the major source of intestinal IgA+ B cell induction (Fig. 1.11) [453].  These structures 
are composed of several B cell GCs on a network of FDCs, with interfollicular regions 
containing T cells and DCs.  Tfh cells are essential for IgA class-switching, and can arise from 
the plasticity of other CD4+ T cell subsets within PPs, including Tregs and Th17 cells [454]–
[457].  CXCR5+ PD-1hi FoxP3+ T follicular regulatory cells are required to limit Tfh numbers 
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and dampen GC B cell responses in order to maintain commensal microbiome fitness [456]–
[458].  
While CD40-deficient mice exhibit normal levels of IgA-producing cells, in the absence of GCs, 
these cells have not undergone SHM, as in WT mice [240], [459].  Furthermore, Aicda-deficient 
mice and AIDG23S knock-in mice (with a specific defect in SHM) exhibit intestinal dysbiosis, B 
cell hyperplasia, bacterial translocation, and susceptibility to enteropathogenic challenge [460], 
[461].  Therefore, while T-B interactions are not required for low-affinity TI IgA responses, they 
are required to mount specific IgA responses to microbes and orally administered T-dependent 
antigens.  Non-cognate T-B interactions have been shown to be sufficient for GC formation 
and SHM in PPs.  B cells expressing non-antigen-specific surrogate Ig receptors can induce 
GC formation in PPs, dependent on non-cognate T cells and the microbiota [462].  Therefore, 
under certain circumstances, BCR-independent B cell activation can support TD IgA 
production in PPs. 
Other than T cells, other PP-resident haematopoietic and non-haematopoietic cells influence 
IgA class-switching and subsequent LP-homing, including DCs and FDCs.  Gut-imprinting via 
the upregulation of CCR9 and α4β7 is mediated by retinoic acid (RtA)-producing GALT DCs 
[463], [464].  A recent study by Reboldi et al. demonstrated that CCR6-dependent B cell 
migration to RtA-producing DCs within the PP sub-epithelial dome was required for IgA class-
switching.  In the absence of CCR6, antibody production was skewed towards IgG1 [8].  PPs 
DCs are also a source of NO, which has also been demonstrated to promote both TD and TI 
IgA CSR in GALTs via regulation of B cell TGF-β receptor expression, and the production of 
APRIL and BAFF, respectively [52].  Indeed, TGFβ can support CSR to IgA in vitro, and TGFβ 
receptor-deficient mice do not generate IgA-producing plasma cells following immunisation 
[465]. 
FDCs have also been implicated in IgA CSR.  As well as presenting antigen to B cells within 
follicles, FDCs produce CXCL13, BAFF, and molecules that facilitate the secretion and 
activation of TGF-β1 in response to microbial stimuli and RtA [53]. 
1.7.2.1. IgA generation and maintenance in the lamina propria 
Whether CSR occurs in the intestinal LP is disputed.  While certain CSR-associated factors 
are expressed within the LP in humans and mice, convincing evidence of AID expression by 
LP-resident plasma cells is lacking.  Instead, the intestinal mucosa may provide local niches 
that support plasma cell survival (Fig. 1.12) [42] 
Intestinal DCs and IECs can contribute to plasma cell survival through production of IL-6, 
CXCL12, BAFF and APRIL [466]–[468].  Eosinophils are abundant in the GI tract, although 
their local functions are not well understood.  In vitro, eosinophils can support IgA class-
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switching, while eosinophil depletion in vivo resulted in defects in TGFβ-mediated events, 
including IgA CSR in PPs and the formation of Tregs [469], supporting a local homeostatic role 
for these cells in IgA production.  Indeed, TGF-β production is abundant within the LP from 
many cell types [42], [465].  Intestinal Tregs are reported to support gut IgA maintenance within 
the gut LP through production of TGF-β [470], although their contribution to IgA CSR itself is 
not known. 
Therefore, several immune cells can contribute to the maintenance of intestinal plasma cells 
through the secretion of B cell survival factors.  However, whether these are sufficient to drive 








Figure 1.11.  Known and hypothesised mechanisms of Ig CSR in GALT.  Primary signals 
initiate B cell activation and the induction of CSR, such as BCR stimulation, BAFF and APRIL, 
or TLR ligation.  CSR to IgA and gut homing via CCR9 and α4β7 is critically dependent on 
secondary signals from GALT-resident DCs and T cells, including TGFβ, iNOS, and RtA.  
Th1/17 and DC signals are known to regulate IgG class-switching in mice, including IL-17A, 




Figure 1.12.  Plasma cell niches in the lamina propria.  TGFβ, IL-10, BAFF and APRIL 
production are abundant in the GI tract, and may be derived from a variety of immune cells.  
Epithelial cell-derived cytokines may also promote IgA CSR in the LP.  Alternatively, these 
factors may promote plasma cell survival within the LP.  Numerous inflammatory networks may 
contribute to TI IgG generation, plasma cell survival, or the induction of glycosylation 
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1.7.3. IgG in intestinal inflammation 
While IgA is the predominant Ig isotype at rest, increasing evidence points towards a critical 
role for IgG antibodies within the GI tract in the defence against infection, during intestinal 
immune development, and in chronic inflammatory disorders, such as IBD [471]. 
1.7.3.1. IgG in gastrointestinal infection 
Murine models of infections have identified a role for B cells in gastrointestinal immunity.  An 
IgA/IgM-independent role for B cells in the clearance of C. rodentium was shown to be 
dependent on IgG [283], [284], [472], with antibodies shown to target virulence factors 
essential for pathogen entry [473], [474].   
Several studies in non-human primates have also identified roles for IgG in anti-microbial 
mucosal immunity.  Passive transfer of serum rotavirus-specific IgG has been shown to delay 
rotavirus infection in naïve pigtailed macaques [475], while anti-HIV IgG administration to 
rhesus macaques can prevent viral transmission [476]. 
1.7.3.2. IgG in intestinal immune development 
The acquisition of maternally-derived IgG antibodies in utero and through breast milk provides 
neonates with an important source of immunity prior to the development of the host immune 
system.  Recent studies in mice have demonstrated that TI, TLR-dependent anti-commensal 
IgG generation forms part of normal adult immunity, and that this IgG is essential for the 
maintenance of host-commensal symbiotic relationship and protection from systemic microbial 
infection [477]–[479].  In the absence of maternally-derived IgG antibodies, neonates exhibit 
exacerbated mucosal Tfh responses and GC B cell activation [477], [480], as well as altered 
tissue-resident immune cell subsets, including reductions in ILCs and macrophages [479].  
Furthermore, homeostatic anti-Gram-negative IgG has been shown to confer protection 
against systemic pathogenic challenge by targeting conserved antigens on pathogens [478].  
This humoral response is plastic, as anti-commensal IgG antibodies have been shown to 
compensate for defects in innate immunity for the maintenance of host-commensal symbiosis: 
defective TLR signalling or oxidative burst production resulted in enhanced anti-commensal 
IgG titres that maintain mutualism in vivo [481].  As such, IgG-mediated anti-commensal 
responses represent an essential and plastic mechanism required to maintain host-microbe 
mutualism and mediate systemic pathogen immunity. 
Anti-commensal IgG antibodies and plasma cells are also present in humans [240], and 
similarly to IgA,  have been shown to be generated locally within GALT and MLNs, challenging 
the assumption that anti-commensal IgG is a phenomenon arising from systemic dissemination 
of commensal antigens [477]. 
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While encouraging as to the key functional role of anti-commensal IgG antibodies in immunity, 
the mechanisms by which IgG operates have not been investigated.  Indeed, how anti-
commensal IgG responses are regulated, how they may contribute to dysbiosis, and their 
mechanistic contribution to inflammatory conditions remains largely unexplored. 
1.7.3.3. IgG in IBD 
As previously mentioned, one of the robust associations with UC susceptibility is a SNP in 
human FcγRIIA that enhances IgG binding.  In addition to historical observations of IgG-
producing plasma cells in the inflamed mucosa of IBD patients [427], this supports the 
hypothesis that detrimental local IgG generation may contribute to inflammation via the 
induction of FcγR signalling pathways.   
In line with this, Blumberg and colleagues demonstrated that anti-flagellin IgG is generated 
following exposure of WT mice to the colitogen DSS, and passive transfer of anti-flagellin IgG 
was detrimental in colitis [482].  Mice exhibit enhanced weight loss and pathology scores, but 
the mechanism of this enhancement was not described.  Furthermore, how the character of 
this IgG changes with regard to homeostatic anti-commensal IgG is not discussed.  However, 
this supports work by several groups that demonstrated an increase in mucosal IgG+ plasma 
cells in IBD [241], [430]. 
In summary, recent seminal studies have demonstrated that anti-commensal IgG is a normal 
facet of adult immunity during homeostatic conditions that contributes to mutualism in the gut.  
However, IgG responses are exacerbated in colitis and can contribute to detrimental 
inflammation, although the mechanisms by which this occurs are not understood. 
1.8. The intestinal macrophage system 
Macrophages play a central role in tissue homeostasis and inflammation, with increasingly 
appreciated non-immune roles in tissue function [483]–[485].  However, through their 
voracious phagocytic capacity and ability to secrete both pro- and anti-inflammatory cytokines 
and chemokines, they have essential roles in the coordination of immunity within the gut and 
in shaping of systemic responses. 
1.8.1. Identification 
The distinction between tissue-resident DCs and macrophages, which both belong to the 
population of mononuclear phagocytes (MNPs), has often proved confusing, given their shared 
overlap of several cell surface markers, including CD11c, CX3CR1, and MHC-II.  This is further 
compounded by the monocyte-derived origin of certain DC subsets.   
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The recent demonstration that FcγRI is unique to intestinal macrophages has helped to resolve 
this issue [68].  Indeed, this study demonstrated that as Ly6Chi monocytes enter the LP, these 
cells mature by the stepwise acquisition of MHC-II, loss of Ly6C expression, and the 
upregulation of F4/80 and FcγRI, bone fide macrophage markers, as well as CX3CR1 and 
CD11c.  This allows for a so-called waterfall gating strategy within the CD11b+ CX3CR1+ MNP 
population based on Ly6C and MHC-II, which will be used throughout this thesis (Fig. 1.13).  
Generally, we have dissected this waterfall into three subpopulations: 
1. CX3CR1int Ly6Chi MHC-II- monocytes 
2. CX3CR1int Ly6C+ MHC-II+ monocytes/immature macrophages 
3. CX3CR1hi Ly6Clo MHC-IIhi macrophages, which also express F4/80 and CD11c. 
During inflammation, monocytes give rise to a secondary macrophage population, 
characterised by inflammatory cytokine production [82].  This can be distinguished by lower 
CX3CR1 and F4/80 expression compared to tissue-resident macrophages.  However, in 






Figure 1.13.  Waterfall gating strategy of MNP subsets by flow cytometry.  MNPs are 
identified as CD11b+ CX3CR1+ cells within the LP.  MNPs are then subdivided into monocytes 
(red), MHC-II+ monocytes/immature macrophages (green), and macrophages (blue) based on 
expression of Ly6C and MHC-II. 
 
Despite this classification, it seems likely that both macrophages and DCs contribute in 
complementary ways to inflammation.  For example, although classically associated with 
antigen presentation, CD103+ DCs can also contribute to flagellin-induced IL-23 production, 
while macrophage MHC-II expression demonstrated antigen presentation capacity by these 



















Elegant studies by Mowat and colleagues demonstrated that, while neonatal intestinal 
macrophages are derived from embryonic precursors cells that seeded the intestinal mucosa 
and proliferated in situ, adult intestinal macrophages are derived from continuous CCR2-
dependent Ly6Chi monocyte recruitment in response to the microbiota [280].  This is distinct 
from other tissue-resident macrophages, such as microglia and Kupffer cells, which are shown 
to be derived from yolk-sac progenitors and self-renew throughout life [487]. 
Environmental and host factors condition monocyte maturation within the LP to avoid overt 
inflammatory responses, although this area remains poorly understood [82], [488].  While 
intestinal macrophage numbers are suggested to be generally unaltered in GF mice [489], 
commensal microbes influence macrophage activation within the GI tract [490], [491].  Indeed, 
SCFAs, particularly butyrate, derived from the microbiota have been implicated in the 
appropriate maturation of intestinal macrophage and microglia [492], [493].  Butyrate acts to 
suppress inflammatory IL-6 and IL-12 production, likely contributing to the maintenance of 
mutualism.  GF mice exhibit also reduced bone marrow myelopoiesis and susceptibility to 
systemic bacterial challenge, with implications for the de novo generation of monocyte 
precursors and the continuous seeding of the GI tract [494], [495].   
Intrinsic IL-10R signalling appears to be essential for the restriction of intestinal inflammation 
through the maintenance of an anti-inflammatory macrophage phenotype [425].  Recently, 
BMDMs were shown to adopt a tissue-resident phenotype within the peritoneum in response 
to RtA [496].  Given the pleiotropic roles of RtA in the maintenance of the symbiotic niche, it is 
may be that a similar role exists in the gut. 
In summary, gut-resident macrophages are derived from circulating monocyte precursors 
throughout life and are subject to regulation by the local cytokines and the microbiome for 
appropriate maturation and activity. 
1.8.3. Intestinal macrophages in homeostasis 
Within the GI tract, macrophages are continuously exposed to microbial stimuli and play a 
central role as key guardians of the homeostatic milieu.  They are characterised by their 
prominent phagocytic capacity and an anti-inflammatory phenotype, being hypo-responsive to 
TLR stimulation and potent producers of IL-10 [497], [498].  Some of these functions are 
summarised in Figure 1.14.   
1.8.3.1. Scavenging 
One of the primary homeostatic functions of intestinal macrophages is scavenging of self and 
foreign antigens, such as apoptotic cells and bacteria, respectively.  To this end, these cells 
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express an array of cell surface receptors, including TLRs, C-type lectin receptors, Nod-like 
receptors, and FcγRs [3].  Despite this, intestinal macrophages are relatively anergic to 
microbial stimuli [499], [500]. 
These phagocytic functions are essential in the gut, given the continuous turnover of the 
intestinal epithelium and challenge by microbial products.  Defective apoptotic clearance by 
macrophages and epithelial cells has been shown to drive autoimmunity and colitis [271], 
[501]–[503].  Furthermore, as well as promoting the clearance of DAMPs and preventing the 
emergence of self-reactive adaptive immunity, apoptotic cell internalisation also imprints 
macrophages with inflammation-suppressive transcriptional signatures and the production of 
TGFβ and PGE2 [500], [504], [505]. 
1.8.3.2. Cytokine production 
Gut macrophages are characterised by their elevated production of IL-10 and TNF, as well as 
CXCL chemokines involved in neutrophil recruitment into tissues [82].  Macrophage-derived 
IL-10 is required to dampen IL-23-mediated inflammation and likely contributes to autocrine 
suppression, although these functions may be redundant with other IL-10-producing cells 
[425], [498].  However, via their secretion of IL-10, RtA, and exogenous TGFβ, intestinal 
macrophages can also induce Tregs in vitro [497].  Furthermore, homeostatic IL-1β secretion 
by intestinal macrophages is required for the priming of tolerogenic Treg-inducing DCs through 
IL-1β-dependent GM-CSF secretion by ILC3s [506].   
Given their close proximity to the epithelium, macrophage-derived secreted factors are also 
suggested to contribute to epithelial wound repair in colitis, including COX-2-derived 
prostaglandins and Wnt family proteins [490].  
As well as in the LP, macrophages are also present between the circular and longitudinal 
muscle layers of the GI tract.  These muscularis macrophages are skewed towards anti-
inflammatory function, with elevated levels of IL-10 and arginase, and lower production of IL-
12p40 and NOS2.  Furthermore, these cells can response directly to neurotransmitters, which 
boost the anti-inflammatory function of these cells in vivo [484].  
1.8.3.3. Antigen presentation 
Other than the maintenance of Tregs within the LP itself, macrophages play dual roles in 
antigen presentation to T cells.   
Firstly, CX3CR1+ MNPs within the intestinal LP have been shown to acquire antigens directly 
from the lumen via intraepithelial projections and transfer antigen to migratory DCs for transport 
to the MLN [507]–[509].  Furthermore, while less efficient than DC subsets, evidence suggests 
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that CX3CR1+ macrophages can transport internalised antigens directly to draining LNs 
through intrinsic expression of CCR7 and MHC-II [82], [497]. 
1.8.3.4. Physiology 
Recent studies have demonstrated roles for macrophages in intestinal physiology.  
Macrophages located within the intestinal muscularis externa regulate the peristaltic activity of 
the colon through the secretion of bone morphogenic protein 2 (BMP2) in response to microbial 
stimuli [483].  BMP2 regulates enteric neuron activity, which subsequently maintain 
macrophages through the production of macrophage-colony stimulating factor (M-CSF).   
In summary, intestinal macrophages have critical roles in intestinal homeostasis, from the 
engulfment of apoptotic cells, the production of anti-inflammatory mediators, the induction and 
maintenance of Tregs, and the regulation of intestinal motility. 
1.8.4. Intestinal macrophages in intestinal inflammation 
1.8.4.1. Development 
Macrophage infiltrates are a common feature of inflammation and pathology [3].  As intestinal 
macrophages under both inflammatory and homeostatic conditions are derived from blood 
monocytes, the MNP dynamic differs significantly during colitis.  In response to DSS 
administration, Ly6Chi monocytes are redirected from an anti-inflammatory phenotype to one 
of elevated inflammatory cytokine production [510].  Indeed, these cells now adopt a CX3CR1int 
MHC-IIhi phenotype, rather than CX3CR1hi, and come to dominate the LP.  Unsurprisingly, 
therefore, CX3CR1int macrophages are principle mediators of tissue inflammation and skewing 
the MNP-driven response to one of leukocyte recruitment and local immune cell activation [82]. 
1.8.4.2. Inflammatory cytokine production 
Macrophages are identified as a major source of TNF in the inflamed LP.  TNF-producing 
macrophages are observed close to the epithelium in UC, while they are distributed throughout 
the mucosa in CD [511]. 
Furthermore, several murine models have implicated CX3CR1+ MNPs, particularly monocytes 
and Ly6C+ CX3CR1int immature macrophages, as essential mediators of inflammation via their 
production of IL-23 and IL-1β, as previously mentioned [82], [295], [510].  IL-23 production by 
CD11c+ MNPs was also shown to be key to driving H. hepaticus-induced colitis: in the absence 
of CD11c-specific IL-23, IFN-γ and IL-17A responses were severely inhibited and improved 
disease progression [295].  Furthermore, IL-1β, IL-23 and TL1A derived from CX3CR1+ 
macrophages supports colitis-associated IL-22 and GM-CSF production by ILC3s in vivo, 
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which may contribute to the pathogenic response [291], [292], [360], while IL-1β-mediated 
Th17 accumulation is associated with chronic H. hepaticus-induced colitis [296]. 
An important example of type 17-mediated immune responses in the GI tract regulated by 
CX3CR1+ macrophages is the response to segmented filamentous bacteria (SFB) in mice.  
These bacteria are important inducers of intestinal Th17 cells, enhancing defence against C. 
rodentium infection [310].  An elegant study by Littman and colleagues demonstrated that SFB 
induced IL-23-driven IL-22 production by ILC3s and the subsequent induction of local IL-17A 
production by Th17 cells in response to SAA1/2 secreted by the intestinal epithelium [512].  
Therefore, macrophages coordinate ILC3 and Th17 cells for distinct aspects of intestinal 
immunity. 
Furthermore, SFB-driven IL-17 responses are associated with extra-intestinal pathologies.  For 
example, SFB-induced Th17 cells exacerbated arthritis development in the murine K/BxN 
model via an IL-17-dependent mechanism [513].  Specifically, IL-17 supported GC formation 
and autoantibody generation.  Similarly, SFB promoted EAE via Th17 cell induction [514], while 
trafficking of intestinal IL-17A-producing γδ T cells to the leptomeninges is associated with 
increased ischemic brain injury in a murine model of stroke [515]. 
Given the demonstration that CD103+ DCs also express IL-23 in response to flagellin, it seems 
likely that these functions are shared with other MNP subsets in a context-dependent manner 
[486]. 
Tissue-resident macrophages not only drive inflammation through the production of 
inflammatory cytokines, they may also directly orchestrate immune cell recruitment via the 
production of chemokines.  Tissue-resident CX3CR1hi macrophages directly secrete CCL2 and 
CCL8 in murine models of DSS-induced colitis, driving monocyte recruitment to the inflamed 
mucosa.  Furthermore, these cells also express high levels of neutrophil-recruiting 
chemokines, including CXCL1 and CXCL2 [82], [516].  While this is likely to contribute to 
mucosal immune defence, it can potentially drive sustained detrimental inflammation if 
unchecked.  
1.8.4.3. Antigen presentation 
As well as the induction of Tregs, FcγRI+ macrophages are able to directly induce pathogenic 
Th1 responses within MLNs during colitis [68].  Whether these cells arise from migration from 
the LP is not clear, but is consistent with the upregulation of CCR7 on gut-resident 
inflammatory macrophages [82].   
Therefore, inflammation alters the developmental profile of gut-infiltrating monocytes from one 
of IL-10 production and Treg induction to one of inflammatory cytokine production, 
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characterised by IL-1β and IL-23 secretion, the induction of Th1 and Th17 responses, and the 
orchestration of tissue damage.  
 
Figure 1.14.  Macrophage functions in homeostasis and inflammation in the GI tract.  
Macrophages are continuously derived from blood monocytes that seed the gut.  These 
monocytes mature into IL-10-producing phagocytic macrophages under homeostatic 
conditions.  Under inflammatory conditions, tissue-resident macrophages produce pro-
inflammatory cytokines, such as IL-1β and IL-23, and chemokines, including CXCL1 and 2 






























1.8.5. The role of FcγRs on intestinal macrophages 
FcγR-mediated effector functions have been shown to be essential in several circumstances 
of mucosal anti-microbial immunity. 
One Fc receptor that has received growing attention as a vehicle for IgG-mediated immunity 
is the FcRn, driven by pioneering work by Blumberg and colleagues.  Classically associated 
with its role in the bidirectional transport of IgG across epithelial surfaces [517], FcRn is also 
expressed by intestinal immune cells, particularly myeloid cells, whereby it increases the half-
life of monomeric IgG by preventing its degradation.  Furthermore, FcRn promotes antigen 
presentation of immune complexed-antigens via MHC class I and II [518], [519].  
FcRn binding is required for IgG-mediated enhancement of DSS-induced colitis [482].  
Furthermore, FcRn binding enhances the anti-microbial activity of IgG in several models, 
including HIV and SIV challenge [520], while cancer immunity by CD8+ T cells is enhanced by 
FcRn-mediated IL-12 production by DCs [521], [522]. 
Other than FcRn, anti-microbial activities ascribed to IgG in the defence against 
enteropathogens, such as C. rodentium, is dependent on binding to canonical FcγRs [523].  In 
the absence of the common γ-chain, Fcer1g, mice readily succumb to C. rodentium challenge, 
exhibit enhanced tissue damage, reduced DC maturation, reduced TNF production, and 
impaired macrophage bacterium phagocytosis.  Similarly, in vitro studies by Uo et al. 
demonstrated that stimulation of CD14+ macrophages with opsonised bacteria induced 
elevated expression of IL-1β, TNF and TL1A versus bacteria alone, with little effect on IL-12 
and IL-23 [430]. 
Therefore, while the dissection of the roles of FcγR signalling on intestinal macrophages is in 
its infancy, studies support a role for local IgG and FcγR engagement in inflammation and 
immunity in the GI tract.  Furthermore, the study by Uo et al. raises the possibility that 
macrophage-intrinsic FcγR signalling may drive colitis through the production of several key 
IBD-associated cytokines.  In addition, it seems likely that FcγR signalling in intestinal 
macrophages contributes to anti-inflammatory mechanisms, such as IL-10 production.  
However, how these observations translate in vivo to murine models and human disease is 




1.9. Innate lymphoid cells 
1.9.1. Overview 
ILCs are a recently identified class of immune cells that are enriched at mucosal sites, such as 
the GI and respiratory tracts [12], [524].  The subject of intense research in the last half-decade, 
ILCs are increasingly appreciated to play diverse and critical roles in the maintenance of tissue 
homeostasis and in driving and shaping inflammatory responses, primarily through their 
elevated production of cytokines [12], [524]–[530]. 
1.9.2. ILC subsets 
Despite initial confusion as to the nature and relationship between described subsets, ILC 
classification has improved with time, and is likely to diversify in future as novel functions are 
discovered [531].  Strikingly, ILCs subsets mirror those seen for T cells.  NK cells represent 
the innate cytotoxic equivalent of CD8+ T cells, and will not be discussed in detail here, whereas 
non-cytotoxic helper ILCs resemble Th cells.  All helper ILCs, hereafter referred to simply as 
ILCs, express IL-2Rα and IL-7Rα, but unlike T cells and B cells, they do not express 
somatically-rearranged antigen-specific receptors [528].   
There are three major groups of ILCs, classified based on cytokine profile and TF dependence 
(Fig. 1.15).  Group 1 ILCs (ILC1s) produce IFNγ and TNF in response to IL-12 and IL-18, and 
are implicated in immunity against intracellular bacteria and viruses.  Despite their similarities 
to NK cells, ILC1s do not produce granzymes or perforin and their development is dependent 
on T-bet, unlike Eomes-dependent NK cells [532].  Group 2 ILCs (ILC2s) produce Th2-
associated cytokines, including IL-5, IL-9 and IL-13, as well as amphiregulin, in response to 
the epithelial-derived cytokines IL-33, IL-25, and TSLP.  As such, they drive allergic 
inflammation, anti-helminth immunity and tissue repair [533], [534].  These cells are dependent 
on RORα, GATA3, TCF1, and Bcl11b [535]–[540].  Via their expression of MHC class II, ILC2 
can also licence adaptive immunity via antigen presentation and DC priming [541]–[543].  
Finally, group 3 ILCs produce type 17 cytokines, including IL-17A, IL-17F, IL-22, GM-CSF and 
TNF, particularly in response to IL-23 and IL-1β [292], [296], [359], [544], [545].  All ILC3s are 
dependent on the TF RORγt [546], but can be divided into three subsets, based on T-bet and 
NKp46 expression, each with distinct functions [547]: 
1. T-bet+ NKp46+ ILC3s, also known as NK cell receptor-positive (NCR+) ILC3s, 
2. T-bet+ NKp46- ILC3s, and 
3. T-bet- NKp46- CCR6+ CD4+/- ILC3s, also known as lymphoid tissue-inducer (LTi) cells. 
Mature NKp46+ ILC3s reside primarily in the intestinal mucosa and, as well as RORγt and T-
bet, require aryl hydrocarbon receptor (AHR), TCF-1 and the microbiota for their development 
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[547]–[549].  Here, these cells primarily regulate protective barrier function via IL-22 
production, as shall be discussed in detail. 
LTi cells represent a distinct ILC3 subset that develops partly independently of other helper 
ILC subsets [550].  Originally identified as cells required for the development of lymphoid 
tissues via their production of lymphotoxin-α1β2 (Ltα1β1) [546], [551], these cells 
predominantly reside within SLOs and are also associated with production of IL-22 and IL-17A, 
and MHC class II-dependent T cell interactions [552]–[554].  While less dependent on AHR, a 
seminal study demonstrated that RtA derived from maternal vitamin A and cell-autonomous 
RtA signalling is required for transcription of the Rorc locus and LTi development [555].  
Other than developmentally programmed phenotypes, tissue-residency imparts unique ILC 
functionality.  For example, small intestinal ILCs across several subsets commonly expressed 
unique transcriptional traits distinct from corresponding subsets in distant tissues [556], [557]. 
Therefore, ILCs represent a unique subset of innate immune cells that provide complementary 
and unique functions to T cells, and likely act to bridge the temporal gap between activation of 
innate immunity and the development of antigen-specific responses. 
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Figure 1.15.  Development and function of cytotoxic and helper ILC subsets.  Cytotoxic 
NK cells develop from the EILP in a Eomes and T-bet-dependent manner.  Helper ILCs are 
derived from the ILCP, apart from LTi cells, such differentiate from the CHILP.  Transcription 
factor and cytokine-dependence of ILC subsets is demonstrated on the right-hand side of each 







































































Many multipotent progenitors have been identified that are able to generate ILCs (Fig. 1.15).  
In accordance with their lymphocyte origin, all ILCs develop from CLPs: CLPs isolated from 
the fetal liver and bone marrow being able to generate ILCs in vitro and in vivo [558], [559].  
ILC development then proceeds through a series of progenitors with increasingly restricted 
potential, firstly through the loss of T and B cell developmental potential.  These early innate 
lymphoid progenitors (EILPs) are NFIL3, TCF-1 and TOX dependent [550], [560], [561].  An 
ID2-dependent common helper ILC progenitor (CHILP) then gives rise to all helper ILCs, but 
not NK cells [562]–[564].  While lacking significant expression of GATA-3, T-bet, RORγt or 
RORα, this heterogeneous population includes a subset that express PLZF and PD-1 [559], 
[565].  PLZF+ CHILPs are more differentiated, with GATA-3 expression and an inability to form 
LTis, and are called helper ILC progenitors (ILCP).  Indeed, although classically associated 
with mature ILC2s, GATA-3 expression by ILCPs is necessary for the development of all ILCs 
[566], [567].  In humans, circulating and tissue ILCPs have been identified that are homologous 
to murine ILCPs, and exhibit a poised chromatin landscape with multi-ILC lineage potential 
[568].   
Therefore, although in its relative infancy, ILC developmental programmes are being 
uncovered that demonstrate significant similarity between helper ILC, and identifying NK cells 
and, to a lesser extent, LTis, as developmentally restricted populations from other ILCs. 
1.9.4. ILC3s in the GI tract 
The GI tract represents one of the major sites of ILC colonisation, with a particular abundance 
and functional significance attributed to ILC3s, which will be the major subject of discussion 
here (Fig. 1.16) [569].   
1.9.4.1. ILC3s in epithelial barrier integrity 
Through their production of IL-22, ILC3s play a critical role in the reinforcement of the intestinal 
epithelial barrier.  This is required for protection against the dissemination of opportunistic 
commensal species and pathogens, and has been well described in the literature.   
Early studies demonstrated that C. rodentium infection induced innate intestinal IL-22 
production that was dependent on IL-23 and the microbiota [285], [287].  Although initially 
ascribed to DCs, RORγt-dependent ILC3s were later identified as the predominant source of 
IL-23-induced IL-22 in both mice and humans [292], [552], [570]–[572]. 
IL-22R signalling induces STAT3 activation in IECs, driving the production of Reg family anti-
microbial peptides and mucus that regulate microbial invasion [512], [545], [573], [574].  IL-22 
and lymphotoxin-dependent IEC fucosylation was also shown to be required for protection 
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against Salmonella typhimurium infection [575].  Hanash and others have demonstrated roles 
for IL-22 in the protection and turnover of intestinal Lgr5+ stem cells in several models of 
epithelial damage and in organoid systems [576]–[579].  ILC3s are maintained in close 
proximity to the epithelium via a CXCL16/CXCR6 axis, whereby gut-resident CX3CR1+ MNPs 
secrete this chemokine in response to microbial stimulation [580].  Therefore, the ILC3s are 
well placed to effect widespread control over the intestinal epithelium through secretion of IL-
22. 
In addition to the well-described roles of IL-23 and IL-1β in the activation of ILC3s, several 
other stimuli have been uncovered that regulate IL-22 production.  Systemic LPS 
administration was shown to promote PGE2 production and the activation of intestinal IL-22 
production via PTGER4 signalling on ILC3s [544].  Furthermore, other MNP-derived cytokines, 
such as TL1A [291], and CD1d-mediated cross-talk with invariant NK T cells have also been 
shown to promote IL-22 production by these cells [581].  Finally, glial cell-derived neurotrophic 
factor receptor, produced in response to TLR and alarmin stimulation, could induce IL-22 and 
promote protection against DSS-induced inflammation, highlighting a neuroimmune feature of 
ILC3 functional regulation [582]. 
Given its largely beneficial roles, a promising avenue in IBD therapy would be to specifically 
target damaging Th17 immune responses, while maintaining IL-22 production by ILC3s to 
repair damage to the epithelium.  To this end, Wither et al. were able to transiently suppress 
Th17 cells during C. rodentium infection using a RORγt inhibitor, while preserving ILC3 activity.  
This arises due to the differential requirements of these two cell populations for continuous 
RORγt signalling, and resulted in reduced disease severity [289].  
However, care must be taken in extrapolating the effects of IL-22, as not all functions of ILC3s 
on the intestinal epithelial barrier are beneficial to the host.  IL-22 was recently demonstrated 
to induce IL-18 production by IECs directly, which, while protective in C. rodentium infection, 
resulted in enhanced IFNγ-driven pathology following T. gondii challenge [583].  In addition to 
the well-documented roles of IL-22, ILC3s are also a source of IL-17A [552]. ILC-derived IL-
17A exacerbated intestinal cancer progression in response to hyperactivated IL-23R signalling, 
although IL-17A alone was not sufficient for tumorigenesis [584].  
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Figure 1.16.  Functions of ILC3s within the GI tract.  Via their production of IL-22, IL-17A, 
and GM-CSF, ILC3s potentially can influence immune responses in epithelial cells and 
macrophages.  Furthermore, via expression of MHC-II, ILC3s can induce anergy and apoptosis 
or activation of CD4+ T cells, depending on co-expression of CD80 and CD86. 
 
1.9.4.2. ILC3s in anti-microbial immunity 
The roles of ILC3s in regulating anti-microbial immunity have received relatively little attention 
compared to effects on the epithelium.  However, emerging data suggests that ILC3s play 
critical roles in the coordination of immune cells at mucosal sites. 
A recent study by Xiong et al. demonstrated that monocyte-derived TNF promoted ILC3 
recruitment to the lung following Klebsiella pneumoniae infection.  This initiated a positive 
feedback loop that resulted in IL-17A-mediated enhancement of monocyte anti-microbial 
immunity [585].  Whether these observations translate to the intestine is yet to be seen, but 
directly implicates ILC3s in the regulation of macrophage biology. 
ILC3s are also an important source of GM-CSF, a key regulator of tissue immunity.  In 

































granulocyte recruitment to the inflamed LI LP in anti-CD40 and H. hepaticus models of colitis 
[297], [586]. 
Given studies demonstrating the role of GM-CSF in regulating macrophage glycolysis and 
cytokine production, ILC3s could directly regulate intestinal macrophage anti-microbial 
capacity and inflammatory phenotype via regulation of cellular metabolism.  However, this 
remains to be investigated in vivo.  
1.9.4.3. ILC3s in tolerance 
In addition to their roles in cytokine production, ILC3s have also been demonstrated to induce 
anergy and apoptosis in intestinal anti-commensal CD4+ T cells via their expression of MHC-
II in the absence of co-stimulatory molecules [554], [587].  This effect seems to be largely 
restricted to LN-resident LTi cells, which are well-placed in the T cell paracortex to influence T 
cell responses [588], although MHC-II expression is widespread amongst ILCs in different 
tissues.  In contrast, splenic and lung ILC subsets have been show to induce T cell division in 
model antigen systems [543], [589]. 
As well as via MHC-II, ILCs have also been shown to express other inhibitory molecules in 
vivo, such as PD-L1 [590], a co-inhibitory molecule known to have key roles in the inhibition of 
Tfh and GC responses [591], and CTLA4, a CD28-binding CD80/86 antagonist [360]. 
Seminal studies by Mortha et al. demonstrated that microbiota- and IL-1β-dependent ILC3 GM-
CSF production was critical for the maintenance of tolerogenic DCs with in the GI tract [506].  
Supporting the idea of macrophage-ILC crosstalk, IL-1β production was itself dependent on 
GM-CSF production.   
1.9.4.4. ILC3 regulation within the GI tract 
Intestinal ILC3s are heavily dependent on external signals for their survival and activation in 
the GI tract.  These are derived from other tissue-resident immune cells, such as macrophages, 
but also from external ligands.   
One ligand-dependent TF required for ILC3 biology is AHR.  AHR binds directly to exogenous 
ligands, such as the pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and dietary ligands 
from the Brassicaceae family of vegetables, and endogenous ligands, such as 6-
formylindolo[3,2-b] carbazole (FICZ).  Inactive cytosolic AHR is part of a complex with 90-kDa 
heat shock protein (HSP90).  Ligand binding triggers a conformational change that allows AHR 
phosphorylation and its entry into the nucleus, where it interacts with AHR nuclear translocator 
(ARNT) and other co-activators to bind target genes [592]. 
AHR has also been shown to be essential for IL-22 production and ILC3 survival [288], [548], 
with AHR deficiency severely impairing, and exogenous administration of AHR ligands 
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promoting, ILC3 maintenance and activity in the GI tract.  AHR is proposed to drive Notch 
signalling in ILC3s, key to ILC3 development, as well as synergising with RORγt to drive 
expression from the Il22 locus [288], [593].  In the absence of AHR, reduced IL-22 expression 
allows for the expansion of SFB and the induction of pathogenic Th17 cells [594].    
Vitamin A and its metabolite RtA have been shown to have critical roles in intestinal ILC3 
biology.  LP-resident ILC3s were shown to be severely compromised in number and IL-22-
producing capacity in the absence of vitamin A, resulting in enhanced susceptibility to C. 
rodentium infection [569], [595].  As well as development and maintenance, RtA has been 
suggested to promote ILC3 migration to the gut via induction of CCR9 expression [596].  
However, these studies were conducted largely on in vitro-generated ILC3s from progenitors 
in the spleen. 
1.9.5. ILC plasticity 
Rather than representing terminally-differentiated subsets, it is increasingly clear the ILCs 
exhibit remarkable plasticity, allowing for their adaptation to the needs of the tissue 
microenvironment.  ILC1s accumulate at inflamed mucosal sites [597].  While migration of ILCs 
has been suggested in certain circumstances [588], [598], parabiosis experiments have 
demonstrated that ILC migration is not commonplace [599].  Therefore, ILC subset expansion 
is at least partially driven by reprogramming of tissue-resident ILCs in situ. 
Within the GI tract, RORγt+ ILC3s can lose RORγt expression and induce IFNγ production in 
response to IL-12 and IL-15 (so-called ex-ILC3s) [600].  CD-associated CD14+ MNPs promote 
polarisation of human ILC3s to ILC1s via their production of IL-12, while IL-1β, IL-2, IL-23, and 
RA induced the reconversion of ex-ILC3s (RORγt- IFNγ+) back into RORγt+ ILC3s capable of 
producing IL-22 [601].  IL-2 and AHR signalling have also been implicated in promoting the 
transition to ILC1s and ILC3s, respectively [357], [602]. 
Similarly, within the lung, IFNγ-producing ILC1s arise from ILC2s in an IL-12-dependent 
manner in severe chronic obstructive pulmonary disease.  This effect could be reversed by 
eosinophil-derived IL-4 [603].  A separate study demonstrated that IL-1β could also drive an 
ILC2-to-ILC1 transition by upregulating IL-12Rβ2 and T-bet expression [604].  However, the 
mechanistic underpinning of ILC plasticity is still largely unknown.  In this regard, insights from 
Th plasticity may inform our understanding, given the similarities between these two classes 
of cells. 
Balanced STAT3 and STAT5 signalling seems to control the emergence of T cell subsets.  
STAT3 phosphorylation is induced downstream of IL-23, IL-6 and IL-21 receptors, promoting 
Th17 differentiation in vitro and in vivo.  In contrast, IL-2-mediated STAT5 phosphorylation 
favours the emergence of Th1 cells.  STAT3 signalling was shown to be necessary for IL-22 
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and IL-17A production by intestinal CD4+ T cells and the control of C. rodentium infection [605].  
This TF targets several Th17-associated genes, including Il17a, Ahr, and Rorc, and is required 
for the development of T cell-dependent colitis [606].  In contrast, STAT5 signalling promotes 
Th1 development via the induction of IL-12Rβ2 and T-bet expression [607].  Furthermore, IL-
2 actively inhibits Th17 development via the suppression of IL-6 signalling and interference 
with STAT3 binding to target genes [608].  
Veldhoen et al. demonstrated that AHR promotes Th17 differentiation by limiting the activation 
of STAT5 and the effects of IL-2 [609].  Furthermore, STAT3 and AHR cooperate to regulate 
the chromatin landscape of Th17 cells via the induction of Aiolos (encoded by the IKZF3 gene), 
an epigenetic modifier that silences the Il2 locus [610].  Therefore, the ILC3 defects in Ahr-
deficient mice may result from altered ILC3 maintenance within tissues and augmented 
transition to alternative ILC states. 
Together, these observations support the hypothesis that IL-23R, AHR, and STAT3 signalling 
contribute to the maintenance of ILC3s via the suppression of ILC1 differentiation programs, 
inhibition of IL-2 signalling, and the induction of epigenetic modifiers and type 17-associated 
genes, such as RORC. 
1.9.6. FcγRs and ILCs 
Several lines of evidence suggest that FcγR signalling may regulate ILC function, either directly 
or indirectly.  However, how IgG regulates ILC biology in vitro and in vivo is not known. 
Firstly, several studies support the hypothesis that FcγR signalling on MNPs may drive ILC3 
activation through the production of type 17-inducing cytokines, such as IL-1β and TL1A [74], 
[430], [611], [612].  Secondly, FcγRIII on murine ILC3s has been suggested in transcriptomics 
analyses and ILC3-like cell lines [613], [614].  Finally, the close relationship to NK cells, which 
are known to express activating FcγRs in both mice and humans, suggests that FcγR 
expression may be a function shared between cytotoxic and helper ILC subsets. 
However, no functional significance to date has been ascribed to these observations and 






1.10. Hypotheses and aims of PhD 
The research pursued over the course of this PhD has resulted in three independent areas of 
interest.  The hypotheses and aims governing these sections will be discussed in turn, as 
presented in the subsequent results chapters.  Nonetheless, all chapters share conceptual and 
experimental relevance, which should be taken into account. 
1.10.1. The role of anti-commensal IgG and Fcγ receptors in IBD 
Hypotheses: 
1. An anti-commensal IgG response is induced in IBD 
2. This mucosal IgG engages FcγRs on local and recruited immune cells 
3. FcγR signalling on intestinal immune cells drives intestinal inflammation 
The aims of this section of the thesis are to: 
1. Characterise the IgG response in patients with UC and in a murine model of intestinal 
inflammation 
2. Identify major inflammatory networks associated with FcγR signalling in vivo 
3. Identify major FcγR-expressing cells within the GI tract and how FcγR expression 
changes with inflammation 
4. Determine the effect of FcγR cross-linking on intestinal macrophage activation and its 
ability to induce Th17-polarising cytokines 
5. Investigate the contribution of dysregulated macrophage FcγR signalling to the severity 
of intestinal inflammation in a murine model of DSS-induced colitis 
1.10.2. Profiling Fcγ receptor expression and function on innate lymphoid cells 
Hypotheses: 
1. Intestinal ILC3s express FcγRs and IgG IC signalling induces ILC3 activation 
The aims of this section of the thesis are to: 
1. Determine the FcγR expression repertoire of intestinal ILC subsets 
2. Investigate the effect of FcγR cross-linking on canonical FcγR signalling pathways and 
antigen internalisation 
3. Determine the effect of FcγR signalling on the expression of cytokine and antigen 
presentation genes 
4. Profile the effect of FcγR on global expression patterns by RNAseq  
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1.10.3. Innate lymphoid cells in the coordination of intestinal immunity 
Hypotheses: 
1. ILC cross-talk with co-resident intestinal immune cells is critical for intestinal immune 
defence 
The aims of this section of the thesis are to: 
1. Determine the effect of ILC depletion on defence against C. rodentium infection and 
DSS-induced colitis 
2. Profile tissue-resident immune cell activation in the absence of ILCs 
3. Identify key ILC-derived cytokines and chemokines that may regulate immune cell 
activation 
4. Determine the mechanistic role of these mediators in immune cell activation 
5. Determine the effectiveness of targeting ILC-derived inflammatory mediators in 






Mice were maintained in specific pathogen-free conditions at a Home Office-approved facility 
in the UK.  All procedures were conducted in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986. 
2.1.2. Sourcing 
All mouse lines used here are on a C57BL/6 background.  C57BL/6 mice were obtained from 
Jackson Laboratories or from Charles River Laboratories (Margate, UK) and were used as 
controls.  Fcgr2b-deficient mice on a C57BL/6 background were kindly provided by J. Ravetch 
(Rockefeller University) and S. Bolland (US National Institutes of Health, US National Institute 
of Allergy and Infectious Diseases (NIAID)).  M-TG mice and non-transgenic (N-TG) controls 
were bred in-house.  FcγRIIB overexpression was achieved using a construct in which FcγRIIB 
mRNA was placed under the control of the CD68 promoter [205].  RORγt-eGFP mice were 
kindly provided by D. Littman (New York University School of Medicine, USA).  Rag2-deficient 
mice were kindly provided by Alex Betz (MRC Laboratory of Molecular Biology, UK). 
2.1.3. Genotyping 
Mice were identified and genotyped using ear punch biopsies.  For genotyping, tissue was 
digested overnight at 55°C using DirectPCR (Tail) lysis reagent (Viagen) containing 0.3 mg/ml 
proteinase K (Sigma-Aldrich).  Samples were then heat-inactivated at 86°C for 1 h.  Digested 
samples were subjected to a touchdown polymerase chain reaction (PCR), as outlined in Table 
2.1, using MyTaq reagent (Bioline) and the primers listed in Table 2.2 (Sigma-Aldrich).  
Samples were subsequently mixed with Orange G DNA loading buffer (BioVision) and run on 
a 1.5 % agarose gel (1.5 g agarose (BioGene) in 100 ml Tris/Borate/ 
ethylenediaminetetraacetic acid (EDTA) buffer (distilled H2O containing 1.08 % wt/vol Tris, 
0.55 % wt/vol boric acid, 2 mM EDTA) containing SYBR Safe (Thermo Fisher Scientific) 






Table 2.1.  Genotyping touchdown PCR protocol. 
Step Temperature (°C) Time (min) Notes 
1 95 3  
2 95 0.5 Repeat steps 2-4 29 more times, 
decreasing from 60°C by 0.5°C per cycle 3 60 0.5 
4 72 0.5 
5 95 0.5 Repeat steps 5-7 29 more times 
6 45 0.5 
7 72 0.5 
8 72 7  
9 12 Infinity  
 
 
Table 2.2.  Genotyping primers. 
Strain Primer Sequence (5’ to 3’) 
FcγRIIB-KO Forward 1 CTCGTGCTTTACGGTATCGCC 
 Forward 2 AAACTCGACCCCCCGTGGATC 
 Reverse TTGACTGTGGCCTTAAACGTG 
M-TG Forward TTCTCGCCTCTGTGCCTGACA 
 Reverse CAGCCCTCTCTTGGAAAGGAGC 
 
2.2. In vivo procedures 
2.2.1. Induction of experimental DSS-induced colitis 
For all in vivo colitis experiments, 6 to 12-week old sex-matched mice were used. For all M-
TG and Rag2 knock-out colitis experiments, sex-matched littermate controls were used. 
FcγRIIB-deficient mice were matched with littermate controls (Fcgr2b+/+ and Fcgr2b-/- mice 
from two Fcgr2b+/- breeders) or C57BL/6 mice obtained from Jackson Laboratories and 
maintained in-house.  In cases where non-littermate controls were used, mice were co-housed 
for at least 3 weeks prior to the induction of DSS to minimise cage effects. 
Acute colitis was induced by administration of 2 % wt/vol 36,000-50,000 molecular weight DSS 
(MP Biomedicals) as drinking water for 7 days.  Colitis severity was monitored daily through 
changes in body weight, stool consistency, and intestinal haemorrhage, with a scoring system 
for clinical severity devised as outlined in Table 2.3.  Moderate severity limits were imposed, 





Table 2.3.  Clinical scoring system. 
Weight loss (%) Stool consistency Intestinal haemorrhage 
Observation Score Observation Score Observation Score 
<0 1 Normal 0 No bleeding 0 
0-5 2 Loose 1 Positive hemoccult 1 
5-10 3 Watery diarrhoea 2 Slight visible 
bleeding 
2 
10-15 4  Substantial bleeding 3 
15-20 5 Gross bleeding 4 
>20 6 
 
Chronic colitis was induced by subsequent re-administration of 2 % wt/vol DSS for a further 6-
7 days after a recovery period of two weeks following the first course of DSS treatment. 
At experimental endpoints, the small and large intestines, spleen, MLNs and blood were 
harvested from all mice and colitis severity further assessed through morphological changes 
in key organs.  The spleen, MLNs, and colon were weighed to monitor enlargement, and colon 
length measured from cecum to rectum to determine shortening.  The tissues were then 
processed for histology, RNA extraction, or flow cytometric analysis. 
2.2.2. Citrobacter rodentium infection (with Simon Clare) 
Rag2-KO mice were orally infected with 200 μl of C. rodentium ICC180 (109 colony forming 
units (CFUs)).  At day 7, mice were sacrificed and colon processed for flow cytometry and RNA 
analysis.  Caecum, liver, and spleen were homogenised and bacterial burden assessed by 
serial dilution and plating onto agar plates.  CFUs were determined after overnight incubation 
at 37°C.  
2.2.3. In vivo antibody dosing 
For in vivo antibody administration, all dosing was via intraperitoneal injection in a final volume 
of 200 μl PBS.  All antibodies, except anti-IL-1R1 IgG, were administered on day 0 and day 3 
of a 7-day protocol in the quantities listed in Table 2.4.  Anti-IL-1R1 IgG was administered on 
day 0 and day 7 of a 15-day DSS protocol. 
 
Table 2.4.  In vivo dosing monoclonal antibodies 
Antibody Clone Company Dose (mg) 
InVivoMAb anti-CD90.2 IgG 30H12 BioXCell 0.25 
InVivoMAb anti-KHL IgG LTF-2 2BScientific 0.25 
Anti-Escherichia coli IgG - Abcam 0.5 
InVivoMAb anti-IL-1R1 (CD121a) IgG  JAMA-147 BioXCell 1 




2.2.4.1. Terminal cardiac bleeds 
Exsanguination was carried out by direct puncture of the left atrium using a 26-gauge needle 
(BD Microlance) and 1 ml syringe (Terumo) following CO2-induced euthanasia. 
2.2.4.2. Tail-vein bleeds 
Mice were placed in a 40°C heat-box for 10 min to induce dilation of the tail vein.  Mice were 
restrained and exsanguination of the tail vein carried out using a U-100 insulin syringe (Braun). 
2.2.5. Euthanasia 
At experimental endpoints, or when exceeding severity limits, murine euthanasia was carried 
out by a two-step process, in accordance with local regulations.  This was a combination of 
rising CO2 concentration, cervical dislocation, exsanguination, or the onset of rigor mortis. 
2.3. Tissue sample preparation 
2.3.1. Spleen 
Splenic single cell suspensions were obtained by forcing the tissues through a 70 μm cell 
strainer with ice-cold PBS.  The resulting suspension was incubated with red blood cell (RBC) 
lysis buffer (distilled H2O containing 0.83 % wt/vol ammonium chloride, 0.1 % wt/vol sodium 
hydrogen carbonate, 100 μM EDTA) for 1 min before washing twice in ice-cold PBS.   
2.3.2. Lymph nodes 
MLNs were cleaned of any residual fat and digested for 20 min at room temperature (PBS, 1 
% fetal calf serum (FCS), 100 μg/ml DNase I (Sigma-Aldrich), 1 mg/ml Collagenase A (Sigma-
Aldrich)).  The remaining tissue was then passed through a 70 μm strainer and washed twice 
with ice-cold PBS. 
2.3.3. Large and small intestine 
Intestines were isolated and the associated fat and luminal contents gently removed.  The 
tissues were subsequently opened longitudinally, cut into small pieces and washed by 
vortexing in ice-cold PBS with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES).  Epithelial cells and intraepithelial lymphocytes were removed by shaking the tissues 
twice in stripping buffer (RMPI-1640 medium, 2 % FCS, 10 mM HEPES, 1 mM dithiothreitol 
(DTT; Sigma-Aldrich), and 5 mM EDTA) at 37˚C for 20 min.  The underlying tissues were then 
digested for 30 min at 37˚C with an enzyme cocktail (0.42 mg/ml Liberase (Sigma-Aldrich) or 
74 
1 mg/ml Collagenase A (Sigma-Aldrich), with 60 ug/ml DNase I (Sigma-Aldrich)) in RPMI-1640 
medium (Sigma-Aldrich), vortexed, and forced through a 70 μm cell strainer to break up any 
remaining tissue.  The remaining intestinal suspensions were resuspended in RPMI-1640 
containing 40 % Percoll (Sigma-Aldrich) and overlaid onto a solution of 80 % Percoll.  Samples 
were then centrifuged at 600 g for 20 min at 10°C.  Lamina propria mononuclear cells (LPMCs) 
were harvested at the 40 %/80 % interface and washed twice in ice-cold PBS containing 3 % 
FCS. 
2.3.4. Blood 
For serum collection, blood was collected in BD Microtainer serum tubes (BD) and incubated 
for 15 min at room temperature.  Samples were then centrifuged at full speed for 10 min in a 
micro-centrifuge (Thermo Fisher Scientific).  Serum was collected as the fluid top layer. 
For analysis of leukocytes in blood, blood was collected in EDTA-coated Microvette tubes 
(Sarstedt) and subjected to RBC lysis prior to processing for flow cytometry, as outlined below. 
2.3.5. Bone marrow 
Bone marrow was flushed from the femur, tibia and humerus of mice using ice-cold sterile PBS 
and the subsequent cell suspension treated with RBC lysis buffer.  Treated cells were then 
washed in ice-cold sterile PBS before proceeding to downstream applications. 
2.3.6. Human ileum 
The collection of human samples occurs under strict guidance from local surgical teams and 
National Health Service Blood and Transplant (NHSBT).  Ethical approval was granted by the 
local ethics committee (National Research Ethics Service East of England committee – 
reference number: 15/EE/0152).  Risk assessments for the handling of human tissue have 
been fulfilled according to local guidelines. 
Human LPMC isolation was carried out in a similar way to murine LPMC isolation.  Ileal 
samples were opened longitudinally and cleaned of luminal contents.  The mucosa was 
manually dissociated from the muscular layers, cut into small pieces and washed by vortexing 
in ice-cold PBS with 10 mM HEPES.  Epithelial cells and intraepithelial lymphocytes were 
removed by incubation in stripping buffer (RMPI-1640 medium, 2% FCS, 10 mM HEPES, 1 
mM DTT, and 5 mM EDTA) at 37˚C for 1 h.  The underlying tissues were then digested for 1 h 
at 37˚C with an enzyme cocktail (0.42 mg/ml Liberase or 1 mg/ml Collagenase A, with 60 ug/ml 
DNase I) in RPMI-1640 medium, vortexed, and mechanically dissociated using a Gentle-
MACS machine (Miltenyi Biotech, Bisley, UK).  Dissociated tissue was then passed through a 
70 μm cell strainer and centrifuged for 10 min at 1300 rpm.  Intestinal tissue suspensions were 
resuspended in RPMI-1640 containing 40 % Percoll (Sigma-Aldrich) and overlaid onto a 
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solution of 80 % Percoll.  Samples were then centrifuged at 600 g for 20 min at 10°C.  LPMCs 
were harvested at the 40 %/80 % interface and washed twice in ice-cold PBS containing 3 % 
FCS before proceeding to downstream applications. 
2.4. Flow cytometry 
2.4.1. Extracellular staining 
For extracellular staining, cells were blocked with 0.5 % heat-inactivated normal mouse serum 
(NMS) for 20 min, followed by extracellular staining for 1 h at 4°C with a combination of the 
antibodies listed in Table 2.5 (murine) and Table 2.6 (human).  All antibodies were used at a 
1:200 dilution.   
Table 2.5.  Murine extracellular staining antibodies 
Antibody Clone Company 
B220 RA3-6B2 eBioscience 
CD3e 145-2C11 eBioscience 
CD4 GK1.5 eBioscience 
CD11b M1/70 eBioscience 
CD11c N418 eBioscience 
CD19 1D3 eBioscience 
CD25 PC61.5 eBioscience 
CD45.2 104 eBioscience 
CD80 16-10A1 eBioscience 
CD86 GL1 eBioscience 
CD90.2 30-H12 eBioscience 
CD117/cKit 2B8 eBioscience 
CD127 A7R34 eBioscience 
CX3CR1 SA011F11 Biolegend 
F4/80 BM8 eBioscience 
FcγRI X54-5/7 Biolegend 
FcγRIIB AT130-2 eBioscience 
FcγRII/III 2.4G2 BD biosciences 
FcγRIII 275003 R&D systems 
FcγRIV Gift from Mark Cragg (Southampton) 
GL7 GL7 eBioscience 
IgA - SouthernBiotech 
IgD 11-26 eBioscience 
IgG - SouthernBiotech 
IgM eB121-15F9 eBioscience 
KLRG1 2F1 eBioscience 
Ly6C HK1.4 eBioscience 
Ly6C/G RB6-8C5 eBioscience 
MHC class II M5/114.15.2 eBioscience 
NK1.1 PK136 eBioscience 
NKp46 29A1.4 BD biosciences 
PD-L1 MIH5 eBioscience 
TCR beta H57-597 eBioscience 
TCR gamma/delta GL3 Biolegend 
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Table 2.6.  Human extracellular staining antibodies 
Antibody Clone Company 
CD14 61D3 eBioscience 
CX3CR1 2A9-1 eBioscience 
FcγRI 10.1 eBioscience 
FcγRIIA/B CD32 eBioscience 
FcγRIIIA/B eBioCB16 eBioscience 
IgA1/2 G20-359 BD biosciences 
IgG HP6017 Biolegend 
 
2.4.2. Viability staining 
Viability staining was then performed with LIVE/DEAD Fixable Aqua Dead Cell Stain kit 
(Thermo Fisher Scientific) for 20 minutes at room temperature.  Following staining, samples 
were run fresh in PBS, stored in fixative (PBS containing 0.02 % wt/vol sodium azide, 2 % 
wt/vol glucose, 0.01 % wt/vol formaldehyde), or subjected to intracellular staining (see below). 
2.4.3. Intracellular staining 
For intracellular TF staining, cell fixation and permeabilisation was carried out using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience).  For intracellular cytokine 
staining, cells were incubated in RPMI-1640 medium containing 10 % FCS and 1X penicillin-
streptomycin (both Sigma-Aldrich, Gillingham, UK), hereafter referred to as complete RPMI 
(cRPMI), for 3 h with 1X Brefeldin A (eBioscience) solution, prior to fixation and 
permeabilisation using the Cytofix/Cytoperm kit (eBioscience).  For intracellular phospho-
staining, cells were fixed using BD Cytofix fixation buffer (BD biosciences) and permeabilised 
using BD Phosflow Perm buffer III (BD biosciences).  All kits were used as per the 
manufacturer’s instructions.  Staining was then carried out for 1 h at room temperature using 
a combination of the antibodies listed in Table 2.7.  All antibodies were used at a 1:100 dilution.  
Table 2.7.  Murine intracellular staining antibodies 
Antibody Clone Company 
FoxP3 FJK-16s eBioscience 
GM-CSF MP1-22E9 eBioscience 
IL-17A TC11-18H10.1 Biolegend 
IL-22 IL22JOP eBioscience 
Ki67 SolA15 eBioscience 
Phospho-ERK 20A BD biosciences 
Phospho-SYK moch1ct eBioscience 
Pro-IL-1β NJTEN3 eBioscience 
RORγt AFKJS-9 eBioscience 
T-bet 4B10 eBioscience 
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For cell counting, 123count eBeads (eBioscience) were added to single cell suspensions prior 
to antibody staining.  Flow cytometry data collection was performed on a Fortessa cytometer 
(BD biosciences). 
2.4.4. Flow sorting strategies 
For ILC3 flow-sorting, small and large intestinal ILC3s were identified as lineage negative 
(CD3e, CD5, CD19, B220, Gr-1, CD11b, CD11c) CD45+ RORγt+ cells using RORγt-eGFP 
reporter mice.  In non-reporter mice, intestinal ILC3s were identified as lineage- CD45+ KLRG1- 
c-Kit+ cells.  Murine intestinal macrophages were sorted as CD11b+ F4/80+ CX3CR1+ cells in 
uninflamed mice, while inflammatory monocytes and mature macrophages were identified as 
CD11b+ CX3CR1+ Ly6Chi MHC-II- and CD11b+ CX3CR1+ Ly6Clo MHC-IIhi cells, respectively, 
in mice following DSS administration.  Human ileal macrophages were flow-sorted as SSCint 
CX3CR1+ CD14+ cells. 
Cell sorting was performed on FACS Aria (BD biosciences), iCyt Synergy (Sony Biotechnology 
Inc.), and MoFlo (Beckman Coulter) cell sorters.  Data were analysed using FlowJo software 
(Tree Star Inc.). 
2.4.5. Microbial flow cytometry 
Flow cytometry of antibody-bound commensal bacteria was carried out as previously 
described [477].  For murine samples, faecal contents were homogenised and briefly 
centrifuged at 1,000 rpm to remove large aggregates, and the resulting supernatant was 
washed twice in sterile PBS by centrifugation for 1 min at 8,000 rpm.  Bacterial pellets were 
resuspended in sterile PBS containing 1:50 dilution of mouse serum or PBS alone in 96-well 
v-bottom plates and incubated for 20 min at 4°C.  For human faecal samples, no serum 
opsonisation step was included.  Bacteria were washed by centrifugation in sterile PBS at 
3,000 rpm for 10 min in a bench-top Sorvall centrifuge.  Bacterial pellets were then 
resuspended in PBS containing anti-mouse/human IgA or anti-mouse/human IgG antibodies 
and stained for 20 min at 4°C.  Cells were washed and resuspended in PBS or fixative 
containing 1:10,000 SYBR Green (Invitrogen) and analysed by flow cytometry.  For murine 
studies, faecal and serum samples were paired from the same mouse.  Only SYBR Green-
high events were analysed. 
Human UC and control faecal samples were previously collected and supplied by Miles Parkes 
(Department of Gastroenterology, Addenbrooke’s hospital, UK).  Sample collection was carried 
out with the appropriate ethical approval.  Human disease severity was determined previously 
by Parkes and colleagues using the Walmsley clinical activity index (CAI).  Patient information, 
including medication regimen, is listed in Table 2.8. 
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1 1 19/04/2015 12 9 days; 
intermediate 
72 - 
2 2 22/04/2015 1 Still active <4 Prednisolone (15 
mg) 
Salofalk (3 g) 



















5 5 06/10/2015 5 Active but 
improving 
None Adcal 
Asacol (2.4 g) 
Prednisolone (35 
mg) 
6 13 09/09/2015 5 Active but 
improving 




2.4.6. Mitochondrial staining 
Mitochondrial staining was carried out using MitoTracker Green FM (MG; Invitrogen).  
Adherent macrophages were incubated for 30 min at 37°C in RPMI containing 1X MitoTracker 
Green FM.  Media was subsequently removed and the cells resuspended in PBS for analysis 
by flow cytometry. 
2.5. In vitro stimulation assays 
2.5.1. Macrophage generation 
BMDMs were generated by incubation of bone marrow cells in cRPMI, and supplemented with 
100 ng/ml murine recombinant M-CSF (Peprotech).  M-CSF-supplemented cRPMI was 
replaced on day 3 and BMDMs were harvested on day 5.  BMDMs were plated at least 4 h 
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prior to stimulation.  In certain experiments, BMDMs were primed with 20 ng/ml murine 
recombinant GM-CSF (Peprotech) for 16 h prior to downstream stimulations. 
2.5.2. Immune complex generation 
Model ICs were generated in two ways.  Insoluble ovalbumin IC (O-IC) was generated by the 
opsonisation of 40 μg/ml endotoxin-free ovalbumin (OVA; Invitrogen) with 1.2-2 mg/ml 
polyclonal rabbit anti-OVA IgG antibody (Sigma-Aldrich) in PBS at 37°C for 1h.  Soluble IC 
was generated by the opsonisation of 60 μg/ml murine IgG (Abcam) with 600 μg/ml goat anti-
mouse IgG Fab (Thermo Fisher Scientific) in PBS at 37°C for 1 h. 
2.5.3. IC stimulation 
Immune cells were stimulated with IC for 4 h for RNA analysis, including RNAseq and 
quantitative PCR (qPCR), 6 h for intracellular cytokine staining, or 16 h for enzyme-linked 
immunosorbent assays (ELISAs) at 37°C in a 5 % CO2 incubator. 
Flow-sorted intestinal ILC3s and MNPs were plated in cRPMI at a density of 5x103-1x105 cells 
per well in 96-well plates prior to stimulation.  LPMC suspensions and BMDMs were plated in 
cRPMI at a density of 5x105-1x106 cells per well prior to stimulation.  Wells were additionally 
supplemented in various experiments with 50 ng/ml IL-23 (Peprotech), 20 ng/ml IL-7 
(Peprotech), 20 ng/ml IL-1β (Peprotech), 100 ng/ml IFNγ (Peprotech), 100 ng/ml TNF 
(Peprotech), and 200 ng/ml TL1A (R&D Systems).  Cells were then washed extensively, and 
analysed by qPCR, ELISA, and flow cytometry. 
2.5.4. Phagocytosis assay 
Flow-sorted ILC3s were incubated at 37°C for 16 h with 10 μg/ml OVA-647 (Thermo Fisher 
Scientific) or O-IC-647 generated as above.  Phagocytosis was assayed by flow cytometry. 
2.6. Immunofluorescence 
Murine spleens, MLNs, PPs, and intestinal tissues were fixed with 1 % paraformaldehyde 
(Electron Microscopy Services) in PBS for 16 h, washed with PBS, and equilibrated in 30 % 
wt/vol sucrose for a further 16 h.  Tissues were then frozen at -80°C in Optimal Cutting 
Temperature embedding medium (Thermo Fisher Scientific).   
Cryostat sections were cut at a thickness of 20-30 μm, air dried for 1 h, then rehydrated for 10 
min in PBS and blocked with a 0.1 M Tris solution containing 1 % vol/vol NMS, 1 % wt/vol BSA, 
and 0.1 % wt/vol Triton X-100 for 1 h at room temperature.  Sections were stained overnight 
at 4°C with a combination of the antibodies listed in Table 2.5 in blocking buffer at a 1/100 
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dilution.  Additionally, actin was stained in certain experiments using Phalloidin dyes (Thermo 
Fisher Scientific) at a 1/100 dilution. 
Confocal imaging was carried out on a Leica SP8 confocal microscope.  Images were analysed 
using Imaris software (Bitplane). 
2.7. RNA analysis 
2.7.1. Extraction and reverse transcription 
RNA extraction was carried out using commercially available kits as per the manufacturer’s 
instructions.  QIAGEN RNeasy micro kits were used for cell numbers below 5 x 105.  PureLink 
mini kits were used for cell numbers over 5x105.  For whole tissue RNA extraction, tissue 
pieces were first disrupted using a Precellys 24 Homogenizer (Bertin Instruments), before 
extraction using the PureLink mini kit.  RNA concentration and purity was determined using a 
NanoDrop spectrophotometer (Thermo Scientific) prior to cDNA synthesis using a High-
Capacity RNA-to-cDNA kit (Applied Biosystems).  
2.7.2. Quantitative polymerase chain reaction  
All qPCR was carried out in triplicate with Taqman reagents and pre-designed TaqMan Gene 
Expression Assay primers and probes (Thermo Fisher Scientific), as listed in Tables 2.9 
(murine) and 2.10. (human).  qPCR was performed on the Viia 7 PCR machine (Life 
Technologies, Paisley, UK).  Gene expression was normalised to Gapdh or Hprt using the 2-
ΔCt method [615].  The 2-ΔΔCt method was used for normalisation between experimental 











Table 2.9.  Murine qPCR primers 


























Table 2.10.  Human qPCR primers 











2.8. Soluble protein assays 
2.8.1. Cytokine and chemokine analysis 
Quantification of cytokines and chemokines in culture supernatants was carried out using 
commercially available R&D systems Duoset ELISA kits, as per the manufacturer’s 
instructions. 
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2.8.2. Serum anti-commensal IgG quantification 
Measurement of anti-commensal IgG titres in murine sera was carried out as previously 
described [587].  Colonic faecal contents were processed as described in Microbial flow 
cytometry.  Bacteria were homogenised using BugBuster (Novagen), centrifuged at 20,000 g 
for 10 min, and the supernatant recovered for a crude commensal bacterial antigen 
preparation.  Protein concentration was determined using the Pierce BCA protein assay kit 
(Thermo Fisher Scientific).  Subsequently, a 96-well Nunc ELISA plate (Thermo Fisher 
Scientific) was coated with 5 μg/ml commensal antigen preparation overnight at 4°C, washed 
extensively, and murine sera incubated in doubling dilutions for 4 h at room temperature.  For 
small volumes of sera, samples were incubated at a 1:150 dilution.  In the case of serum anti-
flagellin IgG detection, 96-well NUNC plates were coated overnight with 200 ng/ml flagellin.  
Commensal antigen-specific IgG was detected using a goat anti-mouse IgG-horseradish 
peroxidase (HRP) conjugated antibody (Thermo Fisher Scientific, 1:10000 dilution), and 
tetramethylbenzidine (TMB) peroxidase substrate (BD biosciences).  After 15-20 min, the 
reaction was quenched with 1 M Na2SO4 and the optical densities measured at 450 nm using 
a plate spectrophotometer. 
2.8.3. Luminal IgG quantification 
Murine colonic luminal contents were extruded using bicarbonate buffer (15 mM Na2CO3, 35 
mM NaHCO3) at point of death.  96-well Nunc ELISA plates (Thermo Fisher Scientific) were 
coated with primary goat anti-murine IgG or goat anti-murine IgA antibodies (catalogue 
numbers 1037-01 and 1040-01, respectively; SouthernBiotech) for 16 h at 4°C.  Plates were 
extensively washed and incubated with luminal suspensions in serial dilutions for 4 h at room 
temperature.  Bound IgG and IgA were detected using secondary goat anti-murine IgG and 
goat anti-murine IgA antibodies conjugated to HRP (catalogue numbers 1037-05 and 1040-
05, respectively; SouthernBiotech) and TMB peroxidase substrate (BD biosciences).  Ig 
concentration was determined using a standard curve of murine IgG (I5381-5mg; Sigma-
Aldrich) or murine IgA (14-4762-81; Thermo Fisher Scientific).  Ig levels were normalised to 
total luminal protein content, as determined using the Pierce BCA protein assay kit (Thermo 
Fisher Scientific).   
2.9. RNAseq and microarray analyses (with John Ferdinand) 
2.9.1. RNAseq 
2.9.1.1. Cell sorting and RNA extraction 
Following O-IC stimulation, approximately 2x104 RORγt+ ILC3s and 1x105 CX3CR1+ 
macrophages per condition were transferred into 750 μl RLT plus buffer (Qiagen).  Sample 
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eppendorfs were immediately vortexed, snap frozen on dry ice and stored at -80°C.  RNA was 
extracted from cell lysates using the RNeasy plus micro kit (Qiagen) as per the manufacturer’s 
instructions.  Optimal DNA depletion columns were used to remove contaminating genomic 
DNA.  Purified RNA was eluted in nuclease free water (Ambion) and stored at -80°C. 
2.9.1.2. RNA quality control 
Quality and concentration of the purified RNA was assessed using an RNA pico chip (Applied 
Biosystems) using a Bioanalyzer 2000 (Applied Biosystems) as per the manufacturer’s 
instructions.  For all RNAseq experiments, samples had an RNA integrity number greater than 
8, indicating minimal degradation of the RNA. 
2.9.1.3. Library preparation and QC 
For the preparation of libraries, SMARTer stranded total RNA-Seq mammalian pico input kit 
(Takara) was used as per the manufacturer’s instructions.  To produce the libraries, 1.5-3.55 
ng of total RNA was used and libraries were amplified for 14 cycles of PCR.  Library size was 
assessed using 1 μl of undiluted final libraries with a High Sensitivity DNA chip (Applied 
Biosystems) using a Bioanalyzer 2000 (Applied Biosystems) as per the manufacturer’s 
instructions.  Library concentration was quantified by PCR using 1/10000 dilution of the library 
in nuclease free water (Ambion) with ROX low KAPPA library quantification kit (KAPPA 
Biosystems).  Libraries were pooled at an equimolar concentration with up to 12 libraries per 
pool. 
2.9.1.4. Sequencing 
Sequencing of the libraries was carried out using a Hiseq 2500 (Illumina) on a 2x100bp 
sequencing run with 1 pool per flow cell lane.  Sequencing was carried out at Genewiz (NJ, 
USA). 
2.9.1.5. Analysis 
Pooled libraries were de-multiplexed by Genewiz using Casava (Illumina) before transfer of 
the data to the University of Cambridge.  Fastq files were trimmed of the first 3 nucleotides of 
the R1 strand and also to remove contaminating adaptor sequences and poor-quality bases 
(bases with a phred 33 score of <30) using trimgalore! (Babraham bioinformatics) and quality 
of the resulting files was assessed using FastQC (Babraham bioinformatics).  Fastq files were 
aligned to the mm10 genome (Downloaded from https://genome-euro.ucsc.edu/cgi-
bin/hgGateway?db=mm10&redirect=manual&source=genome.ucsc.edu on 18th January 
2016) using hisat2.  All analysis was carried out using R version 3.2.4.  Reads were counted 
and assigned to genes using the Featurecount function from the RSubread package.  
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Differential expression analysis was carried out using DESeq2 using a linear model with an 
appropriate design matrix following the default workflow.  Resulting figures were plotted using 
ggplot2 and heatmap.2 from the gplots package.  Gene-set enrichment analysis (GSEA) was 
performed for RNAseq data by first assigning a rank metric to each gene using the following 
formula: 
Rank metric = 1(P value + 1x10-300)*(|LFC|/LFC) 
GSEA was then run using GSEA 2.1 using the pre-ranked option with the classic setting 
against gene sets from the Molecular Signature Database (MSigDB; 
http://software.broadinstitute.org/gsea/msigdb).  FcγR gene sets are listed in Table S1, 
Appendix. 
STRING analysis was run using the online GUI using the multiple protein entry and the high 
confidence (score > 0.7) setting. 
2.9.2. Microarray 
Publicly available microarray datasets were downloaded from GEO 
(https://www.ncbi.nlm.nih.gov/geo/) along with appropriate chip annotation data.  All analyses 
were carried out using R.  All datasets were downloaded as raw intensity matrices.  Data was 
normalised using RMA.  Probes were reduced to one probe per gene by selecting the probe 
with the greatest variance across the samples using the gene filter package.  Differential 
expression was varied out using limma with an appropriate design matrix.  Graphics were 
produced using the same programmes as for the RNAseq analysis above. 
Listed in Table 2.11 are the publicly-available transcriptomic datasets that were used 










Table 2.11.  GEO transcriptomics datasets 
Accession 
number 
Dataset Additional information 
GSE9452 Endoscopic pinch biopsies from the 
descending colon of ulcerative colitis 
patients and control subjects. 
8 UC samples with macroscopic 
signs of inflammation.  13 UC 
samples without macroscopic signs 
of inflammation.  5 control subjects. 
GSE38713 Endoscopic pinch biopsies from UC 
patients with histologically active UC 
and inactive UC, as well as non-
inflammatory controls.  Sample ages 
ranged from 18-65. 
Active UC defined as Mayo sub 
score ≥ 2 and Matts ≥ 3.  Inactive UC 
defined as Mayo sub score = 0 and 
Matts ≤ 2 and a remission state for a 
minimum for 5 months prior to and 6 
months post-collection.  Uninvolved 
mucosa from patients with active UC 
defined as normal endoscopic and 
histological appearance and 
absence of evidence of previous 
disease.  15 involved active UC; 7 
non-involved active UC; 8 inactive 
UC; 13 healthy controls. 
GSE12251 Endoscopic pinch biopsies from 22 
clinically active UC patients prior to 
infliximab treatment.  Patients 
subsequently stratified on successful 
response. 
Response to infliximab defined as 
endoscopic and histological healing 
at week 8.  12 responders and 10 
non-responders. 
GSE42768 Total RNA from snap-frozen colon 
from mice with acute or chronic 
relapsing colonic inflammation 
induced using several cycles of 
exposure to DSS in drinking water. 
Data analysed from H2O-treated 
healthy controls (n = 5) and mice 
after 1 or 2 cycles of DSS with an 
intervening period of 2 weeks (n = 5 
in each case). 
GSE37448 Gene-expression microarray datasets 
generated as part of the 
Immunological Genome Project. 
 
GSE71253 RNA extracted from human CD14 
monocytes cultured in RPMI and 10 % 
FCS supplemented with either GM-
CSF or M-CSF for 7 days. 
 
GSE42101 RNA from flow-sorted colonic lamina 
propria mononuclear phagocyte 




2.9.3. Hierarchical clustering 
R and the built-in stats package were used for all calculations.  Plots were generated using the 
package dendextend.  For clustering analysis, the RMA normalised intensity for the genes of 
interest (all cytokines (Table S1, Appendix) plus FCGR2A) were selected and a distance matrix 
calculated using Euclidean distance using the function “dist”.  The samples were subsequently 
hierarchically clustered using the function “hclust” using the complete method.  To define 
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clusters, the tree was cut into k clusters at a given height based on visual interpretation of the 
dendrogram (typically k=4/5). The cluster containing FCGR2A was examined further. 
2.10. Statistics 
Statistical analysis was performed using GraphPad Prism software for most experiments.   For 
in vivo colitis experiments, comparison between experimental groups was performed using a 
nonparametric Mann-Whitney test.  A parametric Student’s t test was used for in vitro 
stimulation experiments, unless paired samples were used, where a ratio paired t test was 
used.  For correlations of RNA expression levels, linear regression analysis was used.  For 
bioinformatics analyses, P values were calculated using the standard DESeq 2 method with 
multiple correction using BH.   * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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3. IgG and FcγR signalling in intestinal inflammation 
3.1. Introduction and hypotheses 
IBD is a chronic, relapsing condition that is increasing in prevalence worldwide and causes 
considerable morbidity.  There are two main subtypes, CD and UC, that differ in their clinical 
and pathological presentations, but are both thought to be driven by a predisposition to 
aberrant immune responses to commensal microbes [234].  IBD is associated with the 
production of numerous pro-inflammatory cytokines, including TNFα, and GWA studies have 
identified polymorphisms in the Th17 pathway as a major risk factor in both UC and CD [154], 
[262].  Blockade of IL-12p40 (a common subunit in IL-12 and IL-23) imparts a degree of 
protection in patients with infliximab-refractory disease, demonstrating a pathogenic role for 
this pathway in IBD, while elevated IL-1β levels are associated with severe infliximab-refractory 
IBD [334], [364], [365]. 
One of the strongest non-HLA associations with UC is a SNP in FCGR2A, a human activating 
FcγR found on a variety of immune cells, including macrophages, DCs, and neutrophils [64], 
[154], [156].  This SNP (rs1801274) encodes a histidine-to-arginine (H/R) substitution within 
the IgG-binding domain of FcγRIIA (FcγRIIA-R131) that results in reduced receptor affinity for 
IgG, and confers significant protection against the onset of UC.  This supports the hypothesis 
that IgG plays a pathogenic role in IBD.  Recent studies have demonstrated that anti-
commensal IgG generation is a normal function of the adult immune system, with roles in 
maternally-derived immunity in the foetus, immune cell development, and the protection from 
systemic pathogen challenge [477], [479], [616].  However, seminal work by Per Brandtzaeg, 
and later Blumberg and colleagues, has demonstrated that anti-commensal IgG antibodies are 
significantly increased in IBD and can drive intestinal inflammation in murine models of colitis 
[427], [482].  Indeed, IgG-producing gut plasma cells are found within the inflamed mucosa of 
patients with both UC and CD [430].  Furthermore, the nature of IBD-associated IgG is different 
from healthy individuals, including alterations in the IgG glycome [127].  However, cellular 
mechanistic insights into the pathogenic role of IgG in colitis are lacking. 
A link has been established between FcγR signaling in vitro and in vivo with the induction of 
IL-1β and subsequent induction of Th17 immune responses, raising the possibility that FcγR 
signaling may contribute to a major IBD susceptibility pathway [74], [75], [183].  We therefore 
hypothesized that FcγR signaling may contribute to intestinal inflammation via activation of 
mucosal Th17 immunity. 
3.2. IgG within the gastrointestinal tract 
To first address the concept of IgG as a local mediator of inflammation in the GI tract, analysis 
of transcriptomic datasets was carried out.  Biopsies taken from the descending colon of UC 
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patients demonstrated an enrichment of IGHG1 transcripts, as well as those for IGHM and 
IGHD, relative to healthy controls (HCs) (Fig. 3.1A).  In contrast, IGHA1 transcript levels were 
unchanged, resulting in an increase in the IGHG1/IGHA1 ratio following the onset of 
inflammation (Fig. 3.1B).  IgG1 is predominantly induced in response to protein antigens, 
exhibits high FcγRIIA binding relative to other IgG subclasses, and an ability to activate 
complement.  Therefore, IBD is associated with the emergence of inflammatory IgG 
subclasses. 
 
Figure 3.1. Transcriptomics analysis of IGH gene transcripts in human ulcerative colitis.  
(A) Heatmap showing transcriptomics analysis of human immunoglobulin heavy chain gene 
transcripts in colonic biopsies from UC patients and HCs. Data was derived from GEO dataset 
GSE9452.  (B)  The ratio of IGHG1 to IGHA gene transcripts in UC patients and HCs; values 
derived from A.  P values were calculated using limma with multiple correction using BH.  *** 
P < 0.001. 
 
In order to determine whether this increase in local IGHG1 transcript levels reflects an increase 
in local anti-commensal IgG, flow cytometry was used to detect binding of antibodies directly 
to luminal bacteria (Fig. 3.2).  Bacteria were identified as SYBR greenhi events, as previously 
described [477] (Fig. 3.2A).  As expected, IgA1/2-bound bacteria were prevalent in healthy 
individuals, with little IgG binding, consistent with the role of IgA in homeostasis.  In contrast, 
patients with UC exhibited a marked increase in IgG-bound bacteria within the lumen, 
demonstrating the induction of a potent anti-commensal IgG response in these patients (Fig. 
3.2A).  Interestingly, there was little change in bacteria-bound IgA1/2 levels in UC patients 
versus HHCs.  Furthermore, the extent of IgG-bound bacteria reflected disease severity: UC 
patients with a Walmsley CAI greater than 10 had the greatest levels of IgG-bound bacteria 
































IBD is characterised by the increase in serum anti-commensal IgG antibodies.  To examine 
this in a murine model of intestinal inflammation, we administered mice with DSS ad libitum, a 
chemical colitogen that causes osmotic epithelial damage within the colon.  Mice developed 
de novo anti-commensal (Fig. 3.3A) and anti-flagellin (Fig. 3.3B) IgG serum antibodies, the 




Figure 3.2. Enhanced anti-commensal IgG in human UC.  (A) Microbial flow cytometry 
showing IgG and IgA1/2-bound SYBR greenhi bacteria in UC patients and healthy household 
controls (HHCs); analysed as pairs.  (B) IgG and IgA1/2-bound bacteria quantification stratified 
based on the Walmsley CAI. HHC, n = 6; CAI 1-10, n = 4; CAI > 10, n = 2.  Data was pooled 
from two independent experiments.  P values were calculated using a ratio-paired t test (A) 
and the nonparametric Mann-Whitney test (B).  ** P < 0.01. 
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Figure 3.3. Serum anti-commensal IgG ELISA.  (A and B) ELISAs showing de novo anti-
commensal (A) and anti-flagellin (B) IgG generation following an acute course of DSS 
administration.  n = 6.  Data are representative of three independent experiments.  P values 





Figure 3.4. Enhanced luminal antibody levels following chronic DSS-induced colitis.  (A) 
ELISA showing IgG and IgA standard curves for quantification of luminal protein levels.  (B) 
BSA standard curve for quantification of total luminal protein content.  (C) Luminal protein 
quantification in healthy mice treated with H2O or following chronic DSS administration (cDSS).  
(D) Luminal IgG and IgA protein levels normalised to total protein in healthy mice and inflamed 
mice following cDSS.  (E) IgG to IgA ratio based on ELISA readings.  Data are representative 
of two independent experiments.  P values were calculated using the nonparametric Mann-
Whitney test.  * P < 0.05; ** P < 0.01. 
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Luminal antibody levels were measured in gut washes from uninflamed and DSS-inflamed 
colons.  Serial dilutions of luminal samples were compared to standard curves of recombinant 
murine IgG and IgA (Fig. 3.4A), and normalised to total protein content using a BSA standard 
curve (Fig. 3.4B).  Total luminal protein content was largely similar between groups (Fig. 3.4C).  
However, while total IgG made up a small fraction of protein in uninflamed controls, this was 
significantly increased in the lumen of mice following a chronic course of DSS-induced colitis 
(Fig. 3.4D).  Furthermore, a significant enrichment of IgA protein was also detected.  Notably, 
however, the IgG/IgA ratio was increased during inflammation (Fig. 3.4E), mirroring the 
observation made in human IBD. 
To determine whether this luminal increase in IgG reflected a directed anti-commensal 
response, a microbial flow cytometry assay was once again used.  IgA binding was significant 
during homeostasis, with little change upon pre-incubation with paired serum (Fig. 3.5).  IgG+ 
bacteria were low under these conditions.  However, incubation with paired serum resulted in 
a significant increase in IgG-bound commensal bacteria, in agreement with previous studies 
[477].  Following the onset of inflammation, IgG+ bacteria were significantly increased within 
the lumen of mice, while no change was detected for IgA binding.  Furthermore, pre-incubation 
with paired serum resulted in a more marked increase in IgG+ bacteria compared to uninflamed 
mice, suggesting de novo anti-commensal IgG generation during colitis. 
 
 
Figure 3.5.  Enhanced IgG-bound commensal bacteria following chronic murine 
intestinal inflammation.  (A) Microbial flow cytometry showing IgG and IgA-bound luminal 
SYBR greenhi commensal bacteria in uninflamed (H2O) and inflamed murine colons following 
7-day DSS administration.  Grey = isotype control; black = non-serum-opsonised bacteria; red 
= serum-opsonised bacteria.  (B) Quantification of microbial flow cytometry staining shown in 
A.  Data are representative of two independent experiments.  P values calculated using the 
nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01. 
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These results demonstrate that, while IgA is the dominant antibody isotype under homeostatic 
conditions in both humans and mice, there is a significant increase in de novo-generated anti-
commensal IgG following the onset of intestinal inflammation.  Furthermore, IgA levels do not 
significantly change, suggesting a skew towards the pro-inflammatory IgG isotypes during 
colitis. 
3.3. Profiling intestinal B cell populations in intestinal inflammation 
Given the increase in local IgG, we hypothesised that this was reflective of an increase in local 
IgG+ B cells within the inflamed LP. 
 
 
Figure 3.6.  B cell infiltration characterises chronic intestinal inflammation.  (A) Flow 
cytometry gating strategy for identification of class-switched B cells within the colonic lamina 
propria in uninflamed and cDSS-inflamed mice.  (B) Quantification of total B cells (far left), IgD-
negative B cells (middle-left), IgG-positive B cells (middle-right), and IgA-positive B cells (far 
right) in frequency and absolute number, as shown in A.  (C) tSNE analysis of lymphocytes 
within the inflamed colonic lamina propria.  (D) Quantification of adaptive lymphocytes 21 days 
following an acute course of DSS.  Data are representative of two independent experiments.  
P values were calculated using the nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01. 
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Analysis of LP-resident B cell populations was carried out by flow cytometry.  In contrast to 
uninflamed murine controls, there was a significant influx of CD19+ B220+ B cells into the LP 
following chronic DSS-induced colitis (Fig. 3.6A, B).  Furthermore, a greater proportion of the 
infiltrating B cells were IgD- (Fig. 3.6A, B).  While IgA+ B cells represented the major population 
of class-switched B cells in healthy controls, the frequency of IgG+ B cells was significantly 
increased during inflammation, with equal numbers of IgG+ and IgA+ B cells.  Furthermore, 
analysis of the frequency and absolute number of SSClo lymphocyte subsets in chronic DSS 
colitis demonstrated that B cells represent the major lymphocyte population within the inflamed 
mucosa (Fig. 3.6C, D).  Confocal microscopy of colonic tissue sections from uninflamed or 
chronic DSS-inflamed mice demonstrated a pronounced influx of IgG+ cells into the colon (Fig. 
3.7).  IgG+ cells were localised predominantly within the inflamed submucosa, with scattered 
cells within the LP. 
 
 
Figure 3.7.  IgG+ B cell identification within the inflamed colonic mucosa.  Confocal 
microscopy showing IgG+ B cells within the colonic mucosa following cDSS versus uninflamed 
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These results demonstrate that colonic inflammation is characterised by the influx of class-
switched and IgG+ B cells within the mucosa.  B cells represent the major lymphocyte 
population in this setting, and are located primarily within the submucosa and scattered 
throughout the LP. 
3.4. Fcγ receptor signalling in intestinal inflammation 
One of the key mechanisms by which IgG isotypes drive inflammation is through the 
engagement of Fcγ receptors.  In particular, IC-mediated inflammation relies on the low-to-
medium affinity FcγRs: activating FcγRIII and FcγRIV in mice, FcγRIIA, FcγRIIIA and FcγRIIIB 
in humans, and the inhibitory receptor FcγRIIB.  First, we sought to determine whether FcγRs 
were enriched in the inflamed GI tract.  Analysis of FCGR gene expression within colonic 
biopsies from patients with UC demonstrated enrichment of FcγR gene transcripts in 
accordance with the extent of inflammation (Fig. 3.8A).  All activating FcγR transcripts showed 
significant enrichment, along with FCER1G, encoding the ITAM-bearing common γ-chain 
required for activating receptor signalling.  Although significantly increased, the relatively 
smaller increased in FCGR2B expression resulted in a global increase in the A/I ratio in colitis 
(Fig. 3.8B).  As such, global FcγR levels are skewed towards enhanced IgG responsiveness.  
 
 
Figure 3.8. Fcγ receptor enrichment and increased global A/I ratios in UC.  (A) Analysis 
of transcriptomics data of human Fcγ receptor genes in colonic biopsies from UC patients 
(red), non-inflamed UC patients (blue) or healthy controls (grey).  Data were generated from 
the GEO dataset GSE9452.  HC n = 5, NUC n = 13, UC n = 8.  (B) Global A/I ratio of FCGR2A 
and FCGR3A/B gene transcripts for samples shown in A.  P values were calculated using 
limma with multiple correction using BH (A) or the nonparametric Mann-Whitney test (B).  * P 











































































































Figure 3.9.  Colonic FcγR transcript enrichment in chronic murine DSS-induced colitis.  
(A) Heatmap showing transcriptomic analysis of murine FcγR gene transcripts in whole colonic 
tissue following acute and chronic DSS administration, versus healthy controls.  Data were 
generated from GEO dataset GSE42768.  (B) qPCR confirmation of murine FcγR gene 
transcripts in whole colonic tissue following cDSS, displayed as fold change compared to 
healthy control colonic tissue. n = 6 per group.  qPCR data is representative of two independent 






Figure 3.10.  Enrichment of FcγR signalling pathways in chronic intestinal inflammation.  
(A) GSEA of FcγR crosslinking-associated genes in human UC colonic biopsies (top) and 
murine cDSS-inflamed whole colonic tissue (bottom) compared to healthy controls (GSE9452 
= human IBD [UC = 8, HC  = 5]; GSE42768 = murine DSS [H2O = 5; xDSS = 5]).  (B) GSEA 
of genes involved in FcγR-mediated phagocytosis in human UC colonic biopsies (top) and 
murine cDSS-inflamed whole colonic tissue (bottom) compared to healthy controls.  Gene lists 
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A similar observation was made in murine DSS-induced colitis (Fig. 3.9).  Transcriptomics 
analysis of whole colonic tissue following acute or chronic DSS administration (Fig. 3.9A), and 
subsequently confirmed by qPCR of whole colon tissue (Fig. 3.9B), demonstrated an increase 
in all Fcgr gene transcripts following the onset of inflammation. 
GSEA was carried out to decipher whether FcγR-associated signalling pathways were similarly 
enriched (Fig. 3.10).  Indeed, in both human UC and murine colitis, FcγR-associated signalling 





Figure 3.11.  FcγR signalling is associated with infliximab-refractory UC.  (A) Heatmap 
showing FcγR gene transcripts in colonic biopsies from patients responsive or refractory to 
infliximab therapy prior to the commencement of therapy.  Data was derived from the GEO 
dataset GSE12251.  (B) Global A/I ratios for activating receptors in colonic biopsies from 
patients shown in A.  (C) GSEA of FcγR cross-linking-associated genes (left) and FcγR-
mediated phagocytosis genes (right) in infliximab-responsive and refractory UC patients.  
Gene lists found in Table S1, Appendix.  P values were calculated using the nonparametric 
Mann-Whitney test.  *** P < 0.001. 
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Exacerbated FcγR signalling is associated with enhanced susceptibility to several 
inflammatory disorders, as demonstrated from human GWA studies and murine models [63], 
[64], [162], [206].  While infliximab administration is a cornerstone of IBD therapy, 
approximately 70 % of patients remain refractory to treatment in the long term.  To determine 
whether FcγR signalling was associated with infliximab-refractory disease, the FcγR 
phenotype was analysed in these patients (Fig. 3.11).  Compared to responsive individuals, 
infliximab-refractory patients demonstrated a local increase in FcγR transcripts (Fig. 3.11A), 
increased global A/I ratios (Fig. 3.11B), and the enrichment FcγR signalling pathways (Fig. 
3.11C) in colonic biopsies prior to the beginning of treatment. 
These results demonstrate that intestinal inflammation in humans and mice causes the local 
enrichment of FcγR signalling pathways.  Furthermore, enhanced FcγR signalling is 
associated with increased disease severity, as demonstrated in infliximab-refractory UC 
patients, and may contribute to exacerbated inflammation in these individuals.  These studies 
support the observation that commensal IgG binding correlates with disease activity. 
3.5. Tissue-resident immune cell FcγR expression 
Given the widespread expression of FcγRs and their regulation by the inflammatory milieu, the 
local enrichment of FcγR and signalling pathways could result from cellular infiltration and local 
modulation of FcγR expression within the inflamed GI tract.   
To address this, we first sought to identify the major FcγR-expressing cell populations within 
the inflamed colon by flow cytometry (Fig. 3.12A).  Within the CD11b+ subset of cells, Ly6C/Ghi 
CX3CR1- neutrophils, CX3CR1+ Ly6Clo-int MNPs, including macrophages and monocytes, and 
CX3CR1- MHC-II+ DCs represent major FcγR-expressing myeloid cells.  Furthermore, SSClo 
MHC-II+ B cells are known for their expression of FcγRIIB.  A comparison of FcγR expression 
across these cell types demonstrated significant cell-to-cell variation (Fig. 3.12 B, C).  As 
previously demonstrated, FcγRI expression is highly specific for murine intestinal CX3CR1+ 
Ly6Clo MHC-IIhi macrophages.  Unexpectedly, intestinal macrophages expressed very high 
levels of inhibitory FcγRIIB, with less pronounced staining on DCs and B cells.  Expression of 
the activating receptors FcγRIII and FcγRIV was also highest on macrophages, but also 
significantly expressed on neutrophils and DCs, and absent from B cells.  Therefore, intestinal 










Figure 3.12.  CX3CR1+ MHC-IIhi macrophages express the highest levels of FcγRs in the 
colonic LP.  (A) Flow cytometry gating strategy to identify major FcγR-expressing cell types 
within the colonic LP.  (B) Flow cytometry showing individual FcγR staining across the different 
cell types identified in A.  (C) Quantification of FcγR staining intensity shown in B. n = 3 per 
group.  Data are representative of two independent experiments.  P values were calculated 





























































































Intestinal tissue-resident macrophages are constantly replenished from circulating CCR2+ 
Ly6Chi MHC-II- monocytes.  The maturation of monocytes into macrophages can be 
represented as a “waterfall” plot of CX3CR1+ MNPs by flow cytometry [68] (Fig. 3.13A): as 
monocytes mature, they downregulate Ly6C and upregulate MHC-II, resulting in Ly6Chi MHC-
II- monocytes, Ly6C+ MHC-II+ monocytes/immature macrophages, and Ly6Clo MHC-IIhi 
macrophages.  As MNPs and neutrophils represent the major FcγR-expressing cells in the 
colon, we profiled their enrichment in DSS-induced colitis.  DSS administration results in the 
influx of monocytes into the colonic LP and subsequent enrichment of all CX3CR1+ MNP 
subsets (Fig. 3.13A).  Inflammation also results in local neutrophil recruitment (Fig. 3.13B).  





Figure 3.13.  Cellular infiltration contributes to FcγR enrichment in intestinal 
inflammation.  (A) Quantification of colonic CX3CR1+ MNP subsets by flow cytometry 
following DSS-induced colitis.  (B) Quantification of neutrophilic infiltration into the colonic 
lamina propria following DSS administration.  Data are representative of two independent 
experiments.  P values were calculated using the nonparametric Mann-Whitney test.  * P < 
0.05. 
Given the known effects of cytokines on FcγR expression by immune cells, we profiled 
CX3CR1+ MNP FcγR expression during homeostasis and DSS-induced inflammation (Fig. 
3.14).  FcγRI, FcγRIIB, and FcγRIV expression increased as cells matured from monocytes to 
macrophages, while FcγRIII expression remained relatively constant across all three MNP 
subsets (Fig. 3.14A).  All activating FcγRs trended towards a significant increase in expression 
following the onset of intestinal inflammation (Fig. 3.14B, C).  However, on macrophages, 
FcγRIIB expression decreased slightly with inflammation (Fig. 3.14 B, C), resulting in an 
increase in the A/I ratio of all activating FcγRs in this population (Fig. 3.14D).  Therefore, tissue-
resident and recruited macrophages are more primed to respond to local IgG following the 



















































Figure 3.14.  Altered macrophage A/I FcγR ratios in intestinal inflammation.  (A) Flow 
cytometry staining of FcγRs on colonic CD11b+ CX3CR1+ MNP subsets.  (B, C) Comparison 
of FcγR staining across CX3CR1+ MNP subsets (B) and FcγR quantification of the MHC-IIhi 
macrophages (C) in healthy and DSS-inflamed colons.  Red = monocytes (Ly6Chi MHC-IIlo); 
green = MHC-II+ monocytes (Ly6C+ MHC-II+); blue = macrophages (Ly6Clo MHC-IIhi).  Filled 
histrograms = H2O-treated mice; open histograms = DSS-treated mice. n = 3 per group.  (C) 
Quantification of macrophage A/I ratios based on flow cytometric staining intensity.  Data are 
representative of two independent experiments.  P values were calculated using the parametric 
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We sought to investigate how the FcγR repertoire of human intestinal macrophages compared 
to their murine counterparts.  FcγR profiling of human ileal CX3CR1+ CD14+ macrophages by 
flow cytometry (Fig. 3.15A) and qPCR (Fig. 3.15B) demonstrated predominant expression of 
FcγRIIA, the major UC-associated FcγR, and FcγRIIB.  Therefore, human and murine 
macrophages are characterised by elevated levels of both activating and inhibitory FcγRs, with 
the UC-associated FcγRIIA most highly expressed.  
 
Figure 3.15.  Fcγ receptor expression by human intestinal macrophages.  (A) Flow 
cytometry FcγR staining of human ileal macrophages.  (B) qPCR of FcγR genes in flow-sorted 
human ileal CX3CR1+ CD14+ macrophages.  Data are representative of a sole experiment. 
 
In summary, we have shown that intestinal CX3CR1+ Ly6Clo MHC-IIhi macrophages represent 
the subset with the highest levels of FcγR expression within the murine colon, particularly 
FcγRI and FcγRIIB.  Furthermore, local FcγR enrichment during inflammation results from the 
combined effects of leukocytic infiltration, as expected, and the local modulation of FcγR 
expression levels, with a skew towards an increased A/I ratio and elevated responsiveness to 
IgG following the onset of inflammation. 
3.6. FcγR-associated inflammatory networks in intestinal inflammation 
Aberrant Th17 immunity is strongly associated with intestinal inflammation, with the IL23R-
Th17 signaling axis a major risk factor for the development of IBD [262].  We hypothesised 
that FcγR signalling, and in particular FcγRIIA, may contribute to aberrant Th17 immune 
responses within the inflamed mucosa through the direct regulation of macrophage-derived 
cytokines and chemokines. 
To first address how FcγR signalling may contribute to IBD-associated inflammation, we 
sought to identify major cytokine and chemokine pathways enriched in colonic biopsies from 
UC patients versus healthy controls.  Analysis of transcriptomic data demonstrated that several 
Th17-associated cytokines were significantly enriched in UC mucosa, with IL1B being the most 
upregulated cytokine with IBD (Fig. 3.16A).  Other Th17-associated genes enriched in UC 
biopsies included IL23A and IL17A.  Chemokine gene analysis demonstrated a nucleus of 
































































and CXCL3, and CXCL8, the prototypical neutrophil-recruiting chemokine (Fig. 3.16B).  
Therefore, UC is associated with aberrant Th17 immunity, in particular exacerbated IL-1β 
production, and the expression of neutrophil-recruiting chemokines. 
 
 
Figure 3.16.  Human UC is associated with IL-1β and neutrophil-recruiting chemokines.  
Volcano plot showing enrichment of cytokines (A) and chemokines (B) in colonic biopsies from 
patients with UC versus healthy controls.  Data were derived from the GEO dataset GSE9452. 
HC n = 5; UC n = 8.  P values were calculated using limma with multiple correction using BH. 
 
Having identified major cytokine and chemokine pathways associated with IBD, we sought to 
understand how FcγRIIA may contribute to intestinal inflammation.  Correlation analysis 
demonstrated that FCGR2A expression levels in pooled healthy and UC colonic biopsies 
correlated with several UC-associated cytokine and chemokine gene transcripts (Fig. 3.17).  
Most strongly correlated were the cytokine IL-1β and the chemokines CXCL8, CXCL1 and 
CXCL2 (Fig. 3.17A, B), supporting a role for FcγRIIA in the regulation of these inflammatory 
mediators.  Furthermore, mucosal IGHG1 expression levels also correlated significantly with 
IL-1β and CXCL8 (Fig. 3.17C). 
Secondly, we used an unbiased hierarchical clustering algorithm to investigate how a curated 
list of all known chemokines and cytokines correlated with FCGR2A expression across these 
same samples (Fig. 3.18).  Strikingly, FCGR2A expression clustered most strongly to IL1B 
once more (Fig. 3.18A).  This was subsequently confirmed in an independent cohort (Fig. 
3.18B).  Given the strong association of IL-1β production with UC (Fig. 3.16), these results 
suggest that FcγR signalling may be involved in the regulation of inflammation-associated IL-













































































Figure 3.17.  FCGR2A correlates with IL-1β and CXCL chemokines in UC.  (A) Correlation 
of FCGR2A gene transcripts with IL1B and CXCL8 in pooled healthy control (black), non-
inflamed UC (blue), and inflamed UC (red) colonic biopsies.  Data were derived from the GEO 
dataset GSE9452.  (B) Summary of FCGR2A correlations with UC-associated cytokine and 
chemokine gene transcripts in pooled healthy controls, non-inflamed UC, and UC patient 
colonic biopsies.  (C) Correlation of IGHG1 gene transcripts with IL1B and CXCL8 gene 
transcripts in pooled colonic biopsies from UC patients.  P values were calculated using linear 
regression analysis. 
 








































































Figure 3.18.  FCGR2A clusters consistently with IL1B in UC biopsies.  Hierarchical 
clustering of chemokine and cytokine genes with FCGR2A expression levels in two datasets 
of pooled healthy controls and UC patient colonic biopsies (GSE9452 = top; GSE38713 = 




We sought to investigate whether similar networks are also associated with chronic murine 
DSS-induced colitis.  Transcriptomics analysis of murine colons following chronic DSS 
administration revealed Il1b as the most significantly enriched cytokine compared to healthy 
controls (Fig. 3.19A), while chemokine analysis once again demonstrated significant 
enrichment of several neutrophil-associated chemokines, including Cxcl2 (Fig. 3.19B). 
 
 
Figure 3.19.  IL-1β and CXCL chemokines are associated with chronic murine colitis.  
Volcano plot showing enrichment of cytokines (A) and chemokines (B) in whole murine colonic 
tissue following chronic DSS administration versus healthy controls.  Data were derived from 
the GEO dataset GSE42768. H2O n = 5; cDSS n = 5.  P values were calculated using limma 
with multiple correction using BH. 
 
qPCR analysis confirmed the enrichment of numerous inflammatory cytokines in chronically 
inflamed murine colons.  These included the macrophage-associated cytokines Il1b, Il6, Tnf, 
and Il10 (Fig. 3.20A), as well as Th17-associated cytokine genes, such as Il17a, Il22, and Csf2 
(Fig. 3.20B).  In addition to its significant enrichment, Il1b was also the most highly expressed 
inflammatory cytokine of those investigated within the inflamed colons of mice, suggesting a 
dominant role in driving colitis (Fig. 3.20C).  Finally, analysis of neutrophil- and monocyte-
recruiting chemokines demonstrated a significant increase in Ccl2, Ccl8, Cxcl1, and Cxcl2 (Fig. 



































































Figure 3.20.  Chronic DSS administration is associated with IL-1β production, Th17 
immunity, and chemokine production.  qPCR of macrophage-associated cytokine genes 
(A), Th17-associated cytokines (B), and macrophage-derived chemokines (D) in whole colonic 
tissue following cDSS versus healthy controls.  Relative expression of cytokines (C) and 
chemokines (D) in whole colonic tissue following cDSS.  Data are representative of two 
independent experiments.  P values were calculated using the nonparametric Mann-Whitney 








































































































































































































































































































In agreement with human data, we observed a strong correlation between FcγRIII expression 
levels and several Th17 cytokines and neutrophil-recruiting chemokines (Fig. 3.21A).  
Strikingly, the most robust correlations were once again with CXCL1 and IL-1β gene 




Figure 3.21.  Correlation of Fcgr3 with Il1b and Cxcl1 in murine chronic colitis.  (A) 
Correlation of Fcgr3 expression levels with Th17-associated cytokine and chemokine gene 
transcripts by qPCR in whole colonic tissue following cDSS.  (B) Correlation of Fcgr3 with Il1b 
and Cxcl1 in whole colonic tissue by qPCR.  Data are representative of three independent 
experiments.  P values were calculated using linear regression analysis. 
 
Therefore, chronic DSS administration results in a pronounced increase in local IL-1β 
production, the induction of local Th17 immunity, and neutrophil-recruiting chemokine 
expression, with expression levels correlating strongly with Fcgr3, the murine homologue of 
FcγRIIA.  As such, chronic DSS-induced colitis is a useful model for studying the effects of 
FcγR signalling in intestinal disease progression. 
3.7. Immune complex stimulation of intestinal leukocytes 
We have identified IL-1β as a major UC-associated cytokine and demonstrated a robust and 
reproducible correlation with FcγRIIA in humans and FcγRIII in mice.  Furthermore, we have 
demonstrated that intestinal macrophages, known sources of pro-inflammatory IL-1β, express 
the highest levels of FcγRs within the GI tract, while in vitro studies have demonstrated a role 
for IgG in supporting IL-1β-dependent Th17 cells in co-cultures with DCs and macrophages 
[74], [75], [82], [279]. 
To investigate whether IgG may have a direct role in driving intestinal Th17 immunity via IL-
1β, we firstly isolated inflamed murine LPMCs at day 14 following 2 % DSS administration and 
stimulated them with O or O-IC for 16 h.  O-IC stimulation induced production of IL-1β, but no 
change in IL-23 levels, as determined by ELISA (Fig. 3.22A).  Furthermore, O-IC stimulation 








































resulted in increased production of the key Th17 mediators IL-17A and IL-22 (Fig. 3.22B), and 
the neutrophil-recruiting chemokines CXCL1 and CXCL2 (Fig. 3.22C).  These observations 
were mirrored in human LPMCs: O-IC stimulation of human ileal LPMCs resulted in increased 
expression of IL-1β and CXCL8 (Fig. 3.22D).  Therefore, IgG potently stimulated intestinal 
immune cells and resulted in the induction of an inflammatory network resembling that 





Figure 3.22.  Immune complexes induce IL-1β and CXCL chemokine production by 
intestinal immune cells.  ELISA of macrophage-associated IL-1β and IL-23 (A), Th17-
associated IL-17 and IL-22 (B), and neutrophil-recruiting chemokine production by inflamed 
murine intestinal LPMCs stimulated with O or O-IC for 16 h.  Paired samples represent cells 
derived from the same mouse.  (D) Expression of CXCL8 and IL-1β mRNA by human LPMCs 
following 16 h stimulation with O or O-IC for 16 h.  n = 3 per group.  Data are representative of 
three independent experiments.  P values were calculated using ratio-paired t tests (A-C) and 
the parametric Student’s t test (D). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
To address whether anti-commensal IgG could directly drive inflammatory cytokine expression 
in vivo, anti-E. coli IgG antibodies were passively transferred into mice during an acute course 
of DSS administration.  Colonic E. coli levels are known to increase with the onset of intestinal 
inflammation and exacerbate disease [305]–[308].  As such, they are likely to represent a major 






































































































































did not induce significant changes in weight loss, an increase in clinical disease activity was 
noted (Fig. 3.23A).  Furthermore, qPCR analysis of whole inflamed colonic tissue 
demonstrated an increase in expression of macrophage-associated cytokines, including Il1b 
and Tnf (Fig. 3.23A), as well as Il17 and Csf2 (Fig. 3.23B), and several chemokines, including 
Cxcl1 and Cxcl2 (Fig. 3.23C).  Therefore, anti-commensal IgG antibodies can directly promote 
the inflammatory response in vivo. 
 
 
Figure 3.23.  Anti-commensal IgG induces colonic inflammation and cytokine 
production.  (A) Weight loss of WT mice treated with PBS or 1 mg anti-E. coli IgG (i.p.) at day 
0 and day 3 of 7-day acute DSS protocol.  n = 3 per group. Clinical disease score calculated 
as described in Table 2.3.  (B-D) qPCR of macrophage-associated cytokines (B), Th17-
associated cytokines (C), and macrophage-derived chemokines (D) in whole inflamed murine 
colonic tissue following injection of anti-E. coli IgG or PBS and acute DSS administration.  n = 
3 per group.  Data are representative of two independent experiments.  P values were 








































































































































































































































































































Figure 3.24.  CX3CR1+ MNPs are the major source of colonic IL-1β production in 
inflammation.  (A) Flow cytometry of pro-IL-1β-producing subsets in the inflamed colonic 
murine lamina propria.  (B) Quantification of pro-IL-1β+ subsets in A.  Data are representative 
of three independent experiments. 
 
Tissue-resident macrophages and monocytes are known to be potent producers of intestinal 
IL-1β, and we hypothesised that they would be the major IL-1β source in these cultures.  This 
was confirmed by flow cytometry, with minor contributions from neutrophils and dendritic cells 


































































3.8.1. Anti-commensal IgG is increased in UC and correlates with disease activity 
IgA is the predominant immunoglobulin isotype in the GI tract during homeostatic conditions, 
playing key roles in the maintenance of host-commensal mutualism through immune exclusion 
[42].  Recent seminal studies, however, have demonstrated that anti-commensal IgG forms 
part of normal adult immunity, with consequences for vertical transfer of immunity to neonates, 
immune cell development, and resistance to systemic infection [477], [479], [616].  This IgG is 
thought to be largely TCR-dependent and TI, suggesting a non-GC origin.   
Under inflammatory conditions, such as infection and IBD, an increase in local and systemic 
IgG is observed in humans and mice [283], [430], [482].  However, little is known about GI IgG 
subclass distribution, antigen-specificity, FcγR binding capacity, or glycosylation status, 
creating a void in our understanding of how mucosal IgG contributes to inflammation.   
Here, we sought to investigate the nature of the IgA and IgG response in patients with UC.  We 
demonstrated a significant enriched of IGHM, IGHD, and IGHG1 transcripts in UC biopsies 
compared to controls, with little change in IGHA.  Although only a small cohort of patients, here 
we observed a significant increase in total IgG-opsonised luminal bacteria in patients with UC 
compared to HHCs, which correlated with disease activity: patients with a Wormsley CAI over 
10 exhibited the highest levels of IgG-bound luminal bacteria.  Once more, no significant 
difference in IgA1/2 opsonisation was observed between HHCs and UC patients, consistent 
with transcriptomics data.  Further stool sample collection would help to increase the power of 
these observations, and is currently in progress. 
Unfortunately, IgG subclasses were not investigated here, and remains an open avenue of 
investigation.  Due to sequence similarity amongst IGH transcripts, specific probes to all IGH 
gene transcripts are not available in transcriptomics datasets.  As such, it is not possible to 
analyse the distribution of IgG subclasses in this manner.  Nonetheless, these observations 
have several implications.  IgG1 in humans, along with IgG3, is potently pro-inflammatory and 
dominates adaptive humoral immune responses to protein antigens.  IgG1 can activate 
complement and bind FcγRs with higher affinity that IgG2 and IgG4, suggesting that the local 
engagement of inflammatory mechanisms is likely in UC following IgG generation.  Increases 
in IGHM and IGHD, the latter not contributing to the secreted immunoglobulin repertoire, likely 
reflect a combination of increased immune IgM secretion and B cell infiltration into the inflamed 
mucosa.  Therefore, these results suggest that B dynamics and isotype distribution of Ig is 
significantly altered during IBD, with a switch away from non-inflammatory IgA to inflammatory 
IgG, including IgG1.   
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We observed a striking association between the extent of IgG opsonisation and disease 
activity.  Whether IgG subclass distribution is associated with differential pathology is of 
particular interest: IgG1 and IgG3 could contribute to enhanced inflammatory responses 
relative to IgG2 and IgG4.  For example, could individuals with high IgG titre but lower disease 
activity be associated with an enrichment of IgG2 and IgG4?    It should be noted that of those 
individuals investigated, patients with high IgG titres consistently had a high CAI score, while 
individuals with little IgG had low disease activity.  Of particular interest are those UC patients 
that exhibit intermediate IgG levels and differential disease progression/prognosis.  As well as 
subclass, IgG glycosylation profile may affect disease management.  Indeed, a systems 
serology approach in IBD may help to clarify some of these observations. 
Whether IgG is a driver of inflammation or simply a surrogate of the inflammatory state is not 
clear from these results.  However, it seems possible that they go hand-in-hand.  Local disease 
activity is a function of inflammatory cytokine production in the gut, with IL-1β, IL-23, and Th17 
immunity successfully targeted in IBD therapeutics [364], [365].  Th17 immunity has been 
implicated in class-switching to IgG subclasses, while an IL-23/Th17 axis has been 
demonstrated to promote desialylation of IgG in mice, augmenting its pro-inflammatory 
capacity in vivo in models of RA [178].  Therefore, exacerbated type 17 immune responses 
may contribute to the emergence of local IgG and the induction of a pro-inflammatory glycome.  
Furthermore, several studies have shown that IgG may potently activate Th17-inducing 
inflammatory profiles in human M2 macrophages and DCs [74], [611].  As such, IgG-mediated 
FcγR signalling may then promote a positive feedback loop in which Th17 immune responses 
are augmented, leading to severe detrimental inflammation. 
3.8.2. Anti-commensal IgG is increased in murine DSS-induced colitis 
Several murine models of IBD exist, as discussed in Chapter 1.  However, the majority of these 
models are not appropriate for the investigation of B cells.  T cell-transfer and anti-CD40 
monoclonal antibody models rely on the use of immunodeficient mice lacking T or B cells [299], 
[303].  Furthermore, H. hepaticus infection is often carried out in similarly immunocompromised 
strains [298].  This has led to the general assumption that B cells are not involved in the 
pathogenesis of chronic inflammatory disorders of the GI tract.  This seems surprising, given 
that sterilising immunity to C. rodentium, a widely used model of human A/E E. coli infection, 
is critically dependent on B cells and IgG [283], [284], [473].  This model has yielded invaluable 
insights into basic immunological mechanisms of inflammation that have proved useful to the 
understanding of IBD, including the involvement of IL-23 and Th17 cells [310], [617]–[619], 
and support the notion that IgG may be pathogenic.  Similarly, anti-flagellin IgG transfer has 
been shown to directly promote DSS-induced colitis [482]. 
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Further considerations revolve around the nature of the immune response elicited in distinct 
models.  While C. rodentium infection can recapitulate analogous inflammatory mechanisms 
to IBD, it does not induce the overwhelming inflammation associated with human disease.  We 
settled on the use of the colitogen DSS.  As DSS acts to erode the epithelial monolayer, it 
mirrors defects in epithelial barrier integrity and disease pathology associated with UC.  This 
is of particular importance, given the stronger association of FcγRIIA-H131 with UC over CD.  
Furthermore, this model is dependent on the microbiota, can be used for acute or chronic 
colitis, induces inflammation in immunocompetent mice, and has been associated with IgG 
generation in the past. 
In agreement with a previous study [482], we demonstrated that DSS administration induced 
de novo serum anti-flagellin and bulk anti-commensal IgG antibodies.  Unlike other studies, 
we also demonstrated significant enrichment of IgG within the inflamed colonic lumen and 
binding to luminal commensal microbes.  The effect of DSS administration on IgG opsonisation 
was smaller than the differences observed in UC patients compared to HHCs.  However, the 
acute nature of this model (only 7 days) likely underlies these observations.  Nonetheless, 
DSS-induced colitis is a reasonable model for the investigation of IgG-driven inflammation in 
the gut. 
3.8.3. IgG+ B cells are increased in the inflamed murine colon 
We hypothesised that the increased IgG response may result from gut-infiltrating B cells.  
Consistent with this, we observed a significant influx of CD19+ B220+ B cells into the inflamed 
colonic mucosa of mice following chronic DSS administration, and a skewing to from IgA to 
IgG.  This was confirmed by confocal microscopy.  Surprisingly, B cells made up the major 
adaptive lymphocyte population in this setting and demonstrates a considerable aspect of 
mucosal immunity that is omitted from several murine models of colitis. 
The nature of this B cell response remains unknown.  In line with the study by Koch et al., 
inflammation-associated IgG may arise in a TI, TLR-driven manner within the GALTs or 
intestinal LP itself [477].  Whether APRIL and BAFF are significantly induced in the gut 
following DSS has not been investigated here, but may contribute to the formation of local 
niches for IgG plasma cell survival or local CSR, particularly at early timepoints following DSS 
administration.  However, high-affinity IgA responses are known to be induced in response to 
pathogens.  Given the inflammatory milieu induced by DSS administration, it seems likely that 
otherwise low-affinity IgA-inducing microorganisms may induce higher affinity Ig responses 
during colitis as a result of secondary signals and increased bacterial penetration beyond the 
epithelial barrier.  One might expect these high affinity IgG clones to arise later in inflammation 
following rounds of SHM and selection within GALT GCs.  A systematic characterisation of 
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CSR-associated signals that are differentially induced during chronic colitis versus healthy 
controls are lacking, both here and in the literature. 
3.8.4. FcγR signalling is enriched in intestinal inflammation 
FcγR signalling is critically implicated in UC pathogenesis and protection against C. rodentium 
infection [523].  These results raise the possibility that FcγRs can contribute to inflammatory 
mechanisms in the GI tract.  Following the observed increase in local IgG and microbial 
opsonisation in intestinal inflammation, we decided to characterise the FcγR expression and 
signalling profile in UC patients and DSS-induced colitis. 
We demonstrated that FcγR transcripts are enriched in UC colonic biopsies, with a smaller 
enrichment of FcγRIIB gene transcripts relative to the activating FcγRs.  As such, global FcγR 
A/I ratios are skewed towards activation.  This was confirmed in inflamed murine colonic tissue, 
and GSEA demonstrated that FcγR signalling pathways, as well as FcγR genes themselves, 
are enriched in UC and DSS-induced colitis.  Furthermore, FcγR signalling was associated 
with severe inflammation, with FcγR transcript enrichment, elevated global A/I ratios, and 
enriched FcγR signalling pathways in infliximab-refractory IBD biopsies.  These observations 
were supported by characterisation of FcγR expression profiles on gut-infiltrating cells in mice, 
demonstrating enrichment of FcγR-expressing macrophages and neutrophils, as well as 
increased macrophage A/I ratios during colitis relative to healthy mice.  Whether or not 
enhanced FcγR signalling in infliximab-resistant IBD is reflective of a generalised exacerbated 
inflammatory response or a bone fide mechanism of resistance is to be elucidated, but 
demonstrates a strong association between this pathway and colitis. 
Macrophages were of particular interest.  These cells expressed the highest levels of FcγRs, 
are known to predominantly reside within the LP, and directly sample luminal contents.  
Therefore, during inflammation, these cells are perfectly positioned to interact with IgG-
opsonised bacteria that may penetrate the damaged epithelium.  Indeed, macrophage 
infiltration is common during various inflammatory disorders, including colitis.  In this setting, 
macrophages have been shown to drive intestinal inflammation through production of TNF, IL-
1β, and IL-23, as demonstrated in humans and several murine models [82], [279], [295], [511].  
These cells also orchestrate the recruitment of immune cells through the production of 
chemokines, including CXCL1 and 2, and CCL8.  Our results demonstrate that tissue-resident 
macrophages upregulate expression of activating FcγRs during inflammation, with implications 
for FcγR-driven inflammatory responses.  In this way, the intestinal immune system is poised 
to respond to local IgG during inflammation, which we previously demonstrated to include 
significant IgG1 production.  How FcγR expression is regulated is not clear, but may include 
IFNγ secretion: DSS administration is known to induce colonic IFNγ production which can drive 
intestinal inflammation [301], [393].  IFNγ can downregulate expression of FcγRIIB and induce 
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activating FcγR expression [84].  Furthermore, PGE2 has been shown to have important roles 
in the activation of intestinal immune cells, such as ILC3s [544], and can modulate FcγR 
expression on human monocytes.  Therefore, it is likely the several factors in the GI milieu 
contribute to this differential FcγR expression during colitis.  Despite its association with many 
immune cells, including B cells and DCs, macrophage expression of FcγRIIB was strikingly 
higher than other immune populations in the gut.  This raises the possibility of a relatively 
targeted macrophage response by modulating FcγRIIB expression in vivo.  
It is of interest whether these mechanisms act in concert with IgG CSR.  For example, CD8+ T 
cells were shown to induce IgG CSR in mice following adoptive transfer via an IFNγ-dependent 
mechanism.  Therefore, IFNγ could potentially promote local IgG generation and the modulate 
of FcγR-expressing cells for enhanced sensitivity to IgG in a cooperative manner. 
As well as in mice, we demonstrated that human ileal macrophages also express high levels 
of FcγRs, in particular FcγRIIA and FcγRIIB.  Therefore, this raises the possibility that FcγRIIA 
polymorphisms directly influence the activity of these cells, and macrophage-mediated 
inflammatory mechanisms may underlie the association with FcγRIIA-H/R131 and IBD 
susceptibility.  Whether FcγR A/I ratios similarly change in human IBD have not been 
investigated here, but are supported by the observations of enhanced global A/I ratios within 
the inflamed GI tract. 
3.8.5. FcγR signalling is associated with IL-1β production in humans and mice 
Several inflammatory cytokine pathways are associated with IBD, which can cause some 
confusion.  This includes exacerbated Th17 responses in both CD and UC, elevated IL-13 
production in UC, and IFNγ production in CD [318]–[320].  Therefore, IC signalling could 
potentially influence a variety of inflammatory pathways.  In order to tackle this problem, we 
took an unbiased approach to understanding predominant UC-associated pathological 
pathways and their association with FcγR signalling. 
We demonstrated elevated IL-1β expression in UC and a strong correlation with FcγRIIA 
expression levels.  Strikingly, this association was confirmed by hierarchical clustering 
algorithms investigating FcγRIIA correlation with all cytokines and chemokines in two 
independent UC datasets.  IL-1β expression was also characteristic of chronic DSS-induced 
colitis and strongly associated with FcγRIII expression, the murine homologue of FcγRIIA.   
These results firstly demonstrate that IL-1β is a major inflammatory cytokine in both human 
and murine colitis, and is consistent with several studies that have demonstrated therapeutic 
benefit to IL-1β blockade or inflammasome deficiency in chronic intestinal pathology [279].  
Furthermore, these results support the hypothesis that FcγR signalling may regulate Th17 
immunity in the gut through production of several upstream cytokines.  It is notable that, while 
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elevated in UC biopsies, IL-23A expression was not significantly correlated with FcγR 
expression or with chronic murine colitis.  IL-1β has roles in the systemic inflammatory 
response, neutrophil recruitment to tissues, and in the activation of Th17 immunity.  Its role in 
the latter is of particular interest here: in the presence of IL-1β, IL-23-induced Th17 cells exhibit 
an elevated inflammatory profile, with T-bet and IL-33 expression [352].  Therefore, FcγR 
signalling may act to potentiate mucosal Th17 responses initiated by IL-23 production through 
an IL-1β-dependent mechanism.  This is consistent with a study by Uo et al., which 
demonstrated that IL-23 expression in intestinal macrophages was refractory to FcγR 
stimulation, and the previously established link between FcγR signalling and IL-17A production 
in a model of fatal glomerulonephritis [183], [430]. 
Care should be taken at this point not to over-interpret these results, however.  Correlation 
may simply be reflective of a broader inflammatory network, in which both IL-1β and FcγR 
expression is increased.  However, the tight, reproducible association suggests these proteins 
may be at least expressed by the same cells, and regulated in unison.  
3.8.6. Immune complexes induce IL-1β and Th17-associated cytokine production by 
intestinal immune cells 
To address this association more directly, LPMCs were isolated from the inflamed colonic LP 
following DSS administration or the human ileum and stimulated with IC.  IL-1β was 
consistently induced in response to IC stimulation in both mice and human LPMCs, while IL-
23 was refractory to stimulation.  Furthermore, IL-17 and IL-22 production was significantly 
increased, Th17 cytokines downstream of IL-1β.  
These results support previous associations between FcγR signalling and IL-1β, but not IL-23, 
and demonstrate that IgG signalling is sufficient to promote Th17 inflammatory pathways in 
vitro.  It is tempting to speculate that this increase in IL-17 and IL-22 is specifically IL-1β-
dependent, but we cannot rule out the induction of IL-1β/IL-23-independent inflammatory 
cytokines that may be induced following IC.  This includes PGE2 and TL1A, both of which have 
been shown to be induced by IC signalling on macrophages [79], [612]. 
Consistent with these results, we demonstrated that passive transfer of anti-E. coli IgG into 
mice during DSS-induced colitis augmented inflammatory cytokine production within the 
mucosa, including IL-1β, TNF, IL-10, TL1A and several chemokines.  Outgrowth of E. coli is 
characteristic of inflammation, including in DSS-induced colitis [305]–[308].  Therefore, anti-E. 
coli IgG likely represents a reasonable model antigen that would be present in patients with 
IBD and in murine models.  It is noteworthy that this passive transfer did not induce significant 
IL-17 or IL-22 production, but elevated GM-CSF levels.  This may result from the 7-day nature 
of the protocol in this instance: T cell-derived IL-17 and IL-22 may require a more chronic 
exposure to DSS in order to induce adaptive Th17 immunity.  However, chronic DSS exposure 
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would confound the results of the passive transfer, as endogenous IgG would be generated 
de novo beyond this point. 
3.8.7. Summary 
Here, we have demonstrated the emergence of an anti-commensal IgG response during 
intestinal inflammation and its association with an IL-1β-mediated Th17 response (Fig. 3.25).  
Macrophages were identified as the major source of IL-1β in the inflamed colon.  Therefore, 
these results raise the possibility that macrophage-intrinsic FcγR signalling may drive IL-1β 
production and the induction of type 17 immunity.  This hypothesis is consistent with previous 
studies in humans, demonstrating that TLR-FcγR co-stimulation on M2 MDMs induces IL-1β 
production, but is contrary to reports on murine macrophages that suggest FcγR-induced 
PGE2 production suppresses LPS-induced IL-1β production in vitro [74], [611], [612].  It should 
be noted that PGE2 is also known for its ability to support Th17 immunity [544], and so its 
effects may be heavily context dependent.  This is also true of macrophages: while M2 TLR-
FcγR co-stimulation induces IL-1β, this is not the case for M1 macrophages.  Therefore, care 
must be taken in extrapolating in vitro observations to biological effects in vivo.  The 
macrophage dynamic within the GI tract is complex.  Intestinal macrophages resemble a mixed 
M1/M2 phenotype, with IL-10 and TNF production, while IL-1β is potently induced during colitis.  
Therefore, FcγR signalling could have differential effects on macrophages under homeostatic 
and inflammatory conditions.  This is further confounded by the complex canonical and non-
canonical caspase-mediated processing of pro-IL-1β, which may be subject to regulation by 
FcγR signalling directly or indirectly through secondary mediators. 
Given these observations, we sought to investigate the effect of macrophage-intrinsic FcγR 
signalling on the production of inflammatory mediators that may contribute to intestinal 
inflammation.  Of particular interest was the effect of IC on IL-1β, given its association with 
human and murine colitis, and its upregulated production by LPMCs following IgG stimulation.  
Furthermore, we sought to investigate the effects of FcγR signalling in vivo through the use of 
murine models in which the A/I ratio of macrophages was altered.  Fcgr2b-deficient mice lack 
the inhibitory FcγR on all cells and are characterised by exacerbated inflammation in murine 
models of infection and autoimmunity [62], [180], [183], [206].  In contrast, M-TG mice exhibit 
specific overexpression of FcγRIIB on macrophages, driven by the human CD68 promoter, 
and are protected from overwhelming inflammation and IgG-driven pathology [205].  We 
hypothesised that Fcgr2b-deficient mice would exhibit worse pathology during chronic DSS-
induced colitis, driven by exacerbated pro-inflammatory cytokine and chemokine responses, 






Figure 3.25.  Chapter 3 graphical summary.  During homeostasis, IgA is the predominant Ig 
isotype in the GI tract, where it is transported across the epithelium and functions via immune 
exclusion.  During chronic inflammatory conditions, such as UC and DSS-induced colitis in 
mice, an anti-commensal IgG response is induced that results in significant microbial 
opsonisation within the lumen.  FcγRIIA, a canonical activating FcγR in humans associated 
with UC susceptibility, and FcγRIII in mice correlate strongly with IL-1β within the inflamed 
colonic mucosa.  Furthermore, IgG IC stimulation results in IL-1β production by intestinal 
immune cells in both mice and humans.  As macrophages express the highest levels of FcγRs, 
have A/I ratios skewed towards activation during inflammation, and produce high amounts of 
IL-1β, these results lead us to hypothesise that macrophage-intrinsic FcγR signalling may drive 
IL-1β-dependent Th17 immunity and inflammation in vivo, directly contributing to intestinal 





















4. Fcγ receptor signalling drives IL-1β-dependent intestinal 
inflammation 
4.1. Introduction and hypotheses 
We previously identified an increase in mucosal IgG responses in murine colitis and UC, 
reflective of an increase in LP-infiltrating IgG-producing plasma cells, as well as an enrichment 
of FcγR signalling pathways in UC and infliximab-refractory UC.  FcγR expression was tightly 
associated with IL-1β and neutrophil-recruiting chemokine production, with highly significant 
correlations between FCGR2A and Fcgr3 with IL-1β expression levels in humans and mice, 
respectively.  IL-1β and chemokine production was directly regulated by FcγR signalling, as 
demonstrated by increased cytokine and chemokine expression in IgG-IC-stimulated LPMCs, 
as well as in response to passive transfer of anti-E. coli IgG antibodies during DSS-induced 
colitis. With a focus, specifically on IL-1β, we identified macrophages as the major source of 
this cytokine in vivo. 
Next, we hypothesised that IgG-induced IL-1β production by intestinal macrophages can drive 
intestinal inflammation in human IBD and in murine models of colitis.  Several studies have 
demonstrated that modulation of FcγR expression in vivo through the use of transgenic mice 
is sufficient to alter the progression of IgG-mediated disorders, with the absence of the 
inhibitory receptor, FcγRIIB, conferring increased disease severity in several murine models, 
while SNPs in human FcγR genes alter susceptibility to numerous autoimmune and 
inflammatory disorders [144], [161]–[163], [180], [206].  Therefore, we also hypothesised that 
modulation of the A/I ratio in vivo through the use of FcγRIIB-transgenic mice could be 
sufficient to alter disease severity in DSS-induced colitis, potentially mirroring the effect of 









4.2. Transcriptomic analysis of FcγR signalling in intestinal macrophages 
Tissue-resident intestinal macrophages, which express high levels of FcγRs, are known to be 
a major source of the inflammatory cytokines induced by FcγR signalling.  We therefore 
hypothesised that direct FcγR signalling on intestinal macrophages may drive the production 
of inflammatory cytokines, including IL-1β and the neutrophil-recruiting chemokines CXCL1 
and CXCL2.  
To first address this question, we performed transcriptomics analysis on BMDMs stimulated 
with O-IC for 4 h to identify upregulated cytokines that were previously shown to be associated 
with UC (Fig. 4.1A).  O-IC stimulation resulted in expression of Il1b, Il1a, Tnf, and Cxcl1.  
Unfortunately, Cxcl2 did not pass quality control in this dataset, and so was absent from the 
analysis.  We confirmed these observations at the protein level, with O-IC stimulation alone 
resulting in low level production of IL-1β, and production of CXCL1 and CXCL2 (Fig. 4.1B). 
 
Figure 4.1.  Immune complexes induce IL-1β, CXCL1 and CXCL2 production by BMDMs.  
(A) Heatmap of UC-associated cytokines and chemokines in BMDMs following IC stimulation.  
(B) ELISA of IL-1β, CXCL1 and CXCL2 protein production by BMDMs stimulated with O or O-
IC for 16 h.  n = 3 per group.  Data are representative of three independent experiments.  P 
values were calculated using the parametric Student’s t test.  ** P < 0.01; *** P < 0.001; **** P 
< 0.0001. 
 
Whilst this data is encouraging, BMDMs do not fully recapitulate the phenotype of intestinal 
macrophages.  Furthermore, macrophages are known to undergo reprogramming under 
different inflammation conditions (e.g. M1 versus M2 macrophages) and, as such, may 
potentially respond differently to FcγR ligation in an inflamed colon.  We therefore sought to 
investigate the effect of IgG IC stimulation on flow-sorted colonic CX3CR1+ Ly6Clo MHC-IIhi 
macrophages isolated from uninflamed and DSS-inflamed mice by RNAseq.  Principle 
component analysis (PCA) of IC-stimulated macrophages demonstrated that macrophage 
samples clustered based on source (i.e. inflamed or uninflamed colon) and whether they had 



















































in both sets of macrophages, demonstrating IgG as a potent stimulus for tissue-resident 
macrophages (Fig. 4.2B).  
 
Figure 4.2.  Immune complexes induce profound stimulation of intestinal macrophages.  
(A) PCA plot of intestinal macrophages flow sorted from uninflamed (circles) or DSS-inflamed 
(triangles) colons stimulated with O (turquoise) or O-IC (red) for 4 h.  (B) Heatmap showing all 
differentially expressed genes in uninflamed (left) or DSS-inflamed (right) macrophages 
stimulated with O or O-IC.  
 
Analysis of top differentially expressed genes in both sets of macrophages demonstrated large 
changes to several immune-associated genes, including Cxcl1, Cxcl2, Il10, Ptgs2 (the gene 
encoding Cox2), and Inhba, the subunit of Activin and Inhibin (Fig. 4.3A).  The general effect 
of IC stimulation was largely independent of whether macrophages were isolated from 
uninflamed or inflamed mice, although the magnitude of IC-induced changes was variable (Fig. 
4.3B).  One notable exception, however, was IL-6: IC stimulation resulted in increased IL-6 
expression in inflamed macrophages, while it had the opposite effect on uninflamed 
macrophages.  Given the largely similar nature of IC stimulation, and inflamed macrophages 
more likely representing the cells that would encounter IgG in vivo, we decided to focus our 









































Figure 4.3.  Immune complex-induced transcriptional changes are independent of 
inflammation state.  (A) Volcano plot showing O-IC-induced transcriptional changes in colonic 
macrophages flow-sorted from uninflamed (left) and DSS-inflamed (right) colons.  (B) 
Comparison of O/O-IC uninflamed and inflamed macrophages.  P values were calculated using 
the standard DESeq 2 method with multiple correction using BH. 
 
123 
GSEA of Hallmarks pathways demonstrated that IC stimulation had a widespread inflammatory 
effect on macrophages, with several significantly enriched pathways, including TNFA 
SIGNALLING, INFLAMMATORY RESPONSE, and HYPOXIA (Fig. 4.4).   
 
 
Figure 4.4.  Immune complexes induce widespread macrophage activation.  GSEA of 
Hallmarks pathways in macrophages stimulated with O-IC. 
 
However, given their association with UC pathogenesis, we decided to first focus on IC-
inducible cytokine/chemokine production (Fig. 4.5A).  IC stimulation resulted in increased 
expression of several key inflammatory cytokines: Th17-inducing Il1b, Il23a, Spp1, and Il12b; 
monocyte and neutrophil-recruiting Ccl2, Ccl7, Cxcl1, and Cxcl2; and other UC-associated 
genes, including Tnf, and Osm. Interestingly, several anti-inflammatory genes are also induced 
by O-IC and may act to limit IC-induced inflammation, including Il10, as previously mentioned, 
as well as Il1rn, encoding IL-1Ra.  Analysis of UC-associated genes induced by IC stimulation 
revealed a nucleus of Th17-inducing genes associated with both conditions, including Il1b, 
Il23a, and Spp1, in accordance with previous studies on the pathogenesis of UC and our data 
suggesting IC can support Th17 immunity (Fig. 4.5B).  Notably, UC and IC-stimulated 
macrophages are both significantly associated with elevated Cxcl1 and Cxcl2 expression, 
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Figure 4.5.  Immune complexes induce UC-associated inflammatory gene expression.  
(A) Heatmap of differentially expressed cytokines and chemokines in intestinal macrophages 
following IC stimulation.  (B) Comparison of intestinal macrophage IC stimulation with 
significant UC-associated cytokine and chemokine transcripts (adjusted P val. < 0.05).  P 







































































































Figure 4.6. Immune complexes regulate macrophage production of cell surface 
receptors and transcription factors.  Heatmaps showing significant differentially expressed 
cell surface receptors (A) and transcription factor (B) in inflamed flow-sorted intestinal 











































































































Analysis of cell surface receptor and TF expression in intestinal macrophages also 
demonstrated significant changes in gene expression in response to IC (Fig. 4.6).  Several cell 
surface receptors were downregulated by IC, including Il10ra and numerous TLRs (Fig. 4.6A), 
suggesting a shift in how IC-stimulated cells sense their local environment.  Furthermore, there 
was widespread reprogramming of TFs, with over 50 significantly increased genes following 
stimulation (Fig. 4.6B), including Hif1a, a hypoxia-inducible TF associated with IL-1β 
production [343], Stat genes, and NFκB.  One of the most highly induced TRs is Atf3, a TF 
suggested to suppress inflammatory cytokine production, and may represent a negative 
feedback mechanism to dampen IC-induced responses. 
In summary, IC induces widespread inflammatory transcriptional reprogramming of intestinal 
macrophages centred on the production of Th17-inducing inflammatory cytokines, including 
IL-1β, and neutrophil-recruiting chemokines, supporting the observed correlations between 
FcγRs and these same genes in murine and human colitis. 
4.3. Manipulation of the A/I ratio using FcγRIIB-transgenic mouse models  
FcγR signalling induces a UC-associated inflammatory network in macrophages centred on 
the production of IL-1β and CXCL1 and CXCL2.  Given the importance of these mediators in 
intestinal inflammation in both mice and humans, we hypothesised that modulation of A/I ratios 
would alter disease severity via differential production of these cytokines.  In humans, this may 
be through SNPs affecting FcγR expression or function, such as the FCGR2A SNP affecting 
IgG binding affinity, while in mice, this can be artificially manipulated in transgenic mouse 
models in which FcγR expression is modified.   
FcγRIIB is essential for the inhibition of activating FcγR signalling, with Fcgr2b KO mice more 
susceptible to several IgG-mediated inflammatory disorders [62], [63].  As FcγRIIB is most 
highly expressed on intestinal macrophages, Fcgr2b KO mice represent a useful tool to 
interrogate the function of IgG and FcγR signalling and IgG in intestinal disease progression.  
In contrast, macrophage transgenic (M-TG) mice overexpress FcγRIIB specifically on 
macrophages through transgenic Fcgr2b expression from the human CD68 promoter [205].  
As such, these mice allow for refined cell-specific dissection of the role of FcγR signalling in 
intestinal disease (Fig. 4.7A). 
To determine whether A/I ratio modulation could influence cytokine expression in vitro, BMDMs 
generated from WT, M-TG, and Fcgr2b-deficient mice were stimulated with O-IC for 4 h.  
Cytokine and chemokine production was indeed dependent on the A/I ratio: M-TG BMDMs 
expressed lower levels of IL-1β, CXCL1 and CXCL2 compared to WT mice in response to O-
IC, while Fcgr2b-deficient BMDMs demonstrated enhanced cytokine and chemokine 





Figure 4.7. Modulation of macrophage A/I ratio regulates inflammatory cytokine 
production.  (A) Schematic of A/I ratio modulation by human FCGR2A single nucleotide 
polymorphisms and transgenic mouse models.  (B) qPCR of WT, Fcgr2b-deficient, and M-TG 
BMDMs stimulated with O or O-IC for 3 h. n = 2 per group.  Data are representative of two 
independent experiments. 
 
4.4. Chronic DSS-induced colitis in Fcgr2b-deficient mice 
4.4.1. Clinical parameters 
In order to investigate the role of FcγR signalling in chronic intestinal inflammation, Fcgr2b KO 
and WT mice were subjected to chronic DSS administration.  DSS administration resulted in 
weight loss in WT mice, as expected (Fig. 4.8A).  Fcgr2b-deficient mice exhibited greater 
weight loss, particularly from day 10 onwards.  At endpoint, while no difference was observed 
in colon length, Fcgr2b-deficient colons weighed more and trended to a greater weight per 
centimetre of tissue (Fig. 4.8B).  Furthermore, SLOs were significantly enlarged in Fcgr2b-
deficient mice following chronic DSS administration (Fig. 4.8C). 
 
















































Figure 4.8.  Enhanced chronic intestinal disease in Fcgr2b-deficient mice.  (A) Weight 
loss in WT and Fcgr2b-deficient mice following chronic DSS administration.  (B) Colonic clinical 
disease parameters following cDSS for mice shown in A.  (C) MLN and spleen enlargement in 
WT and Fcgr2b-deficient mice following cDSS.  Data are representative of three independent 
experiments.  P values were calculated using a two-way ANOVA (A), and the nonparametric 
Mann-Whitney test (B, C).  * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
Confocal microscopy of colonic tissue was performed to investigate leukocyte infiltration and 
tissue architecture (Fig. 4.9).  Fcgr2b-deficient mice exhibited increased CD45+ leukocyte 
infiltration and abscess formation in the mucosa, identified as clusters of CD45+ cells within 
areas of disrupted mucosal architecture, as well as submucosal expansion, characteristic of 
enhanced inflammation. 
 




























































































































Figure 4.9.  Leukocyte infiltration and submucosal expansion in Fcgr2b-deficient mice.  
Confocal microscopy of WT and Fcgr2b-deficient colon sections following cDSS.  Blue = 
phalloidin; green = CD45; red = Ki67.  Arrows indicate CD45+ leukocyte foci.  Data are 
representative of two independent experiments. 
 
4.4.2. Inflammatory cytokine and chemokine analysis 
In order to dissect the mechanistic underpinning of this enhanced disease severity, global 
cytokine and chemokine expression levels in WT and Fcgr2b-deficient whole colon tissue were 
quantified by qPCR (Fig. 4.10).  Notably, of MNP-derived cytokines, global Il1b levels were 
significantly increased (Fig. 4.10A).  The genotype effect on Il23a and Tnf expression was 
more modest, while minor change was observed in Tnfsf15 or Il10 levels.  Of the Th17-
associated cytokines, an increase in Il17a and Csf2 levels was observed in Fcgr2b-deficient 
colons, while there was also trend towards increasing Il22 (Fig. 4.10B).  Chemokine analysis 
demonstrated a significant enrichment in Ccl2 in Fcgr2b-deficient colons, while trends towards 
increasing levels of Cxcl1 and Cxcl2 were also seen (Fig. 4.10C).  Finally, Fcgr2b-deficient 
colons were associated with an enhanced anti-microbial peptide response, with all Reg genes 
either significantly enriched or trending so compared to WT controls (Fig. 4.10D).  Therefore, 
global cytokine and chemokine expression in Fcgr2b-deficient mice is dominated by 
exacerbated IL-1β production, enhanced Th17 immunity, and increased expression of 





Figure 4.10.  FcγRIIB deficiency promotes an inflammatory profile in chronic DSS-
induced colitis.  qPCR of macrophage-associated cytokines (A), Th17-associated cytokines 
(B), chemokines (C), and epithelial-derived anti-microbial peptides (D) in whole murine colonic 
tissue from WT (black) and Fcgr2b-deficient (red) mice following cDSS.  n = 8-9 per group.  
Data are representative of three independent experiments.  P values were calculated using 
the nonparametric Mann-Whitney test.  * P < 0.05. 
 
The sources of enhanced IL-1β production in Fcgr2b-deficient mice were investigated by flow 
cytometry (Fig. 4.11).  Intracellular staining for pro-IL-1β demonstrated that in WT mice, the 
majority of pro-IL-1β+ cells were CD11b+ CX3CR1+ MNPs, with an equal abundance of Ly6Chi 
and Ly6Clo cells, consistent with monocytes and macrophages, respectively (Fig. 4.11A).  
Fcgr2b-deficient mice had significantly higher numbers of pro-IL-1β+ cells, the majority of which 
were Ly6Chi (Fig. 4.11A, B).  To address whether this was due to monocytic infiltration or 
increased IL-1β expression by Fcgr2b-deficient monocytes, analysis of the MNP “waterfall” 
was carried out [68] (Fig. 4.11C).  This demonstrated that Fcgr2b-deficient monocytes and 
immature macrophages expressed higher amounts of pro-IL-1β compared to WT cells, with a 
diminishing genotype effect as monocytes mature into macrophages, consistent with previous 
observations that newly recruited monocytes are the major source of intestinal IL-1β 
production.  Furthermore, no IL-1β production was observed in splenic monocytes, 





























































































































































Figure 4.11.  Enhanced IL-1β production by intestinal mononuclear phagocytes in the 
absence of FcγRIIB.  (A) Flow cytometry of pro-IL-1β-producing cells in the colonic lamina 
propria of WT and Fcgr2b-deficient mice following cDSS.  (B) Quantification of cells in A.  (C) 
Pro-IL-1β production by colonic CX3CR1+ MNP subsets following cDSS.  (D) Pro-IL-1β 
production by WT and Fcgr2b-deficient splenic monocytes following cDSS.  n = 5-7 per group. 
Data are representative of three independent experiments.  P values were calculated with the 
nonparametric Mann-Whitney test.  * P < 0.05. 
 
To determine the contribution of dysregulated FcγR signalling on widespread cytokine 
production by intestinal Ly6Chi MHC-II- monocytes and Ly6Clo MHC-IIhi macrophages from the 
inflamed LI-LP of WT and Fcgr2b-deficient mice, flow-sorted cells were analysed by qPCR.  In 
agreement with global mRNA levels, Il1b was the most highly expressed cytokine analysed in 
intestinal macrophages, consistent with a key role in mediating intestinal inflammation (Fig. 
4.12A).  Il1b expression was similar between WT monocytes and macrophages, with its 
expression significantly enhanced in Fcgr2b-deficient monocytes, consistent with protein level 
data (Fig. 4.12B).  Il1b expression was also trending to be higher in the macrophage subset.  
Il23a expression followed a similar pattern.  As expected, both Il10 and Tnf were most highly 
expressed in macrophages, with Tnf expression significantly higher in Fcgr2b-deficient 
macrophages (Fig. 4.12B).  Curiously, no difference in Il10 expression was seen between WT 





















































































Il6 was equally expressed by both monocytes and macrophages, but the effect of FcγRIIB 
deficiency was most pronounced in the macrophage subset.  Finally, no difference in Tnfsf15 
expression was seen in the absence of FcγRIIB, although its expression was much higher in 
the macrophage subset.  These results are largely consistent with inflammatory profiles 
induced in intestinal macrophages by IC stimulation ex vivo, and suggest a prominent role for 




Figure 4.12.  Enhanced inflammatory cytokine profile of Fcgr2b-deficient CX3CR1+ 
MNPs.  (A) qPCR of cytokine gene expression in flow-sorted CX3CR1+ Ly6Clo MHC-IIhi 
macrophages 14 days after acute DSS administration, normalised to Gapdh.  (B) qPCR of 
inflammatory cytokines in WT and Fcgr2b-deficient monocytes (Ly6Chi MHC-IIlo) and 
macrophages (Ly6Clo MHC-IIhi) following DSS administration.  Data represent a single 



































































































































Similarly, chemokine expression was analysed in WT and Fcgr2b-deficient macrophages by 
qPCR.  Cxcl2 was the most highly expressed chemokine of those analysed in WT mice (Fig. 
4.13A).  However, both Cxcl1 and Cxcl2 expression were significantly higher in Fcgr2b-
deficient macrophages, supporting a role for FcγR signalling in neutrophil recruitment via the 
production of these chemokines (Fig. 4.13B).   
 
 
Figure 4.13.  Enhanced chemokine production by Fcgr2b-deficient CX3CR1+ 
macrophages.  (A) qPCR of chemokine expression in WT intestinal macrophages after 14 
days of acute DSS, normalised to Gapdh.  (B) qPCR of chemokine gene expression by WT 
and Fcgr2b-deficient macrophages following acute DSS administration.  Data represent a 
single experiment.  P values were calculated using the nonparametric Mann-Whitney test.  * P 
< 0.05. 
 
In summary, global FcγRIIB deficiency is associated with enhanced IL-1β production by 
intestinal CX3CR1+ MNPs, with a particular effect on newly recruited Ly6Chi monocytes and 
immature Ly6C+ MHC-II+ macrophages.  Furthermore, IL-1β was the most highly expressed of 
all inflammatory cytokines investigated, and likely represents a dominant effect of the 
genotype, as expression level differences for other cytokines were less apparent in Fcgr2b-
deficient mice versus controls.  
4.4.3. Leukocyte profiling of the inflamed colon 
Given the increased expression of several monocyte- and neutrophil-recruiting chemokines in 
Fcgr2b-deficient mice, we sought to investigate myeloid cell infiltration into the inflamed colon 
of these mice.  Confocal microscopy demonstrated a pronounced enrichment of CD11b+ cells 
within the inflamed submucosa of Fcgr2b-deficient mice compared to WT controls following 







































































Figure 4.14.  Submucosal CD11b+ leukocyte infiltration in Fcgr2b-deficient mice.  
Confocal microscopy of WT and Fcgr2b-deficient colonic tissue following cDSS.  Blue = 
phalloidin; green = CD11b; red = Ki67.  Data are representative of two independent 
experiments. 
 
Flow cytometric tSNE analysis of chronically inflamed colons demonstrated enrichment of 
colonic neutrophils in Fcgr2b-deficient mice (Fig. 4.15A).  This was reflected in an increase in 
the absolute number of these cells, as well as SSChi CD11b+ granulocytes (Fig. 4.15B).  An 
enrichment of monocytes was also observed in the absence of FcγRIIB (Fig. 4.15A).  Analysis 
of the CX3CR1+ MNP waterfall demonstrated an enrichment of mucosal monocyte frequency 
and absolute number in the absence of FcγRIIB (Fig. 4.15C).  No change was detected in 
systemic monocyte levels, consistent with a local effect on monocyte recruitment (Fig. 4.15D).  
However, systemic neutrophil levels were increased in the absence of FcγRIIB, consistent with 





Figure 4.15.  Intestinal neutrophil and monocyte infiltration in the absence of FcγRIIB.  
(A) tNSE analysis of colonic CD11b+ cells by flow cytometry.  (B) Flow cytometry showing 
colonic neutrophil infiltration in WT and Fcgr2b-deficient mice following cDSS, and 
quantification of colonic neutrophil and granulocyte numbers.  (C) Flow cytometry gating and 
quantification of CX3CR1+ MNP subsets following cDSS.  (D) Splenic monocyte and neutrophil 
counts following cDSS.  Data are representative of three independent experiments.  P values 
were calculated using the nonparametric Mann-Whitney test.  * P < 0.05. 
 
Finally, given the enlargement of SLOs in Fcgr2b-deficient mice following DSS-induced colitis, 
and the role of FcγRIIB in regulating B cell activation and survival, we sought to profile the B 
cell phenotype in mice following chronic intestinal inflammation.  Activated B cells were 
enriched in Fcgr2b-deficient mice.  Antibody isotype staining demonstrated an increased 
proportion and absolute number of class-switched IgD- IgM- B cells in both MLNs and spleens 
of Fcgr2b-defcient mice (Fig. 4.16A, B).  GL7 staining is a marker of GC activation.  The 
number and proportion of GL7+ IgD- B cells was similarly increased in SLOs of Fcgr2b-deficient 






































































































Figure 4.16.  Dysregulated B cell activation in secondary lymphoid organs in Fcgr2b-
deficient mice.  (A) Flow cytometry of MLN and splenic CD19+ B220+ class-switched B cells 
following cDSS.  (B) Quantification of cells shown in A.  (C) Flow cytometry of MLN and splenic 
germinal centre CD19+ B220+ B cells following cDSS.  (D) Quantification of cells in C.  Data 
represent a single experiment.  P values were calculated using the nonparametric Mann-
Whitney test.  ** P < 0.01; *** P < 0.001. 
 
In summary, Fcgr2b-deficient mice exhibit a more severe chronic intestinal disease course, 
characterised by exacerbated tissue inflammation, enhanced local MNP IL-1β and chemokine 
production, colonic monocyte and granulocyte infiltration, and a hyperactivated B cell 
phenotype in local and systemic SLOs.  These results serve to demonstrate the importance of 
the previously identified inflammatory networks in the development and progression of 












































































































































4.4.4. IL-1β blockade in Fcgr2b-deficient mice 
IL-1β has well established roles in the activation and maintenance of IL-17A-producing T cell 
subsets in vitro and in vivo, while IL-1β neutralisation can suppress DSS- and H. hepaticus-
induced inflammation.  We therefore hypothesised that exacerbated mucosal immune 
responses in Fcgr2b-deficient mice may be abrogated by blockade of IL-1R1 signalling.  To 
achieve this, WT and Fcgr2b-deficient mice were treated with anti-IL-1R1 blocking IgG 
antibody or an equivalent amount of Syrian hamster IgG in serum at weekly intervals during a 
course of DSS administration. 
 
 
Figure 4.17.  IL-1R1 blockade improves clinical disease severity in Fcgr2b-deficient 
mice.  (A) Weight change following acute DSS administration and treatment with control or 
anti-IL-1R1 IgG antibody.  (B, C) Colon weight (B) and SLO weight (C) at day 15 post-DSS 
administration of mice shown in A.  Data are representative of two independent experiments.  
P values were calculated using the nonparametric Mann-Whitney test.  * P < 0.05. 
 
Fcgr2b-deficient mice lost more weight than WT mice on DSS, although this was not as 
significant as previous experiments, while those receiving anti-IL-1R1 IgG lost less weight 
compared to littermates receiving control IgG (Fig. 4.17A).  While not significant, this may be 
limited by the relatively small number of mice per group (5-6).  Analysis of colon weight 
demonstrated a trend towards reduced colon weight per centimetre in Fcgr2b-deficient mice 
treated with anti-IL-1R1 IgG compared to control mice (Fig. 4.17B).  Interestingly, while splenic 
weight remained unchanged with anti-IL-1R1 treatment, MLN weight was significantly reduced 
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in Fcgr2b-deficient mice receiving anti-IL-1R1 IgG, supportive of reduced local inflammation 
(Fig. 4.17C).  Of note, there was less pronounced clinical differences between WT and Fcgr2b-
deficient mice compared to previous experiments.  This may be due to the duration of disease 
course, as samples were collected at day 15, rather than the later timepoints used in previous 
experiments.  Furthermore, colitis induction was not as successful in this case, as 
demonstrated by relatively minor changes in weight loss despite 7 days of DSS administration 
(Fig. 4.17A).  Strikingly, treatment of WT mice with anti-IL-1R1 IgG did not significantly affect 
any measure of clinical disease severity. 
Flow cytometric analysis of the colon demonstrated that while Fcgr2b-deficient mice exhibited 
enhanced colonic neutrophil recruitment relative to WT controls, IL-1R1 blockade restored 
neutrophil numbers back to WT levels in Fcgr2b-deficient mice (Fig. 4.18A).  No change in 
neutrophils was seen in WT mice treated with anti-IL-1R1 IgG.  Systemic neutrophils, as 
demonstrated by staining in the spleen, were also trending towards a reduction in frequency 




Figure 4.18.  Reduced colonic neutrophil infiltration following IL-1R1 blockade.  (A) 
Representative flow cytometry plots showing CD11b+ Ly6C/G+ neutrophils in the colonic LP at 
day 15 post-DSS administration and treatment with antibodies.  (B) Analysis of splenic 
neutrophil populations at day 15 post-DSS.  Data are representative of two independent 
experiments.  P values were calculated using the nonparametric Mann-Whitney test.  * P < 












































































In contrast to the effect on neutrophils, anti-IL-1R1 IgG administration had a smaller effect on 
CX3CR1+ MNP numbers in colon of Fcgr2b-deficient mice (Fig. 4.19A).  While colonic 
CX3CR1+ MNP subsets were once again increased in frequency and number in Fcgr2b-
deficient mice relative to WT controls, IL-1R1 blockade in these mice, or WT mice, had little 
effect (Fig. 4.19B).  This supports a role for IL-1β downstream of monocyte recruitment.  





Figure 4.19.  IL-1R1 blockade does not affect frequency or number of MNP subsets.  (A) 
Flow cytometric quantification of total CX3CR1+ cells in the colonic lamina propria.  (B) 
Quantification of CX3CR1+ MNP subsets by flow cytometry.  (C) Quantification of splenic 
monocyte frequency and number.  All samples are taken at day 15 post-DSS administration.  
Data are representative of two independent experiments.  P values were calculated using the 





















































































































IL-1R1 blockade did not profoundly affect IL-1β production by CD11b+ CX3CR1+ MNP subsets, 
as demonstrated by flow cytometry, in both WT and Fcgr2b-deficient mice (Fig. 4.20).  
However, the variability of IL-1β staining in CX3CR1+ MNP subsets in this case does not allow 
for complete dissection of the effect of IL-1R1 blockade on this aspect of MNP biology.  
 
 
Figure 4.20.  IL-1R1 blockade slightly reduces colonic MNP IL-1β production.  
Quantification of percentage and absolute number of colonic pro-IL-1β+ MNP subsets as 
determined by flow cytometry at day 15 post-DSS administration.  Data are representative of 
two independent experiments. 
4.4.5. Analysis of intestinal Th17 immunity in Fcgr2b-deficient mice 
We hypothesised that Fcgr2b-deficient mice would exhibit enhanced colonic IL-1β-dependent 
Th17 numbers, given the increase of global IL-1β and IL-17A, IL-22, and GM-CSF levels in 
Fcgr2b-deficient mice (Fig. 4.10).   
Colonic IL-17A-producing T cells were significantly increased in Fcgr2b-deficient mice 
following chronic DSS administration, as determined by flow cytometry (Fig. 4.21A).  Total 
CD3ϵ+ T cell numbers were increased in the absence of FcγRIIB (Fig. 4.21B), with an 
increased frequency of T cells expressing IL-17A+, as well as an increase in the total number 
of IL-17A+ T cells (Fig. 4.21B).  While the total number of T cells was unaffected by treatment, 
the increase in IL-17A production was IL-1β-dependent, as administration of the anti-IL-1R1 
blocking antibody reduced IL-17A-producing T cells back to near WT levels.  T cells were also 
subdivided into γδ CD4- T cells (Fig. 4.21C) and CD4+ αβ T cells (Fig. 4.21D), with increases 
in the total number of both subsets in the inflamed colons of Fcgr2b-deficient mice that was IL-

































































17A and an increase in total number of IL-17A-producing T cells in the absence of Fcgr2b, with 
a larger effect within the γδ T cell pool.  These effects were IL-1β-dependent, with a significant 
reduction in frequency and absolute numbers of IL-17A-producing cells in the presence of anti-
IL-1R1 blocking antibody.  Finally, while IL-1R1 blockade trended towards reducing the 
frequency of WT IL-17A-producing T cells, this was not translated into a reduction in absolute 
numbers of IL-17A-producing cells.  Therefore, these effects were specific to T cells in Fcgr2b-
deficient mice. 
IL-22 production by intestinal T cells was also investigated.  While IL-22-producing γδ T cells 
and CD4+ αβ T cells were not as prevalent as their IL-17A-producing counterparts, there 
remained a significant increase in IL-22 production in the absence of FcγRIIB in both subsets 
(Fig. 4.22).  This was apparent as an increase in the frequency of T cells that expressed IL-22 
and the total number of IL-22-producing T cell subsets.  There was a trend towards the 
reduction in the frequency of IL-22 producing T cells following IL-1R1 blockade in both subsets 
in Fcgr2b-deficient mice, but not WT mice, as well as a significant reduction in the total number 
of IL-22+ CD4+ αβ T cells in the absence of IL-1R1 signalling.  ILC3s are major sources of 
intestinal IL-22 and are known to be regulated by IL-1 signalling.  This will be discussed in 
Chapter 5. 
MLNs drain the intestinal mucosa and are the major site of local T cell activation.  We identified 
the same cell T cell subsets in the MLN, and once again demonstrated an increase in both γδ 
T cells and CD4+ αβ T cells locally that was unaffected by IL-1β blockade.  However, little IL-
17A production was observed compared to the colon, and this was largely unaffected by anti-
IL-1R1 IgG administration.  This is consistent with the role of IL-1β as an inflammatory cytokine 
that sustains local IL-17A production within the mucosa, rather than influencing Th17 cell 
generation in draining lymph nodes.  Curiously, the enrichment of MLN CD19+ B cells seen in 





Figure 4.21.  Enhanced intestinal IL-1β-dependent Th17 cells in Fcgr2b-deficient mice.  
(A) Flow cytometry of IL-17A production by intestinal T cell subsets in WT or Fcgr2b-deficient 
mice treated with a blocking anti-IL-1R1 or control antibody, following 15 days post-acute DSS 
administration.  (B-D) Quantification of total (left) and IL-17A-producing (middle, right) colonic 
CD3ϵ+ T cells (B), γδ T cells (C), and αβ T cells (D).  Data are representative of two independent 
experiments.  P values were calculated using the nonparametric Mann-Whitney test.  * P < 

























































































































































































Figure 4.22.  IL-22-producing T cells are increased in Fcgr2b-deficient mice.  
Quantification of the frequency (left) and absolute number (right) of colonic IL-22-producing γδ 
T cells (top row) and αβ T cells (bottom row) in WT and Fcgr2b-deficient mice following cDSS.  
Data are representative of two independent experiments.  P values were calculated using the 





















































































Figure 4.23.  The effect of IL-1R1 blockade on MLN-resident lymphocyte populations.  
(A, B) Flow cytometric quantification of the total number (left), percentage IL-17A+ (middle), 
and absolute number of IL-17A+ (right) γδ T cells (A) and CD4+ αβ T cells (B) in MLNs at day 
15 post-DSS administration in WT or Fcgr2b-deficient mice treated with anti-IL-1R1 blocking 
antibody or control IgG.  (C) Quantification of total CD19+ B cells in the MLN by flow cytometry.  
Data are representative of two independent experiments.  P values were calculated using the 
nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01. 
 
In summary, while the earlier endpoint for this experiment (day 15) may have diminished the 
chronic effect of FcγRIIB deficiency on certain features of inflammation, cellular differences 
between WT and Fcgr2b-deficient mice remained apparent.  Mice lacking inhibitory FcγRIIB 
exhibit enhanced IL-17A and IL-22 production by CD3ϵ+ T cells, in particular γδ T cells, within 
the inflamed colonic mucosa, while also exhibiting an increase in the total numbers of T cell 
subsets residing within the inflamed tissue.  Furthermore, anti-IL-1R1 blockade dampened 
exacerbated immunity in Fcgr2b-deficient mice, with a restoration of neutrophil recruitment and 
IL-17A and IL-22 production by T cells back to WT levels.  Strikingly, however, several other 
features of FcγRIIB deficiency remain unaccounted for by IL-1β blockade, including monocyte 
recruitment, cytokine production by CD11b+ CX3CR1+ MNP subsets, and T cell expansion, 
consistent with a role of FcγR signalling on a wide range of immune mechanisms.  Importantly, 





























































































































4.5. Chronic DSS-induced colitis in macrophage transgenic mice 
4.5.1. Clinical parameters 
Although FcγRIIB expression is highest among CX3CR1+ MNPs within the GI tract, the 
widespread expression profile of this receptor means that certain clinical manifestations in 
Fcgr2b-deficient mice may result from broad immune hyperactivity.  As such, refined models 
of FcγR signalling are required to assess the cell-intrinsic role of FcγR signalling in vivo on cell 
types of interest.  To investigate the cell intrinsic role of FcγRIIB on macrophages in vivo, 
macrophage M-TG mice were used.  Firstly, macrophage-specific overexpression of FcγRIIB 
was confirmed within the intestinal MNP populations by flow-cytometry (Fig. 4.24).  Differential 
FcγRIIB expression was most prominent in Ly6Chi MHC-IIlo monocytes and immature 
macrophages (Fig. 4.24A).  Consequently, A/I ratios for all activating receptors were 
significantly reduced in M-TG mice, making this model useful for discriminating the cell-intrinsic 
effect of FcγRIIB in intestinal MNPs (Fig. 4.24B). FcγRIIB overexpression did not influence 
expression of other FcγRs on intestinal MNPs (Fig. 4.24C) and was highly specific to the 
macrophage lineage (Fig. 4.24D). 
 
 
Figure 4.24.  Reduced A/I ratios of intestinal CX3CR1+ MNPs in M-TG mice.  (A) Flow 
cytometry staining of FcγRIIB in intestinal CX3CR1+ MNP subsets.  (B) Quantification of 
monocyte A/I ratios from flow cytometry FcγR staining intensities.  (C) Quantification of all 
FcγRs on intestinal monocytes in M-TG and N-TG mice.  (D) FcγRIIB expression on other 
intestinal immune cell subsets known to express FcγRIIB.    Data are representative of two 
independent experiments.  P values were calculated using the parametric Students t test.  * P 
























































































Opposite to the observed phenotype of Fcgr2b-deficient mice, M-TG animals lost less weight 
compared to littermate N-TG controls over the course of DSS-induced colitis, evident from as 
early as 7 days post-DSS administration (Fig. 4.25A).  On day 21 of the chronic DSS protocol, 
M-TG animals demonstrated increased colon length and reduced colon weight, consistent with 
reduced severity of colitis (Fig. 4.25B).  Furthermore, while splenic weight was relatively 
unchanged, MLN enlargement was reduced in M-TG animals, suggesting a localised reduction 
in inflammation in M-TG mice, unlike the more widespread immune dysregulation observed 
with Fcgr2b-deficient mice (Fig. 4.25C). 
 
 
Figure 4.25.  Reduced clinical severity of chronic intestinal inflammation in M-TG mice.  
(A) Weight loss in N-TG and M-TG mice following DSS administration.  n = 6 per group.  (B) 
Colonic clinical parameters in N-TG and M-TG mice following cDSS administration.  (C) MLN 
and spleen size in N-TG and M-TG mice following cDSS.    Data are representative of three 
independent experiments.  P values were calculated using a two-way ANOVA (A) and the 
nonparametric Mann-Whitney test (B, C).  * P < 0.05; **** P < 0.0001. 
4.5.2. Inflammatory cytokine and chemokine analysis 
qPCR analysis of global cytokine transcript levels demonstrated a specific reduction in Il1b 
levels (Fig. 4.26), with a smaller effect on Tnf, Il23a, Il6, and Il10 (not shown), supporting the 
hypothesis that modulation of FcγRIIB expression can directly influence IL-1β-driven chronic 
































































































































Figure 4.26.  Reduced IL-1β production is a prominent feature of M-TG mice.  qPCR of 
cytokines and chemokines in N-TG and M-TG whole colonic tissue following cDSS 
administration.  Data are representative of two independent experiments. 
 
Pro-IL-1β expression by CX3CR1+ MNP subsets was interrogated flow cytometry (Fig. 4.27).  
Strikingly, MNP-specific FcγRIIB overexpression significantly reduced the frequency (Fig. 
4.27A) and absolute number (Fig. 4.27B) of pro-IL-1β+ colonic MNP subsets following chronic 




Figure 4.27.  Reduced IL-1β production by intestinal CX3CR1+ MNPs in M-TG mice.  (A) 
Flow cytometry of pro-IL-1β production by colonic CX3CR1+ MNPs in N-TG and M-TG mice 
following cDSS.  (B) Quantification of frequency (top) and number (bottom) of pro-IL-
1β+ CX3CR1+ MNP subsets.    Data are representative of two independent experiments.  P 














































































































































4.5.3. Leukocyte profiling in M-TG mice 
Whereas Fcgr2b-deficient mice were characterised by enhanced colonic neutrophil and 
monocyte infiltration compared to WT mice, M-TG mice exhibited reduced neutrophil infiltration 
(Fig. 4.28A), a global reduction in total CX3CR1+ MNPs (Fig. 4.28B), and a reduction of all 
CX3CR1+ MNP subsets (Fig. 4.28C, D), dominated by a reduction in colonic monocyte 
infiltration compared to N-TG mice at day 21 post DSS administration.  Analysis of splenic 
myeloid populations demonstrated a trend towards a reduction in monocytes in M-TG mice, 
but little change in systemic neutrophil levels compared to N-TG, suggesting that the genotype 
effects on neutrophil biology are localised to the colon and recruitment to the tissue out of the 
circulation (Fig. 4.28E).  Alternatively, neutrophil retention in the colon may differ between M-
TG and N-TG mice. 
Unlike Fcgr2b-deficient mice, analysis of total colonic adaptive lymphocyte numbers by flow 
cytometry demonstrated no change in all CD3ε+ T cell subsets analysed or CD19+ B cells with 
genotype (Fig. 4.29A, B).  IL-17A production was proportionally highest within γδ T cells, with 
approximately 10 % IL-17A+ (Fig. 4.29C).  IL-17A production was also observed within CD4+ 
αβ T cells, and less so in CD4- αβ T cells.  Notably, in M-TG animals, IL-17A production was 
significantly reduced within both γδ T cells and CD4+ αβ T cells in the LP.  Little change was 
see in CD4- T cells.  This resulted in a reduction in the absolute number of IL-17A+ T cells in 



















Figure 4.28.  Reduced neutrophil and CX3CR1+ MNP numbers in M-TG mice.  (A) Flow 
cytometry of colonic neutrophil infiltration in N-TG and M-TG mice following cDSS.  (B) Flow 
cytometry of total colonic CX3CR1+ MNPs following cDSS.  (C) Quantification of colonic 
monocyte waterfall frequency following cDSS.  (D) Quantification of N-TG and M-TG colonic 
CX3CR1+ MNP subset numbers following cDSS.  (E) Splenic neutrophil and monocyte 
quantification following cDSS.  Data are representative of two independent experiments.  P 



































































































































































Figure 4.29.  Impaired colonic Th17 immunity in M-TG mice.  (A) Flow cytometry of colonic 
lymphocyte subsets following cDSS. (B) Quantification of lymphocyte subsets shown in A in 
N-TG and M-TG mice following cDSS.  (C) Colonic Th17 T cell subsets in N-TG and M-TG 
mice.  Data are representative of two independent experiments.  P values were calculated 
using the nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01. 
 
In summary, M-TG mice exhibit a reduction in chronic intestinal disease severity compared to 
N-TG littermate controls, opposing the phenotype see in Fcgr2b-deficient mice.  Specifically, 
M-TG mice were characterised by reduced local MNP-derived IL-1β production, colonic 
monocyte and granulocyte infiltration, and a reduction in intestinal IL-17A-producing T cell 
subsets and demonstrate that modulation of the FcγR A/I ratio in intestinal macrophages is 












































































































































4.6.1. Immune complexes promote IL-1β production by intestinal macrophages 
Tissue-resident macrophages play essential roles in homeostasis, physiology, and 
inflammation, including within the GI tract [3].  Here, they are continuously derived from 
circulating monocytes [280], [487] and receive local cues from the environment and tissue-
resident immune cells that direct their development to a predominantly scavenging, anti-
inflammatory phenotype [425], [492], [497], [499], [500], [504].  During inflammation, however, 
monocytes are directed towards a pro-inflammatory phenotype, with elevated production of IL-
1β, IL-23, and chemokines, all of which have been demonstrated to drive intestinal 
inflammation in numerous murine models [82], [279], [293], [295], [516], [620].  How production 
of these inflammatory mediators is regulated, however, is poorly understood. 
We set out to investigate the effect of IC signalling on IL-1β production by intestinal 
macrophages.  Here, we have shown that FcγR cross-linking has a profound transcriptional 
reprogramming of BMDM and flow-sorted intestinal macrophages, with several inflammatory 
pathways upregulated in the presence of IgG.  Central to this was the induction of cytokines 
associated with UC pathology, including IL-1β, IL-23, and neutrophil-recruiting chemokines 
CXCL1 and CXCL2 (and CXCL8 in humans).   
These results support observations in the previous chapter that IC could induce IL-1β and 
chemokine production by LPMCs at the RNA and protein levels.  In addition to IL-1β and IL-
23, we also observed an increase in Spp1, encoding osteopontin, Il6, and Il12b.  Although not 
all of these genes are associated with UC pathogenesis, all are implicated in the activation of 
Th17 immunity, and demonstrate this as a predominant function of FcγR signalling in intestinal 
MNPs.  Given their predominant location within the LP and non-migratory phenotype, FcγR-
induced macrophage-derived cytokines may support the maintenance or enhanced 
pathogenicity of Th17 within the mucosa following generation in local GALTs.  As macrophages 
and DCs exhibit similar cytokine profiles in the gut, as well as prominent FcγR expression, it is 
tempting to speculate that FcγR ligation on DCs may drive CCR7-dependent migration to and 
Th17 induction within local draining MLNs [88].  However, we have not investigated this here. 
Other than Th17-inducing cytokines, we observed an increase in Tnf and Osm transcripts.  
Recently, Powrie and colleagues demonstrated a role for OSM in the activation of intestinal 
stromal cells in infliximab-refractory IBD, although the source of this cytokine was not 
investigated [334].  These results suggest that in the context of chronic inflammation, local IgG 
may promote a cooperative OSM/TNF-driven inflammatory response via their action on local 
non-haematopoietic cells.  IL-10 expression was also significantly induced by IC.  This may 
represent a negative feedback loop to prevent excessive inflammation, consistent with the role 
of this cytokine in preventing IBD-associated pathology.  Preferential engagement of 
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inflammatory FcγR-induced cytokines in the H. hepaticus + anti-IL-10R IgG model of colitis 
may contribute, therefore, to some of the detrimental inflammatory mechanisms in this model, 
although this has yet to be investigated. 
Transcriptomics analyses has also yielded insights into the potential mechanisms that regulate 
IL-1β secretion by intestinal macrophages in response to FcγR cross-linking.  IC induced 
expression of NFκB components and Hif1a, two TFs known to drive expression of IL-1β and 
NLRP3 genes, the latter a component of the canonical inflammasome.  HIF-1α has been 
shown to directly drive IL-1β expression in macrophages during cellular glycolytic 
reprogramming and the accumulation of intracellular succinate [343].  Whether or not FcγR 
signalling may similarly regulate macrophage metabolism has not been investigated here, but 
is currently the subject of research within the lab.  Therefore, FcγR signalling could prime 
macrophages for assembly of the inflammasome, drive a switch to glycolysis, and directly 
induce expression of pro-IL-1β.  How FcγR may cooperate with secondary signals for IL-1β 
secretion is not clear.  IC stimulation of BMDMs only induces minor mature IL-1β secretion, 
but this signal is much greater in LPMCs stimulated with IC.  It is possible that the nature of 
intestinal macrophages, compared to BMDMs, promotes significant IL-1β secretion in the 
absence of secondary signals.  Alternatively, secondary stimuli may be present in LPMC 
cultures, as yet to be identified, that promote pro-IL-1β cleavage.  For example, GM-CSF can 
induce IL-1β secretion in response to LPS via induction of glycolysis and GTPases required 
for processing.  What appears to be clear from these analyses, however, is that FcγR signalling 
has a direct effect on the induction of IL-1β production, rather than inducing secondary signals 
from macrophages that promote basal pro-IL-1β cleavage, although we cannot rule out that 
this may have an effect.  Regardless, these results are contrary to reports that FcγR signalling 
acts to antagonise assembly of the inflammasome [79], and illustrate the requirement to 
analyse macrophages ex vivo.   
The characteristic milieu of the intestine may induce a macrophage phenotype that resembles 
more closely M2 macrophages.  In humans, M2 macrophage FcγR stimulation drives Th17 
induction, but not in M1 macrophages [74].  Therefore, FcγRs could be particularly important 
in the reprogramming of “anti-inflammatory” tissue-resident macrophages to a more pro-
inflammatory state in the context of a local IgG response.  Indeed, as IgG is very low at mucosal 
sites during homeostatic conditions, this could potently act as an alarmin to skew intestinal 
immune responses.  This has potential implications for UC and CD, with whom the FcγRIIA-
H/R131 variant exhibits differential association.  CD is associated with elevated IFNγ 
production and a M1-like macrophage phenotype.  In contrast, UC is associated with elevated 
IL-4 production, which may support an M2-like macrophage phenotype.  In the latter, local 
FcγR ligation on tissue-resident macrophages may have a more profound effect, driving 
macrophage polarisation towards IL-1β and IL-23 production, the induction of a Th17 
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response, and a chronic inflammatory state.  Whether this is the case is unknown, but may be 
addressed by the addition of additional secondary signals to inflamed LPMCs, including IFNγ.  
It is noteworthy that DSS-induced colitis is thought to more closely resemble UC-associated 
pathology, making a useful model to study FcγR-associated phenomena.  Throughout this 
study, we have primarily used O-IC as a model of FcγR stimulation due to its inability to ligate 
TLRs that may confound results.  However, it would be of interest to determine whether 
inflammatory responses following TLR-FcγR co-stimulation on intestinal macrophages exhibit 
a different profile to FcγR engagement alone. 
4.6.2. Enhanced DSS-induced colitis severity in the absence of FcγRIIB 
We have shown that macrophage-intrinsic FcγR signalling has the potential to drive intestinal 
inflammation through the induction of Th17-associated immune networks.  Currently, we are 
in the process of obtaining PBMC samples from individuals with different FcγRIIA variants in 
order to grow MDMs and address whether the magnitude of IL-1β responses in vitro is 
dependent on genotype.  This would help to clarify whether this may represent a relevant 
network contributing to UC susceptibility in these individuals: individuals with the UC-
associated FcγRIIA-H131 high-affinity variant may be at increased risk of exacerbated IL-1β-
driven pathology as a result of increased macrophage FcγR A/I ratios.  
To test this hypothesis, we first sought to investigate the DSS-induced disease course in 
Fcgr2b-deficient mice.  These mice lack the inhibitory FcγR and are susceptible to autoimmune 
and inflammatory disorders, but demonstrate increased resistance to infectious agents.  We 
demonstrated enhanced clinical features of inflammation in Fcgr2b-deficient mice following 
chronic DSS administration, including weight loss, SLO enlargement, and leukocytic infiltration.  
These mice exhibited an inflammatory phenotype consistent with IC-inducible cytokines in 
macrophages, with elevated global and MNP-intrinsic IL-1β and chemokine levels compared 
to WT mice, resulting in increased neutrophil and monocyte infiltration into the colon.  
Strikingly, blockade of IL-1β signalling significantly improved several features of inflammation, 
including weight loss and colonic neutrophil infiltration.  Furthermore, Fcgr2b-deficient mice 
exhibited elevated T cell-derived IL-17A and IL-22 production that was dependent on IL-1β.  In 
particular, FcγR signalling appears to have profound effects on cytokine production by γδ T 
cells, a population of T cells known for their innate production of IL-17A in response to IL-1β 
stimulation [354], [355].   
As previously noted, IL-17A neutralisation itself is detrimental in DSS-induced colitis and 
human IBD, thought to be driven by effects on the epithelial barrier [385]–[389].  IL-22 has also 
been shown to contribute to barrier homeostasis [361], [399]–[402].  Therefore, readouts of 
Th17 immunity in this case are likely a surrogate marker for the function of IL-1β within the GI 
tract, rather than being implicated in driving IL-1β-dependent inflammation.  This is not to say 
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that these cytokines may not be involved.  IL-17A is known to promote neutrophil recruitment 
and monocyte activation within inflamed tissues, and its blockade is beneficial in numerous 
circumstances [366], [367], [378], [381], [383].  It is possible that, in Fcgr2b-deficient mice, 
exacerbated IL-17A is pathogenic via similar mechanisms.  However, its complete 
neutralisation may also be detrimental.  Rather, therapeutic strategies may be better placed 
by modulating IL-17A expression so as to return it to within normal ranges.  Future approaches 
may involve analysing IFNγ and GM-CSF production by Th17, γδ T cells, and ILC3s.  Certainly, 
IFNγ is implicated in driving intestinal inflammation: its expression is significantly increased in 
CD and its blockade is beneficial in several murine models.  However, this has not been 
investigated here.  It is possible that FcγR-driven IL-1β-dominated milieu may drive the 
emergence of pathogenic dual-IFNγ/IL-17A-expressing Th17 cells that contribute to intestinal 
pathology, and may suggest why IL-1β blockade is particularly effective.  The role of GM-CSF 
is less clear.  While its expression is increased in colitis and may contribute to granulocyte 
recruitment and activation, its effects on regulating tolerogenic DCs, coupled with observations 
of anti-GM-CSF antibodies in IBD patients, demonstrate significant homeostatic functions for 
this cytokine within the GI tract.  It is possible that IL-1β and IL-23 blockade are more effective 
in colitis due to their action on several Th1 and Th17 cytokines.  Alternatively, non-T cell-
mediated effects, such as the pyrogenic and neutrophil-activating properties of IL-1β, may be 
involved in driving inflammation.  Alternatively, disease may reflect a combination of all of these 
factors.  
These results raise the question once more as to how FcγR-induced IL-1β and type 17 
immunity may feed backwards to regulate the IgG response?  Could ongoing detrimental IL-
1β-driven inflammation promote the emergence of pathogenic IgG subclasses and altered 
glycosylation profiles, for example? 
Clearly, however, these results demonstrate, for the first time, a link between FcγR signalling, 
IL-1β, and mucosal Th17 immunity, and resemble immunological features of Fcgr2b-deficient 
mice in other organ systems, such as the kidney [183].  C. rodentium infection is often used in 
the study of intestinal Th17 responses and requires IgG and FcγR signalling for sterilising 
immunity [283], [473], [523].  Therefore, it would be of interest to investigate the infection 
resistance and immune pathology of Fcgr2b-deficient mice following C. rodentium challenge, 
as one might expect a similar FcγR-inducible IL-1β-dependent IL-17A network. 
Despite these results, certain caveats exist in this study, both from the use of Fcgr2b-deficient 
mice and blockade strategies.  For IL-1β blockade in vivo, a blocking anti-IL-1R1 IgG 
monoclonal antibody was used.  This receptor is shared by IL-1β and IL-1α, the latter also 
being induced by IC signalling on macrophages.  As such, we cannot rule out that IL-1R1 
blockade has IL-1β-independent effects in the amelioration of disease.  Furthermore, given the 
widespread expression of this receptor, it is unclear whether the dosing used here was 
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sufficient to completely block IL-1-mediated signalling.  To resolve this question, Fcgr2b-
deficient mice could be crossed to Il1b-, Nlrp3-, or Casp1/4-deficient mice to abrogate this 
pathway.   
It is of note that certain clinical features were not significantly different in Fcgr2b-deficient mice.  
For example, colon length is widely used as a measure of inflammation, but was relative 
unchanged here [264], [621].  Given the effect of IC on the induction of anti-inflammatory 
genes, such as IL-10, it seems likely that several pro- and anti-inflammatory mechanisms 
contribute to the dysregulated immune response in these mice.  The balance of these 
mechanisms may contribute to the worsening of certain clinical features but not others.  
Histological analyses have not been carried out here, but remain a priority for future 
experiments to determine the extent to which these mouse models affect tissue destruction. 
As FcγRIIB is most highly expressed on gut macrophages, this represents a reasonable model 
to study FcγR signalling on macrophages, with immunopathology mirroring cytokine profiles 
identified in vitro.  However, FcγRIIB is widely expressed on both haematopoietic and non-
haematopoietic cells.  Therefore, receptor deficiency is likely to affect numerous immunological 
mechanisms.  Indeed, analysis of the B cell phenotype in these mice demonstrates an 
overactive B cell compartment within SLOs after DSS administration, and may support the 
enlargement of these organs.  While these observations may be relevant to individuals with 
polymorphisms causing FcγRIIB loss-of-function, they are unlikely to arise solely from 
macrophage-intrinsic effects.  As Fcgr2b-deficient mice age, they develop autoimmune IgG 
antibodies and autoimmunity, consistent with roles in B cell tolerance [62].  It is likely that 
Fcgr2b-deficient mice also generate higher titres of anti-commensal IgG antibodies that may 
contribute to intestinal pathology.  For example, increased bacterial opsonisation in Fcgr2b-
deficient mice could drive elevated IL-1β expression in the absence of differences in 
macrophage A/I ratios, confounding observations.   
Furthermore, Fcgr2b-deficient strains used here are derived from backcrossing Fcgr2b-
deficient mice on the 129-background, and as such contain additional susceptibility loci.  While 
these loci augment disease severity, the immune mechanisms contributing to inflammation are 
largely similar to B6-generated Fcgr2b-deficient mice [194].  Therefore, while useful in 
illustrating the relevance FcγR mechanisms to disease in vivo, confounding features in these 
mice do not allow for dissection of the contribution of macrophage-intrinsic FcγR signalling to 
intestinal inflammation.  Furthermore, as these mice are prone to hyperactive immune 
responses, profiling of all mouse strains under uninflamed conditions (i.e. non-DSS) is 
essential to determine the extent to which these phenomena are inflammation-dependent or 
arise naturally as a consequence of the strain.  This has not been done here.  A clearer model 
may involve the generation of macrophage-targeted FcγRIIB depletion, such as a LysM-Cre 
or CD11c-Cre mechanism, although these are not without off-target effects.  Alternatively, the 
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use of activating FcγR KO mice could help to support our observations, given their opposing 
phenotype to Fcgr2b-deficient mice in numerous models of IgG-driven inflammation [197], 
[199]–[201], [207], [208].  For example, FcγRIII or FcRγ-deficient strains may exhibit reduced 
IL-1β production within the chronically inflamed colon.  However, use of these mice would have 
similar constraints to pan-FcγRIIB KO mice, and one might argue that ablation of activating 
FcγR signalling is not representative of the FcγR A/I ratio modulation observed in patients with 
IBD.  Specifically, manipulation of the inhibitory receptor is more likely to mirror different 
strengths of activating signalling observed in individuals with the FcγRIIA-R/H131 variant, 
which bind IgG with different affinity.  Some of these issues have been addressed through the 
use of M-TG mice, as will be discussed below. 
It would also be of interest to develop a robust anti-commensal IgG transfer model analogous 
to that used by Blumberg and colleagues [482].  Are the IL-1β-dependent inflammatory 
mechanisms similarly induced by transfer of IgG?  We have addressed this to a small extent 
using the E. coli IgG transfer model, but cellular characterisation and clinical features of 
inflammation are currently lacking. 
4.6.3. M-TG mice are protected from DSS-induced colitis 
Because of the limitations of Fcgr2b-deficient mice, we utilised M-TG mice as a means to 
specifically manipulate the macrophage A/I ratio, as detailed above.  M-TG mice drive 
transgenic FcγRIIB expression via the CD68 promoter and have furthered our understanding 
of the role played by macrophages in IgG-driven disorders [205]. 
The results presented here demonstrate that M-TG mice are protected from overt inflammation 
in DSS-induced colitis.  Compared to littermate N-TG controls, M-TG mice lost less weight, 
had improved clinical features of inflammation, and reduced neutrophil and monocyte 
infiltration into the colon.  Furthermore, the immune phenotype in these mice was dominated 
by a reduction in IL-1β expression by intestinal MNPs and a corresponding decrease in IL-17A 
production by T cell subsets within the LP.  Therefore, these results mirror those observed in 
Fcgr2b-deficient mice, and demonstrate the critical importance of macrophage-intrinsic FcγR 
signalling in mediating intestinal inflammation. 
Unlike Fcgr2b-deficient mice, M-TG mice did not exhibit profound differences in splenic 
enlargement or neutrophil counts within this organ.  This is consistent with the more 
generalised inflammatory defect observed in Fcgr2b-deficient mice, given its expression 
across a wide range of cells.  Interestingly, macrophage-specific overexpression of FcγRIIB 
did affect MLN size.  Although the reason for this is unclear, it possible that the reduced 
inflammatory milieu in these mice suppresses DC migration, lymphocyte activation and GC 
formation.  However, as total T and B cell numbers within the LP are unaffected in M-TG mice, 
reduced IL-17A production may arise specifically from the reduction in mucosal Th17-
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promoting cytokines rather than Th induction in local lymph nodes.  Alternatively, FcγRIIB 
overexpression in M-TG mice has been shown to suppress VEGF-A-mediated enlargement of 
SLOs in response to IC [622].  A similar effect may be occurring here. 
In future, more targeted attempts to model the exact contribution of the FcγRIIA-H/R131 variant 
on susceptibility to IgG-mediated intestinal pathology are required, but were beyond the scope 
of this PhD.  For example, the use of humanised mouse models expressing FcγRIIA in 
combination with other receptors or alone may help to determine the magnitude of the 
contribution of this receptor to disease.  Furthermore, the generation of transgenic mice 
expressing the exact variants of FcγRIIA would help to take these observations one step 
further.  Both approaches would go a considerable way to overcoming the shortfalls of using 
mutant FcγRIIB mice to address signalling from an activating receptor, as this will likely have 
off-target effects on other FcγRs other than FcγRIII (mouse homologue of FcγRIIA), as well as 
potentially other signalling pathways, as discussed in the Introduction chapter. 
4.6.4. Summary 
An outstanding question in these studies is why does FcγR signalling affect IL-1β signalling so 
dramatically, as opposed to other inflammatory cytokines induced by FcγR cross-linking in 
vitro?  For example, exogenous stimulation of macrophages induces IL-23 in addition to IL-1β.  
However, LPMCs do not induce IL-23 in response to IgG and little change is observed between 
Fcgr2b-deficient, WT or M-TG in their expression of IL-23.  Furthermore, effects on TNF are 
relatively smaller compared to flow-sorted macrophages.  There may be several explanations 
for this.  IL-1β expression is highest within the inflamed intestine and in flow-sorted 
macrophages, compared to other cytokines.  Therefore, modulation of this cytokine is likely to 
have a dominant effect on inflammation.  Alternatively, IL-1β is known to be directly induced 
by commensal microbes and further augmented by opsonisation, at least in human 
macrophages [74], [279].  The unique integration of FcγR and TLR signals may preferentially 
boost certain pathways over others, such as IL-23.  This is consistent with a study by Uo et al. 
in which only TLR stimulation had a more pronounced effect on IL-23 expression [430].  In our 
studies, most FcγR cross-linking studies were carried out with model ICs made of OVA, which 
do not engage other PRRs.  Therefore, it is possible that opsonised bacteria elicit a different 
magnitude or response profile, compared to FcγR cross-linking alone, which is more 
representative of inflammation in vivo.  Indeed, classical mature IL-1β production requires two 
steps.  However, Seo et al. demonstrated that certain commensal species contain sufficient 
signals to induce IL-1β secretion directly, unlike LPS alone.  Could opsonisation of commensal 
microbes, therefore, potentiate this mature IL-1β secretion in a manner difficult to model in 
vitro?  It seems clear that, despite our understanding of the major players involved in 
inflammasome assembly and activation, how these processes are regulated is not well known.  
Alternatively, as previously alluded to, the inflammatory mechanisms that underlie a particular 
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IBD model also influence the potential effect of FcγR signalling pathways.  For example, CD 
models, in which IFNγ plays a more major role, may drive alternative mechanisms of 
inflammation that revolve around Th1 activation.   
FcγRs have been shown to bind components of innate humoral immunity, such as pentraxins, 
as well as cross-link to other non-Fcγ receptors on the cell surface.  While anti-flagellin IgG 
transfer has been demonstrated to be pathogenic in DSS-induced colitis, our results do not 
rule out the contribution of non-IgG-mediated effector functions of FcγRs in colitis.  For 
example, FcγRIIB may cross-link to TLRs.  Therefore, FcγRIIB deficiency may result in 
elevated TLR-driven IL-1β production.  These effects would be unrelated to those linked to the 
UC-associated FCGR2A polymorphism.  Additionally, the expression of FcγRIIB on myeloid 
progenitor cells in the bone marrow and the role of this receptor in the apoptosis of bone 
marrow-resident plasma cells may contribute to systemic extra-intestinal effects in these mice, 
such as monocytosis [106], [194].  Furthermore, certain pathological features in vivo could be 
driven by FcγRs in the absence of IgG: binding to CRP or SAP could stimulate inflammatory 
cytokine production within the LP [63], [117]–[120].  Certain studies may help to resolve these 
issues.  Direct stimulation of intestinal or in vitro-derived macrophages with IgG opsonised 
commensal bacteria in the presence or absence of FcγR-blocking antibodies may help to 
ascribe functionality to each component.  For example, FcγRIIB blockade in the presence of 
unopsonised bacteria may result in enhanced inflammatory cytokine production if FcγRIIB 
regulates signalling via IgG-independent pathways.  
In conclusion, the results presented in this chapter demonstrate that FcγR signalling can 
control inflammatory cytokine production by intestinal macrophages and monocytes both in 
vitro and in vivo.  This effect is dominated by IL-1β production, a prototypical inflammatory 
cytokine associated with chronic inflammation in human IBD and murine models of colitis.  A/I 
ratio manipulation on macrophages is sufficient to dictate IL-1β-dependent inflammation, as 
determined by classical clinical features of inflammation and mucosal Th17 activation, and 
targeting this pathway is beneficial in DSS-induced colitis.  These results, therefore, identify 
FcγR signalling as a major determinant of colitis severity, which may be targeted to improve 
disease progression (Fig. 4.30). 
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Figure 4.30.  Chapter 4 graphical summary.  FcγR signalling drives the inflammatory 
activation of intestinal macrophages.  IC induces a transcriptional programme dominated by 
UC-associated cytokines, including IL-1β, IL-23, and TNFα.  IC stimulation also results in the 
production of neutrophil recruiting chemokines.  In vivo, manipulation of this inflammatory 
network by transgenic alteration of the macrophage A/I ratio is sufficient to alter the progression 
of intestinal inflammation, the induction of mucosal Th17 cells, and neutrophil recruitment.  



























5.  Expression and function of Fcγ receptors on group 3 innate 
lymphoid cells 
5.1. Introduction and hypotheses 
We have previously shown that Fcgr2b-deficient mice exhibit enhanced mucosal IL-1β-
dependent Th17 immune responses, with an increase in IL-17A and IL-22-producing T cell 
subsets within the colonic mucosa.  We also observed global increases in Il17a, Il22, and Csf2 
expression levels within the inflamed colon by RNA analysis.  Other than T cells, ILC3s are a 
major source of these cytokines within the GI tract.  ILC3s are innate Th17-like cells enriched 
at mucosal sites, particularly the GI tract, that produce type 17-associated cytokines in 
response to cytokine stimulation [12], [525].  In particular, MNP-derived cytokines, including 
IL-1β, IL-23, and TL1A, are critically implicated in regulating ILC3 biology in vivo [290]–[292], 
[359]. 
Little is known about how FcγR signalling may regulate the functional phenotype of these cells, 
either in vitro or in vivo.  Firstly, FcγR-inducible cytokines produced by macrophages and DCs, 
as highlighted in the previous chapters, may regulate ILC3 activity indirectly.  Secondly, given 
their close developmental relationship with NK cells, it remains unexplored whether helper ILC 
subsets similarly express FcγRs.  Murine NK cells express FcγRIII, the canonical low-affinity 
activating FcγR, while in humans, NK cells express FcγRIIIA (and FcγRIIC in certain 
circumstances) [102], [103].  In these cells, FcγR signalling mediates IFNγ production and 
ADCC, the directed release of cytotoxic molecules and perforin at IgG-opsonised cells for 
target cell killing [104], [105].  Therefore, FcγR signalling drives canonical functions in these 
cells.  This raises the question whether FcγR signalling may control cytokine production or 
antigen presentation by ILCs.  Murine ILCs in particular are well known for their absence of 
PRRs and demonstrates a key feature of ILC biology: the inability to directly sense danger-
associated molecules.  However, if ILCs were to express FcγRs, this would represent a shift 
in our understanding of these cells.  In circumstances of IgG opsonised antigens, such as in 
chronic inflammation or a memory B cell response, ILCs would be able to react directly, without 
the requirement for secondary microbe-sensing cells, and highlighting a novel mechanism of 
innate-adaptive communication.   
Here, we sought to investigate the FcγR expression profile of helper ILC subsets within the GI 
tract and extra-intestinal tissues.  We hypothesised that ILCs would express FcγRIII, similar to 
NK cells, with FcγR cross-linking potentially driving enhanced cytokine production, antigen 
presentation, and migration.  
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5.2. Profiling FcγR expression on innate lymphoid cells 
To first address this question, we analysed small intestinal ILC transcriptomic datasets from 
the Immgen consortium (Fig. 5.1).  ILC1s and all subsets of ILC3s expressed Fcgr3, similar to 
NK cells (Fig. 5.1A).   Furthermore, NKp46+ ILC3s expressed highest levels of FcγRIII.  Minimal 
FcγRIII expression was detected on ILC2s.  A similar expression pattern was seen for Fcer1g, 
the common γ-chain required for signalling from FcγRIII, and Fgr2b.  FcγR expression was 
also analysed on flow-sorted intestinal and splenic RORγt+ ILC3s by qPCR, and demonstrated 
a similar expression pattern, with highest levels of FcγRIII and the common γ-chain, and lower 
levels of FcγRIIB (Fig. 5.1B).  Therefore, ILC3s and ILC1s express a similar FcγR expression 
pattern to NK cells in mice, both at mucosal and non-mucosal sites, with highest levels of the 
prototypical activating FcγRIII and associated adaptor signalling molecule, and lower levels of 




Figure 5.1.  ILC3s and ILC1s dominantly express the prototypical activating FcγRIII.  (A) 
Heatmap showing FcγR gene expression across different SI-resident ILC subsets in a 
transcriptomics dataset (GSE37448).  (B) qPCR of FcγR expression in flow-sorted intestinal 
and splenic RORγt+ ILC3s.  Data are representative of two independent experiments. 
 
Flow cytometry was used to profile FcγR expression on all helper ILC subsets in the SI.  ILCs 
were identified as Lin- CD45+ IL-7Rα+.  ILC3s were firstly identified as Lin- CD45int IL-7Rα+ 
RORγt+ cells (Fig. 5.2A).  Three ILC3 subsets were then identified based on expression of 
NKp46 and T-bet: 
1. T-bet+ NKp46+ 
2. T-bet+ NKp46- 
3. T-bet- NKp46- 
All three subsets expressed FcγRs, as determined by FcγRII/III staining using the 2.4G2 










































































ILC2s were identified as RORγt- KLRG1+ cells, while ILC1s could be identified as RORγt- 
KLRG1- T-bet+, and further subdivided into NKp46+ and NKp46- subsets (Fig. 5.2C).  
Interestingly, of the remaining ILC subsets, only the T-bet+ NKp46+ ILC1s expressed FcγRs, 
mirroring the expression pattern in ILC3 subsets and the known expression of FcγRIII by 




Figure 5.2.  Intestinal ILC3s and ILC1s express Fcγ receptors.  (A) Flow cytometric gating 
strategy for the identification of SI-resident ILC3 subsets based on NKp46 and T-bet 
expression.  (B) ILC3 subset FcγR staining and quantification using the anti-FcγRII/III antibody 
clone 2.4G2.  (C) Identification and FcγR expression by SI-resident KLRG1+ ILC2s and T-bet+ 
ILC1s.    n = 3 per group.  Data are representative of three independent experiments.  P values 
were calculated using the parametric Student’s t test.  ** P < 0.01. 
 
 
Figure 5.3.  ILC3s express similar levels of FcγRs to NK cells.  Flow cytometric 
quantification of FcγRII/III expression across small intestinal ILC subsets compared to NK 
cells.  n = 3 per group.  Data are representative of two independent experiments.  P values 
























































































Comparison with NK cells demonstrated that SI-resident ILC3s had a very similar level of FcγR 




Figure 5.4.  cKit-mediated ILC identification and FcγR expression.  Flow cytometry 
showing ILC3 identification based on cKit expression for flow-sorting ILC3s from non-RORγt-
GFP reporter mice.  Data are representative of two independent experiments. 
 
We confirmed by flow cytometry that cKit could be used to identify ILC3s, a strategy that would 
be essential for flow-sorting live cells from non-reporter mouse strains (Fig. 5.4).  cKitint KLRG1- 
(blue) and cKithi KLRG1- (red) subsets dually expressed RORγt and FcγRs, as determined by 
2.4G2.  A minority of cKitint cells expressing KLRG1 also expressed RORγt, but otherwise was 
comprised predominantly of RORγt- cells, consistent with ILC2s.  This was confirmed by the 
absence of FcγR staining on these cells. 
In addition to SI-resident cells, ILC3s and ILC1s expressed FcγRs across all murine tissues 
examined, including the colon, MLNs, and spleen (Fig. 5.5A, B).  Therefore, IgG can potentially 
activate ILCs via FcγR ligation throughout the body, not just at mucosal surfaces.  
In summary, we have demonstrated that T-bet+ NKp46+ ILC1s and all subsets of ILC3s express 
FcγRs, while ILC2s were devoid of FcγRs, as determined by flow cytometry.  Furthermore, 
FcγR characterisation at the RNA level in mice demonstrated significant expression of FcγRIII 
and minimal expression of the inhibitory receptor, FcγRIIB, consistent with the expression 
pattern of NK cells.  Therefore, ILC1s and ILC3s may potentially be activated by cross-linking 






















Figure 5.5.  ILCs express FcγRs throughout the body.  Flow cytometry showing FcγRII/III 
staining on Lin- IL-7Rα+ RORγt+ ILC3s (A) and NKp46+ T-bet+ ILC1s (B) in different organs.  
Data are representative of two independent experiments. 
 
5.3. Immune complex stimulation of ILC3s in vitro 
Given the enrichment within the GI tract, ease of identification by several strategies, and key 
roles in regulating immune responses within the colonic mucosa, we focused predominantly 
on the effect of FcγR signalling on ILC3s.  In particular, we hypothesised that FcγR cross-
linking may regulate cytokine production and antigen presentation by these cells, given the 
canonical roles of FcγRs in regulating these processes across various innate immune cell 
populations.   
To determine whether IgG ICs could promote IL-22 production, colonic inflamed LPMCs were 
stimulated with O-IC and IL-22 production measured by ELISA.  In paired LPMC samples, IC 
stimulation consistently increased IL-22 production (Fig. 5.6A), while intracellular staining 
demonstrated an increased proportion of LPMCs expressing IL-22, with the majority of IL-22+ 
cells being Lin-.  Flow cytometric identification of Lin- RORγt+ IL-7Rα+ ILC3s demonstrated an 
increased proportion of ILC3s expressing IL-22 and an increase in ILC3 IL-22 MFI in response 
to O-IC (Fig. 5.6B).  However, there was minimal production of IL-17A production by ILC3s in 
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Figure 5.6.  Immune complexes promote IL-22 production by ILC3s.  (A) ELISA of IL-22 
production by inflamed colonic LPMCs stimulated for 16 h with O or O-IC.  (B) Intracellular 
cytokine staining of IL-22-producing cells following 6 h stimulation with O or O-IC.  n = 3 per 
group.  Data are representative of two independent experiments.  P values were calculated 
using a ratio-paired t test (A) or a parametric Student’s t test (B, C).  * P < 0.05; ** P < 0.01; 
*** P < 0.001. 
 
ILC3s are known to express MHC class II molecules.  In the GI tract, and specifically within 
GALT, ILC3s present antigen to T cells in the absence of CD80 and CD86, inducing T cell 
anergy [554], [587].  However, splenic ILC3s can activate T cell proliferation through MHC-II-
dependent mechanisms [589].  MHC class II expression has been reported to be refractory to 
ILC3 stimuli.  Strikingly, however, IC stimulation of LPMCs upregulated MHC-II expression by 
colonic ILC3s (Fig. 5.7A), as well as other cell-surface co-stimulatory molecules, including PD-
L1 (Fig. 5.7B).  Therefore, IgG IC can induce cytokine production and antigen presentation by 



































































Figure 5.7.  ICs induce ILC3 MHC-II upregulation.  (A) MHC class II staining of RORγt+ 
ILC3s in small intestinal LPMCs stimulated with O or O-IC for 16 h.  n = 3 per group.  (B) 
Quantification of cell surface receptor expression on ILC3s after LPMC stimulation.    Data are 
representative of three independent experiments.  P values were calculated using the 
parametric Student’s t test.  * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
In summary, stimulation of mixed colonic leukocyte cultures with IC induces the activation of 
ILC3s, both via induction of an IL-22-dominated cytokine response and the upregulation of 
MHC-II molecules.  Therefore, IgG appears to favour a homeostatic programme in these cells 
that could reinforce barrier function and suppress T cell responses locally during inflammation.  
As such, IgG would be acting in a predominantly anti-inflammatory manner on these cells.  
However, the use of mixed cultures precludes investigation of the contribution of cell-intrinsic 
FcγR signalling towards these observations.  To address this, we cross-linked FcγRs on flow-
sorted ILC3s in vitro. 
5.4. Analysis of canonical FcγR signalling in ILC3s 
In order to dissect the effects of FcγR signalling on ILC3s, we first sought to determine the 
downstream signalling pathways involved.  FcγR cross-linking leads to the activation of SYK-
mediated signalling pathways.  Therefore, we characterised phosphorylation of classical FcγR-
associated signalling molecules.  Indeed, 15 min FcγR cross-linking with 2.4G2 and a 
secondary IgG antibody resulted in enhanced phospho-SYK and phospho-ERK levels (Fig. 
5.8). 
Of note, FcγR cross-linking on flow-sorted ILC3s promoted their survival in vitro, although this 















































Figure 5.8.  FcγR crosslinking activates canonical downstream FcγR signalling 
pathways.  Intracellular phospho-staining and quantification of flow-sorted intestinal ILC3s 
following 15 min FcγR crosslinking with 2.4G2 and anti-rat IgG.  Data are representative of two 






Figure 5.9.  FcγR promotes ILC3 survival in vitro.  Flow cytometric analysis of ILC3 viability 
in vitro after 16 h incubation in complete RPMI in the presence or absence of O or O-IC.  Data 
are representative of three or more independent experiments. 
 
5.5. The role of FcγR signalling on ILC3 antigen presentation 
FcγRs are known to induce the phagocytosis of antigens by professional antigen-presenting 
cells and promote antigen presentation via MHC molecules.  Therefore, we sought to 
determine whether IgG opsonisation increased antigen uptake and influenced MHC-II-
mediated antigen presentation by ILC3s.  Incubation of flow-sorted ILC3s with fluorescent OVA 
resulted in relatively low levels of antigen uptake, consistent with previously published data 
(Fig. 5.10) [543].  However, incubation with O-IC did not result in significant uptake, suggesting 
FcγR-mediated uptake is not a major facet of ILC biology.  Indeed, NK cells are not 




































































Figure 5.10.  FcγR crosslinking does not enhance phagocytosis by ILC3s.  Quantification 
of OVA-647 uptake by flow-sorted ILC3s following 16 h incubation with O-A647 or O-A647 
immune complexes.  n = 3 per group.  Data are representative of three independent 
experiments.  P values were calculated using the parametric Student’s t test.  * P < 0.05; *** P 
< 0.001. 
 
As we had previously demonstrated MHC-II upregulation by ILC3s following IC stimulation of 
cLPMCs, we sought to investigate whether this was due to a direct effect of IC on ILC3s.  
Indeed, FcγR cross-linking with O-IC on flow-sorted intestinal ILC3s upregulated expression 
of MHC-II compared to O-stimulated controls, with little change in CD80 or CD86 expression, 
which remained negligible under all conditions tested (Fig. 5.11A).  Furthermore, analysis of 
ILC3 subsets demonstrated that this effect was most pronounced for NKp46+ ILC3s (Fig. 
5.11B).  While these cells have lower MHC-II expression than LTis, this may reflect their higher 
level of FcγRIII expression.  Therefore, although O-IC does not promote antigen uptake by 






















































































Figure 5.11.  Immune complexes induce MHC class II expression by ILC3s.  (A) Flow 
cytometry showing MHC-II and CD80/CD86 expression by RORγt+ ILC3s following 16 h 
stimulation of small intestinal LPMCs with O or O-IC.  (B) Stratification of RORγt+ ILC3s into 
subsets and quantification of MHC class II upregulation in SI-LPMC cultures following 16h 
stimulation with O or O-IC.  n = 3 per group.  Data are representative of three independent 
experiments.  P values were calculated using the parametric Student’s t test.  *** P < 0.001. 
 
5.6. Modulation of ILC3 FcγR expression during inflammation 
FcγR expression is modified by local inflammation in intestinal macrophages, with an increase 
in A/I ratio driven by upregulated expression of activating receptors.  We therefore 
hypothesised that inflammation may also influence ILC3 FcγR expression.   
Flow-sorted intestinal ILC3s from inflamed mice demonstrated an increased expression of 
Fcgr2b transcripts relative to ILC3s isolated from healthy mice (Fig. 5.12A).  Furthermore, 
Fcgr3 and Fcer1g expression levels were reduced in SI-resident ILC3s, and relatively 
unchanged in colonic ILC3s, isolated from the inflamed GI tract compared to uninflamed 
controls.  This demonstrates a reduction in the A/I ratio following the induction of inflammation, 

















































































Figure 5.12.  An inflammatory milieu induces ILC expression of the inhibitory FcγRIIB.  
(A) qPCR analysis showing fold change in FcγR expression in SI and colon-resident ILC3s 
flow-sorted from DSS-inflamed mice relative to healthy controls.  (B) Heatmap showing 
inflammatory cytokines in DSS-inflamed whole colon tissue compared to healthy control tissue 
(GSE42768).  (C) qPCR analysis showing fold change in FcγR gene expression by flow-sorted 
intestinal ILC3s following 24 h incubation with IFN-γ, TNF and IL-1β relative to untreated ILC3s.  
n = 3 per group.  Data represent a single experiment.  P values were calculated using the 
parametric Student’s t test.  * P < 0.05; ** P < 0.01. 
 
DSS is associated with the induction of a broad local inflammatory response.  We sought to 
identify key DSS-associated cytokines that may play a role in modulating FcγR expression in 
ILC3s through analysis of transcriptomics data (Fig. 5.12B).  As well as increased levels of IL-
1β, DSS-induced colitis also increased expression of several ILC3-activating cytokines, 
including IFN-γ and IL-23.  Culture of flow-sorted intestinal ILC3s from uninflamed mice with a 
cocktail of inflammatory cytokines (IL-1β, IFN-γ, TL1A) resulted in significantly increased 
expression of Fcgr2b, a reduction in Fcer1g levels, and a minor reduction in Fcgr3, consistent 
with in vivo observations (Fig. 5.12C). 
5.7. ILC3 activation in Fcgr2b-deficient mice 
Anti-commensal IgG and commensal opsonisation is significantly induced during chronic 
inflammatory disorders of the GI tract, as demonstrated in Chapter 3.  Therefore, it is likely that 
FcγR ligation on intestinal ILC3s becomes most prominent under these circumstances.  
Therefore, we sought to investigate whether local IgG induction in chronic intestinal 
inflammation may influence ILC3 phenotype and function.  Firstly, we characterised IL-22 and 
IL-17A-producing cell subsets in chronic DSS-induced colitis.  Chronically inflamed colonic 
LPMCs produced increased levels of IL-22 and IL-17A in culture compared to uninflamed cells 
(Fig. 5.13A).  Flow cytometry identified that, although both IL-17A and IL-22 production was 
confined to the CD90.2+ population (Fig. 5.13B), the majority of IL-22-producing CD90.2+ 
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lymphocytes were CD3ϵ- CD4+/-, consistent with ILCs, while IL-17A production was 




Figure 5.13.  Group 3 innate lymphoid cells are the major source of IL-22 in chronic 
intestinal inflammation.  (A) ELISA of IL-22 and IL-17A production by colonic LPMCs per 8 
x 105 cells.  n = 5 per group.  (B) Flow cytometry staining of IL-22 and IL-17A producing cells 
in the inflamed colonic lamina propria following chronic DSS administration.  (C) Quantification 
of the cytokine producing subsets shown in B.    Data are representative of two or three 
independent experiments.  P values were calculated using the parametric Student’s t test (A) 
or a one-way ANOVA (C).  * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
 
Analysis of IL-22 production in Fcgr2b-deficient mouse colons following cDSS colitis 
demonstrated a significant increase in intestinal CD90.2+ IL-22+ ILC3s in the absence of 
FcγRIIB (Fig. 5.14A).  This increase was independent of IL-1 signalling, as IL-1R1 blockade 
had no effect on IL-22 production (Fig. 5.14A, B).  CD4- ILC3s were more abundant than CD4+ 
ILC3s, but both populations were similarly enriched in inflamed colons of Fcgr2b-deficient mice 






































































































Figure 5.14.  IL-22-producing ILCs are enriched in inflamed colons from Fcgr2b-deficient 
mice.  (A) Flow cytometry staining of IL-22-producing CD3ϵ- CD90.2+ cells in the inflamed 
colons of WT and Fcgr2b-deficient mice treated with control IgG or anti-IL-1R1 IgG.  (B) 
Quantification of IL-22+ ILC frequency and subset numbers in mice shown in A.  Data are 
representative of two independent experiments.  P values were calculated using the 
nonparametric Mann-Whitney test.  ** P < 0.01. 
 
In summary, enhanced Th17 responses are characteristic of chronic intestinal inflammation, 
with ILC3s being the major source of IL-22 within the inflamed colonic mucosa.  We observed 
little IL-17A secretion by ILC3s, and was largely confined to the CD3ϵ+ T cell compartment, 
supportive of studies in Chapter 4.  In Fcgr2b-deficient mice, IL-22 production by CD3ϵ- 
CD90.2hi ILC3s was significantly increased relative to WT controls, and this was refractory to 
IL-1R1 blockade.  This is in stark contrast to observations made in Chapter 4 that IL-17A and 
IL-22 production by colonic T cells was heavily dependent on IL-1 signalling.  These results 
reinforce the suggestion that IgG IC supports an IL-22-mediated homeostatic response in 
ILC3s, with little inflammatory IL-17A, and demonstrates IL-1β-independent mechanisms for 












































































































5.8. Global transcriptional profiling of IgG-stimulated ILC3s 
To get a better understanding of how FcγR signalling may contribute to ILC3 biology, we 
performed RNAseq analysis on flow-sorted small intestinal ILC3s stimulated for 4 h with O or 
O-IC.  Surprisingly, GSEA of Hallmarks pathways demonstrated a downregulation of several 
pathways following IC stimulation, as opposed to what is seen in IC-stimulated macrophages 
(Fig. 5.15A).  In particular, notable reductions were seen in TNFA signalling via NFκB, MTOR 
complex 1 (MTORC1) signalling, Glycolysis, Hypoxia, and Cholesterol homeostasis, modules 
classically associated with the inflammatory response (Fig. 5.15B). 
 
 
Figure 5.15.  Transcriptomics analysis of ILC3s reveals an anti-inflammatory profile 
induced by FcγR signalling.  GSEA of Hallmarks pathways in IC-stimulated flow-sorted 
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Analysis of the top differentially expressed genes in response to IC stimulation demonstrated 
a reduction in several activation-associated molecules, including Stat1, Csf2, Il2ra, Ptgs2 and 
Cd69 (Fig. 5.16A, B).  Csf2 encodes GM-CSF, which has been implicated in driving detrimental 
chronic colitis through the local activation of granulocytes.  Therefore, IC-stimulated ILC3s may 
downregulate inflammatory responses predominated by GM-CSF secretion in favour of a 
transcriptional programme supporting barrier function and T cell inactivation.  This would 
represent a novel negative feedback loop to regulate type 17 responses during chronic 
inflammation.  Supporting this, IC-induced genes included those associated with the 
reinforcement of the ILC3 phenotype, such as Il7r, Zfp292, and Ikzf3 (gene encoding Aiolos), 
as well as certain NK-associated genes not previously associated with ILC3 function, including 
Cd226 (Fig. 5.16A, C). 
 
 
Figure 5.16.  Analysis of top differentially expressed genes in response to IC.  (A) 
Volcano plot showing to differentially expressed genes in response to IC stimulation, as a 
function of P value and log2 fold change.  (B, C) Heatmaps showing the top 50 upregulated 
(B) and the top 50 downregulated (C) genes in response to IC stimulation. 
 
Network analysis was performed by STRING analysis on the top 50 up- and down-regulated 
genes (Fig. 5.17).  Amongst downregulated networks were genes associated with the 
spliceosome and amino acid transporters, as well as, most notably, a cluster of genes 
associated with Stat1 signalling, as previously mentioned.  IC stimulation induced pathways 
involved in the regulation of transcription and translation: upregulated networks included genes 
175 
involved in RNA processing, GTPase activity, and IL-7R maintenance.  IC-induced gene 
expression changes were smaller than those in macrophages, and likely reflects the lower 




Figure 5.17. STRING analysis reveals regulation of genes involved in RNA processing 





Given the largescale changes in networks associated with RNA processing, we analysed the 
differential regulation of transcriptional and translational regulators in response to IC 
stimulation (Fig. 5.18).  Strikingly, IC-induced genes included Zfp292, Zbtb16 (gene encoding 
PLZF), Tbx21 (gene encoding T-bet), and Ikzf3 (gene encoding Aiolos, an epigenetic modifier 
associated with the maintenance of Th17 cells), several genes associated with ILC3 
development, maintenance, and function.  These observations support the notion that FcγR 
signalling is beneficial for the maintenance of ILC3s within the GI tract.  Therefore, we sought 
to further investigate transcriptional programmes associated with ILC3 biology within the GI 
tract: SI-associated genes, ILC3-associated cytokine and chemokine receptors, and TF 
pathways. 
 
Figure 5.18.  FcγR signalling modulates expression of transcriptional regulators 
involved in ILC identity.  Heatmap showing differentially expressed transcriptional regulators 
























































RNAseq analysis of ILCs has previously demonstrated that SI-resident ILCs are associated 
with a unique transcriptional signature distinct from ILCs in distal tissues, such as the liver 
[556].  We found that IC stimulation induced widespread changes in this SI-associated 
signature (Fig. 5.19A), suggesting that tissue-residency influences the response of cells to 
FcγR ligation.   
 
 
Figure 5.19.  FcγR signalling induces transcriptional profiles associated with tissue-
residency and ILC3 maintenance.  Heatmaps showing differential gene expression of genes 
associated with SI ILC biology (A), maintenance of Th17 immunity (B), and the regulation of 
AhR signalling in ILC3s in response to IC. 
 
Recent data has demonstrated ILC subset plasticity within tissues in response to local cues: 
IL-2, IL-12, and IL-18 are associated with an ILC3 to ILC1 transition, driven by STAT5 
signalling, while IL-1β, IL-23, and IL-7 promote the maintenance of ILC3s [601]–[608].  We 
therefore sought to determine the role of IC on genes associated with ILC3 maintenance and 
function within the GI tract.  As well as the previously highlighted genes, we also identified 
several other genes associated with reinforcement of the ILC3 phenotype and inhibition of the 
ILC1 transition (Fig. 5.19B): Ahr, Id2, Rora, Il23r, and Tgfbr2.  AHR was of particular interest.  
It is essential for ILC3 maintenance and cytokine production within the GI tract, driven by 
responses to endogenous and exogenous aryl hydrocarbon ligands [592], [594], [609].  AHR 
is maintained in the cytoplasm through interaction with Hsp90.  We observed a decrease in 
Hsp90 subunit expression in response to O-IC (Fig. 5.19C).  Upon ligand binding, AHR 
associates with ARNT to form a functional TF.  Strikingly, Arnt was similarly induced by O-IC, 
demonstrating that FcγR signalling regulates several component of the AHR transcriptional 





Figure 5.20.  IC stimulation regulates ILC3 cytokine production and AhR expression.  (A) 
qPCR of ILC3-associated cytokine genes and Ahr in flow-sorted ILC3s stimulated with IC.  n 
= 6 per group.  (B) qPCR analysis of Ahr expression in flow-sorted ILC3s stimulated with 
different types of IC, insoluble OVA-ICs and soluble IgG-F’ab ICs.  n = 3 per group.  Data are 
representative of two or three independent experiments.  P values were calculated using the 
parametric Student’s t test.  * P < 0.05; ** P < 0.01. 
 
qPCR was used to confirm the effects of IC on flow-sorted ILC3s.  Interestingly, while non-
significantly increased in the RNAseq dataset, Il22 expression was significantly increased by 
qPCR in response to IC (Fig. 5.20A), perhaps due to the increased number of technical 
replicates.  Reduced Csf2 expression and increased Ahr expression was also demonstrated 
(Fig. 5.20A).  Furthermore, Ahr expression was increased in response to stimulation with 
different forms of IC – insoluble OVA-anti-OVA IgG ICs and soluble murine IgG-Fab-anti-IgG 
ICs (Fig. 5.20B). 
Given these changes in core ILC-associated genes, we hypothesise that FcγR signalling 
promotes the maintenance of ILC3s within tissues via the induction of transcriptional 
regulators, such as AHR, RORα, PLZF, T-bet, epigenetic modifiers, such as Aiolos, and 
cytokine and chemokine receptors, including IL-23R and CCR9, while simultaneously reducing 
response to ILC1-inducing factors, such as IL-2, via downregulation of IL-2Rα and STAT1/5 



































































































Figure 5.21.  Transcriptional changes associated with ILC3 maintenance and tissue 
residency.  Schematic showing the regulation of ILC1-to-ILC3 plasticity (above) and IC-



















5.9.1. ILC1s and ILC3s express FcγRs 
ILCs are a recently identified class of immune cells that are enriched at mucosal sites, such as 
the GI tract [528].  Derived from the CLP, ILCs represent a distinct group of innate lymphocytes 
characterised by the absence of somatically-recombined receptors and the potent, rapid 
production of inflammatory cytokines in response to local inflammatory mediators.  Three major 
ILC subsets exist, ILC1s, ILC2s and ILC3s, with ILC3s being particularly enriched in the GI 
tract.  Here, they have important roles in the maintenance of the epithelial barrier and activation 
of local haematopoietic and non-haematopoietic immune cells through production of IL-22, IL-
17A and GM-CSF.  These cells are critically dependent on other tissue-resident immune cells 
for activation, as well as the epithelium, with MNP-derived IL-23, IL-1β and TL1A implicated in 
ILC3 cytokine production in several models of murine colitis [292], [361], [399].  T-bet+ NKp46+ 
ILC3s are predominantly located in the LP in close proximity to the epithelium [580], while so-
called LTi CCR6+ CD4+/- ILC3s are located within the GALT, where they regulate SLO 
development and T cell activation by production of Ltα1β2 and MHC-II-mediated antigen 
presentation, respectively [546], [554], [587].  In contrast, IFNγ-producing ILC1s are 
particularly enriched during colitis, thought to be driven by IL-12-mediated plasticity from local 
ILC3s and ILC2s [597], [601]. 
In this chapter, we set out to profile the expression pattern of FcγRs across ILC subsets within 
the GI tract.  We demonstrated that T-bet+ NKp46+ ILC1s and all subsets of ILC3s expressed 
FcγRs, while ILC2s demonstrated negligible expression.  FcγRIII was the most highly 
expressed, consistent with NK cell expression patterns, with FcγRIIB upregulated in the 
context of inflammation.  FcγR expression was common to ILC1s and ILC3s across several 
tissues, including extra-GI tissues like the spleen.   
The results presented here highlight two important facets of ILC biology.  Most notably, there 
is a clear divide between type 1/17 responses and type 2 responses in their requirement to 
sense IgG.  Type 2 responses are typically associated with allergy and the induction of an IgE 
response.  Therefore, under conditions of IgE-dominated humoral responses in which ILC2s 
are activated, expression of receptors for IgG may seem unnecessary.  It is curious, however, 
that we did not observe significant FcϵR expression by ILC2s in Immgen transcriptomics 
datasets (data not shown).   
Secondly, highest FcγR expression coincided with co-expression of T-bet.  T-bet is required 
for NK cell function and, as such, may contribute to FcγR expression by these subsets directly.  
However, profiling of TF binding sites in FcγR genes has not been carried out here.  More 
importantly, previous studies have highlighted a plastic relationship between ILC3s and ILC1s, 
dictated by environmental stimuli and the regulation of RORγt and T-bet expression [356], 
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[357], [547], [600], [601].  ILC3s can develop in ILC1-like cells under the influence of IL-2 and 
IL-12, giving rise to the possibility that FcγR-expressing ILC1s could arise from the transition 
of FcγR-expressing ILC3s and vice versa.  Furthermore, FcγR ligation could play a direct role 
in regulating this plasticity to suit the needs of the immune response.  For example, FcγR 
signalling in ILC3s may promote a transition to ILC1s to support IFNγ-mediated inflammation.  
Alternatively, FcγR signalling in ILC3s may suppress transition to ILC1s to drive IL-22-
mediated reinforcement of the epithelium during colitis.  Given the differential association of 
ILC1s and ILC3s with inflammation, this would have important consequences for local 
inflammatory responses. 
5.9.2. Immune complexes promote ILC3 activation in vitro 
In support of an ILC3-promoting effect, we observed an increase in IL-22 and MHC-II 
expression by ILC3s following LPMC stimulation with IgG IC.  Minimal IL-17A production by 
ILC3s was observed and was not influenced by stimulation condition.  
The use of mixed LPMC cultures will result in confounding effects by IC-inducible cytokines 
secreted by other cells, for example macrophages.  Indeed, other than the IL-1β-dominated 
response highlighted in Chapter 4, IC signalling has also been shown to promote production 
of IL-23, PGE2, TNF, and TL1A, all of whom have been shown to regulate ILC3 cytokine 
production [291], [360], [544], [570].  These effects may overwhelm any effect of ILC3-intrinsic 
FcγR signalling.  Further studies blocking IC-inducible cytokines individually or in combination 
would be required to resolve this.  However, it remains possible that ILC3-intrinsic FcγR 
signalling cooperates with FcγR signalling on other GI-resident immune cells to induce a 
network that supports IL-22 production.  For example, IC signalling may promote expression 
of IL-1 or IL-23 receptors or co-factors that promote ILC3 responsiveness to stimulation.  
Therefore, these results are important in demonstrating that IgG can regulate ILC3 biology, at 
least in vitro.  Importantly, MHC-II expression by GI-resident ILC3s was previously 
demonstrated to be refractory to cytokine stimulation [554].  As such, it is possible that this 
effect is predominated by FcγR signalling intrinsic to ILC3s. 
Unfortunately, no analysis of IFNγ or GM-CSF secretion by IC-stimulated LPMCs was carried 
out.  Could FcγR signalling would suppress IFNγ secretion by ILC1s?  Doping of LPMC 
cultures with congenic ILC3s would allow for analysis of ILC3-to-ILC1 transition in response to 
FcγR stimulation: if ICs regulate ILC plasticity, one might observe a decrease in the emergence 
of ILC1-like cells in cultures in response to IC.  Exogenous cytokines known to influence ILC 
plasticity could also be added to monitor the effect of FcγR on these transitions. 
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5.9.3. FcγR signalling induces MHC-II expression but not antigen phagocytosis 
We observed an increase in MHC-II expression on flow-sorted ILC3s in response to IC 
stimulation, supporting the hypothesis that this upregulation was intrinsically regulated by IgG.  
MHC-II induction occurred in the absence of changes to CD80/86, which remained minimal.  
These results demonstrate that IC stimulation promotes an anti-inflammatory phenotype 
associated with the induction of T cell anergy and apoptosis.  Splenic ILC3s, however, are 
known to express CD80 and CD86, which can be upregulated in response to cytokines, such 
as IL-1β [589].  FcγR signalling on DCs is known to induce similar changes in MHC-II and 
CD80 and CD86, raising the possibility that FcγR cross-linking on splenic ILC3s promote T cell 
activation, rather than apoptosis. 
The contribution of MHC-II-mediated antigen presentation in vivo remains unclear.  In line with 
other studies [543], we observed a relatively minor capacity for antigen internalisation 
compared to professional APCs.  However, unopsonised antigen uptake was most notable in 
LTi cells, which exhibit highest level of MHC-II expression.  As these ILC3s were flow-sorted 
from the SI, it may be that GALT-resident ILC3s are more specialised for antigen presentation.  
It is notable, however, that we observed the most pronounced upregulation of MHC-II 
molecules by the NKp46+ ILC3 subset: these cells had the lowest MHC-II expression at rest, 
and are known for their residence within the LP itself, rather than the GALT.  Furthermore, 
these cells expressed the highest levels of FcγRs.  Whether significant antigen presentation 
may occur within the LP itself, however, is unclear, given the absence of structured lymphoid 
architecture.  Therefore, the functional significance of these observations in not certain.   
In these studies, we used O-IC, a model of insoluble ICs.  It may be that ILC3s are more 
specialised for the uptake of smaller soluble ICs, consistent with their ability to promote antigen 
presentation of internalised peptides, rather than the efficient processing of large proteins.  
Alternatively, FcγR signalling may promote antigen presentation of smaller acquired peptides 
independently of opsonisation, such that FcγR signalling cooperates with antigen presentation 
but is functionally uncoupled from it.  This would represent a novel function of FcγR signalling 
on innate APCs, but remains to be fully explored here. 
5.9.4. ILC3 FcγRIIB expression is upregulated during inflammation 
Inflammatory cytokines are known to alter the FcγR A/I ratio of several immune cells, such as 
macrophages and DCs [84].  Indeed, we demonstrated in Chapter 4 that macrophages within 
the GI tract increase their A/I ratio during colitis driven by upregulation of activating FcγR 
expression.  Here, we demonstrated upregulation of the inhibitory FcγRIIB on ILC3s following 
chronic DSS-induced colitis, relative to controls.  This effect could be recapitulated in vitro 
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through the incubation of flow-sorted ILC3s with a cocktail of inflammatory cytokines, including 
IFNγ.   
We have hypothesised throughout this chapter that FcγR signalling promotes the 
reinforcement of the ILC3 phenotype, with elevated IL-22 production and MHC-II expression 
in response to IgG IC.  These results raise the possibility that during inflammatory responses, 
upregulation of FcγRIIB actively inhibits this reinforcement, reducing the effect of activating 
FcγR signalling and promoting a transition to an ILC1-like phenotype consistent with the 
emergence of ILC1s during inflammation [597].  In this setting, FcγRIIB would be functionally 
opposed to its canonical role in the suppression of inflammation.  In support of this, Fcgr2b-
deficient mice had elevated IL-22-producing ILC3 numbers that was independent of IL-1 
signalling.  Given the role of FcγRIIB in the suppression of type 17-inducing cytokine production 
by MNPs, it is likely that FcγR signalling contributes indirectly to this elevated cytokine 
production, as stated previously for LPMC stimulations.  In vitro studies with WT and Fcgr2b-
deficient ILC3s isolated from inflamed mice would help to determine the contribution of this 
inhibitory receptor to ILC function in this context.  Gating on IL-22-producing ILC3s did not 
allow for discrimination between a change in the total number of ILC3s between WT and 
Fcgr2b-deficient mice or a change in IL-22 production by the same number of total ILC3s.  An 
increase in the total number of ILC3s regardless of IL-22 production may reflect additional 
developmental/homeostatic programmes that are influenced by FcγR signalling, for example 
migration to the GI tract or survival within tissues.  In contrast, specific effects on cytokine 
production in the absence of FcγRIIB may more directly reflect a role for the inhibitory receptor 
in regulating the activation state of ILC3s, either directly or indirectly. 
Regardless of intrinsic or extrinsic effects of FcγRIIB, the increased IL-22 production in KO 
mice raises numerous potential consequences for epithelial barrier function.  Whether 
intestinal epithelial cells exhibit elevated STAT3 signalling and proliferation, enhanced mucus 
production, or crypt regeneration are all areas of ongoing interest.  Indeed, we previously 
observed an increase in Reg family anti-microbial peptide production in Fcgr2b-deficient 
colons following chronic DSS-induced colitis, a facet known to be dependent on IL-22.  
Whether these effects would translate into secondary resistance to challenge by 
enteropathogens, such as C. rodentium, would be of great interest. 
5.9.5. Global transcriptional profiling of IgG-stimulated ILC3s 
RNAseq analysis of flow-sorted ILC3s stimulated with O-IC yielded global insights into the role 
of FcγR signalling in these cells.  Strikingly, IC downregulated several inflammation-associated 
Hallmarks pathways, including TNFA signalling, MTORC1 signalling, and glycolysis.  
Furthermore, STRING analysis demonstrated significant downregulation of genes associated 
with STAT1 signalling and GM-CSF production in favour of RNA processing machinery. 
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Unlike in intestinal macrophages, the lack of widespread changes to cytokine genes in 
response to FcγR cross-linking was surprising.  However, several factors must be taken into 
consideration.  Firstly, ILC3 FcγR expression is confined to FcγRIII at rest and it expression 
level is considerably smaller compared to intestinal macrophages, which express the whole 
cohort of FcγRs in mice [69].  Therefore, IC-induced transcriptional changes are likely to be 
smaller, of a more directed nature, and may require longer stimulation times to attain significant 
levels.  Secondly, these cells were obtained from the SI of uninflamed WT mice.  It is possible 
that under inflammatory conditions, ILC3s are reprogrammed to respond to FcγR signalling in 
a different manner.  In intestinal macrophages, inflammation had a profound effect on the 
transcriptional profile of these cells, but did not significantly alter the function of FcγR signalling.  
Therefore, it is likely that these transcriptional changes are reflective of both uninflamed and 
inflamed ILC3s.  However, the magnitude of these changes may be significantly altered.  Most 
intriguingly, a recent publication identified ILCs as existing in a primed state within tissues, with 
high basal expression of inflammatory cytokines.  As such, changes in the processing of 
transcripts and proteins may be more relevant in these cells than changes at the transcriptional 
level of immune-associated genes themselves [557].   
One cytokine that was significantly differentially expressed in response to IC was GM-CSF.  
GM-CSF is involved in myelopoiesis and granulocyte and MNP activation within tissues, and 
contributes to the inflammatory milieu in patients with IBD [413].  While the role of GM-CSF in 
chronic colitis is unclear and likely pleiotropic, several studies have demonstrated that this 
cytokine can promote detrimental inflammation through the activation of GI-resident 
granulocytes [297], [414].  Therefore, this raises the possibility that IC suppresses local ILC3-
mediated inflammation by downregulation of GM-CSF expression.  Given the induction of 
macrophage inflammatory programmes by IgG that promote granulocyte recruitment and 
activation, such as IL-1β production, this may act as a negative feedback loop following the 
emergence of local IgG.  Whether this has a dominant effect in vivo, however, is unclear, given 
that Fcgr2b-deficient mice have elevated colonic GM-CSF levels compared to WT mice. 
Of significant interest from these RNAseq studies is the induction of genes involved in ILC3 
development, maintenance and activation.  IC stimulation induced expression of several key 
genes involved in ILC development, including PLZF (encoded by Zbtb16), Id2, and Rora.  
Furthermore, genes encoding ILC3 cytokine and chemokine receptors, including Il7r, Il23r, and 
Ccr9, and transcriptional regulators promoting type 17 responses, such as Ikzf3, Tbx21, and 
Ahr, were induced by IC stimulation.  AHR is particularly important in ILC3 biology: AHR 
deficiency significantly impairs ILC3 maintenance and activity within the GI tract, resulting in 
SFB expansion and Th17 activation [594].  Not only was AHR expression increased by IC, but 
also expression of its co-factor, ARNT. 
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Furthermore, several of these genes have been shown to cooperate, either in ILC biology or 
in the regulation of naïve CD4+ T cell differentiation, for the induction of type 17 responses.  
For example, IL-23R signalling induces STAT3 phosphorylation, which subsequently 
cooperates with AHR for the induction of Th17-associated genes, including Rorc [606], [610].  
Furthermore, STAT3 and AHR induce Aiolos, a Th17-inducing epigenetic modifier that silences 
Th1-associated genetic programmes, such as Il2 expression [610].  In addition to the observed 
suppression of IL-2 and IL-2Rα expression, which drive Th1 polarisation, these results 
reinforce the notion that FcγR signalling acts to directly promote a ILC3 phenotype.  Therefore, 
it is possible that elevated IL-22 expression in vitro following IC stimulation, and in vivo in 
Fcgr2b-deficient mice, is as a consequence of upregulation of AHR, STAT3 signalling, and 
Aiolos expression.  As such, the dynamics of ILC3-to-ILC1 transition in vivo in these mice is of 
great interest.  Currently in progress is the crossing of Rorc-Cre and Fcgr2b-floxed mouse 
strains to attempt to address some of these questions in the future. 
An area of continued research is to investigate the effect of FcγR signalling on ILC1s, although 
this is hampered by the lack of distinct cell surface markers or access to reporter mice.  If our 
hypothesis regarding ILC plasticity is correct, one might expect ILC1s to undergo 
transcriptional reprogramming towards an ILC3 phenotype in response to IC.  However, 
whether so-called ex-ILC3 ILC1-like cells and bone fide ILC1s represent the same cell type is 
not clear.  For example, given the role of FcγR signalling on the closely-related NK cell, one 
might expect IFNγ secretion by ILC1s in response to local IgG.  In a similar vein, it should be 
noted that in this study, ILC3s were identified as Lin- CD45int RORγt+ cells using RORγt-GFP 
reporter mice.  As such, RNAseq data represents a mix of all three ILC3 subsets.  Whether 
FcγR cross-linking has different effects on ILC3 subsets, therefore, is not clear.  LTi cells and 
NKp46+ ILC3s are developmentally distinct, with the latter and ILC1s both deriving from the 
ILCP [550], [567].  Therefore, ILC3-to-ILC1 plasticity may be an attribute specific to the NKp46+ 
subset, a distinction that cannot be resolved here. 
5.9.6. Summary 
In summary, in this chapter we have shown that ILC1s and ILC3s express FcγRIII and FcγRIIB 
under inflammatory conditions, that ICs indirectly promote IL-22 production and induce MHC-
II expression by ILC3s, and ILC3-intrinsic FcγR signalling induces a transcriptional programme 
that reinforces ILC3 maintenance and functionality in detriment of ILC1 responses (Fig. 5.21).  
These results represent a new paradigm for sensing by ILCs, with direct regulation by the 
adaptive immune response, contrasting to the largely innate cell-derived cytokine mechanisms 
of stimulation described in the literature.  This has potential consequences for IgG-mediated 
inflammation within the GI tract.  However, whether these effects are unique to specific ILC3 





Figure 5.22.  Chapter 5 graphical summary.  ILC3s and ILC1s express activating FcγRIII 
and, under inflammatory conditions, upregulate expression of inhibitory FcγRIIB.  FcγR 
signalling induces a transcriptional programme associated with ILC3 maintenance, IL-22 


















6. ILC-macrophage crosstalk mediates intestinal immune defence 
6.1. Introduction and hypotheses 
ILCs are heavily dependent on macrophage and DC-derived cytokines.  Intestinal CX3CR1+ 
MNPs have been shown to drive ILC3 activation through the production of IL-23, IL-1β, and 
TL1A, with implications for defence against enteropathogens and intestinal pathology in T cell-
transfer and anti-CD40 models of colitis [291], [292], [294], [359].  In contrast, the reciprocal 
contribution of different ILC3-derived cytokines to intestinal immunity is just beginning to be 
unravelled.  In the context of intestinal infection, such as in C. rodentium, studies have focused 
on the role of ILC3-derived IL-22 in the regulation of the epithelial barrier and preventing the 
systemic dissemination of bacteria [545].  However, recent data has suggested that ILC3-
derived GM-CSF is required for the survival of tolerogenic DCs within the colon [623], while 
also promoting the accumulation of pathogenic IL-23-producing granulocytes and monocytes 
within the colon in intestinal inflammation [297], [414], [415].  Furthermore, ILC3-derived IL-
17A was shown to improve the anti-microbial capacity of macrophages by the induction of ROS 
and TNFα production [585].  Overall, however, little is known about how ILCs may coordinate 
other local and distal immune cells for the eradication of infection.   
Following some experiments performed as part of the work for chapter 5, we hypothesised that 
ILC3-derived GM-CSF orchestrates intestinal macrophage recruitment and antibacterial 
function, playing a critical pro-survival role during infection.  To address this, we firstly aimed 
to determine whether ILCs were a major source of intestinal GM-CSF and whether they were 
required for appropriate defence against C. rodentium infection and inflammation in DSS-
induced colitis.  Next, we investigated whether ILCs and GM-CSF were required for the 
appropriate recruitment and function of intestinal macrophages in situ and the mechanism by 
which this might occur.  Finally, we sought to determine whether ILC3-derived GM-CSF 
initiated cross-talk via the induction of type 17-inducing cytokines by macrophages that boost 
GM-CSF production.  Studies have demonstrated that GM-CSF in vitro can promote IL-1β 
production by BMDMs, through a combination of enhanced glycolysis and expression of a 
GTPase required for caspase-1-dependent pro-IL-1β processing [410], [411].  Whether 
intestinal macrophage cytokine production is similarly dependent on GM-CSF is poorly 




6.2. ILC depletion in Citrobacter rodentium infection 
To determine the role of ILCs in protection against intestinal infection, Citrobacter rodentium 
infection, a murine model of human attaching-effacing E coli infection, was carried out in Rag2 
KO mice treated with anti-CD90.2 IgG.  We confirmed local ILC depletion by flow cytometry 
(Fig. 6.1): total colonic CD90.2+ cells were reduced in the following anti-CD90.2 IgG treatment.  
In order to overcome confounding effects of anti-CD90.2 IgG treatment on the staining of 
CD90.2 by flow cytometry, ILCs were also quantified based on production of IL-22 and IL-17A, 
both showing a similar reduction in ILCs following treatment (Fig. 6.1).  Mice treated with anti-
CD90.2 IgG exhibited greater bacterial burden at day 7 post-infection, with increased CFUs 
locally within the caecum compared to mice treated with control IgG (Fig. 6.2A).  Furthermore, 
anti-CD90.2 IgG treatment increased hepatic dissemination of bacteria, while few bacteria 
were detected in the spleen (Fig. 6.2B).  Therefore, ILC depletion was successful, with these 





Figure 6.1.  Anti-CD90.2 IgG treatment successfully depletes intestinal ILCs.  Flow 
cytometric quantification of colonic CD90.2+ SCA-1+ ILCs, and IL-22/IL-17A-producing ILCs at 
day 7 post-infection.  Data are representative of three independent experiments.  P values 






















































Figure 6.2.  ILC depletion enhances bacterial burden in Citrobacter rodentium infection.  
(A) Caecal CFU analysis at day 7 post C. rodentium infection in mice treated with anti-CD90.2 
IgG or control IgG.  (B) Analysis of bacterial systemic dissemination at day 7 post Citrobacter 
rodentium infection.  Hepatic dissemination quantification is pooled from two datasets.  
Otherwise, data are representative of two independent experiments.  P values were calculated 







Figure 6.3.  ILC depletion reduces intestinal CX3CR1+ MNPs.  Flow cytometric 
quantification of total colonic CX3CR1+ MNPs (A), MNP subsets (B), and neutrophils (C) at 
day 7 post infection in mice treated with anti-CD90.2 IgG or control IgG.  Data are 
representative of two independent experiments.  P values were calculated using the 
nonparametric Mann-Whitney test.  * P < 0.05. 
 
Increased bacterial dissemination could result from impaired barrier function, likely due to the 
loss of IL-22-producing ILC3s, but may also be due to defective bacterial clearance by immune 
cells, including macrophages and neutrophils.  We, therefore, sought to profile the phenotype 
of other intestinal immune cells in the absence of ILCs.  Analysis of CX3CR1+ MNPs by flow 











































































































































































































6.3A).  Subset analysis using Ly6C and MHC-II as waterfall markers demonstrated a reduction 
in the total number of MHC-II+ monocytes and Ly6Clo MHC-IIhi macrophages following anti-
CD90.2 treatment (Fig. 6.3B).  We also observed a trend towards a reduction in total colonic 
neutrophil numbers in the absence of ILCs (Fig. 6.3C).  Furthermore, analysis of pro-IL-1β 
production by CX3CR1+ MNP subsets demonstrated a striking defect in cytokine production in 
the absence of ILCs (Fig. 6.4A).  This was most apparent in the macrophage population, but 
also detected to a lesser extent in the MHC-II- and MHC-II+ monocyte populations (Fig. 6.4B).  
Given the increased local and systemic bacterial burden, it may seem surprising that 




Figure 6.4.  Defective MNP IL-1β production in the absence of ILCs.  (A) Intracellular flow 
cytometric staining of pro-IL-1β-expressing colonic MNP subsets at day 7 post C. rodentium 
infection in mice treated with anti-CD90.2 IgG or control IgG.  (B) Quantification of frequency 
and absolute number of pro-IL-1β+ MNP subsets.  Data are representative of two independent 
experiments.  P values were calculated using the nonparametric Mann-Whitney test.  * P < 
0.05; ** P < 0.01; *** P < 0.001. 
 
Next, we sought to determine whether other IL-1β-producing cells were similarly affected.  
While intracellular cytokine staining demonstrated that CX3CR1+ MNPs are the major source 
of intestinal IL-1β production in response to C. rodentium infection, cytokine production was 
also identified in CX3CR1- Ly6C/Ghi neutrophils and CX3CR1- Ly6C/G- CD11b+ DC subsets 
(Fig. 6.5A).  Cytokine production by CX3CR1+ MNPs was greatest in terms of number but also 
on a per-cell basis, as determined by pro-IL-1β GMFI (Fig. 6.5B).  The total number of pro-IL-
1β-producing cells was reduced in the absence of ILCs (Fig. 6.5C), with subset analysis 













































































































production by CX3CR1+ Ly6Clo MHC-IIhi was the most significantly affected by anti-CD90.2 
IgG treatment (Fig. 6.5D).  Reduced cytokine production was also observed in the DC 
population, suggesting a predominant defect in cytokine production by tissue-resident 




Figure 6.5.  Analysis of ILC depletion on all IL-1β-producing immune cells.  (A) Unbiased 
analysis of pro-IL-1β-producing immune cells by flow cytometry at day 7 post infection.  (B) 
Quantification of pro-IL-1β GMFI across immune cell subsets identified in A.  (C) Quantification 
of total colonic IL-1β-producing immune cells at day 7 post-infection in mice treated with anti-
CD90.2 IgG or control IgG.  (D) Quantification of IL-1β-producing subsets in A in mice treated 
with anti-CD90.2 IgG or control IgG at day 7 post-infection.  Data are representative of two 
independent experiments.  P values were calculated using a one-way ANOVA (A, B) or the 
nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01; **** P < 0.0001. 
 
Consistent with previous pro-IL-1β analysis, neutrophils were largely unaffected by the 
absence of ILCs: while there was a trend towards reduced numbers of neutrophils in the 
absence of ILCs, CD11b GMFI (a marker of neutrophil activation), and pro-IL-1β production 





Figure 6.6.  Neutrophils are unaffected by ILC depletion.  Flow cytometric analysis of 
neutrophil phenotype at day 7 post-infection in mice treated with anti-CD90.2 IgG or control 
IgG.  Data are representative of two independent experiments.  P values were calculated using 





Figure 6.7.  ILC depletion reduces MHC class II expression by intestinal macrophages.  
(A) Flow cytometry showing MHC-II expression by subsets of the colonic monocyte waterfall 
at day 7 post-infection in mice treated with anti-CD90.2 IgG or control IgG.  (B) Analysis of cell 
surface markers on CX3CR1+ Ly6Clo MHC-IIhi macrophages at day 7 post-infection.  Data are 
representative of two independent experiments.  P values were calculated using the 





































































































































































As well as cytokine production, a variety of other macrophage markers were influenced by ILC 
depletion.  Analysis of MHC-II expression in the CX3CR1+ MNP waterfall demonstrated an 
impaired upregulation of MHC-II expression by monocytes following anti-CD90.2 IgG treatment 
(Fig. 6.7A).  Furthermore, macrophages exhibited reduced side scatter and CD45 expression 
(Fig. 6.7B), consistent with a more general cellular defect rather than solely influencing IL-1β 
production.   
Therefore, ILCs play an essential role in the maintenance of intestinal immunity, particularly 
through the maintenance of an activated macrophage phenotype.  Following anti-CD90.2 IgG 
administration, caecal and systemic bacterial burdens where increased, while cytokine 
production by intestinal CX3CR1+ MNPs was inhibited.  Furthermore, reductions in total MNP 
numbers were also observed, with defects most pronounced within the Ly6Clo MHC-IIhi mature 
macrophage population.   
6.3. ILC depletion in DSS-induced colitis 
To address whether this defective macrophage phenotype in the absence of ILC3s was 
specific to Citrobacter rodentium infection, or whether it was applicable to other forms of 
intestinal inflammation, Rag2 KO mice were treated with anti-CD90.2 or control IgG and 
subjected to an acute 7-day course of DSS-induced colitis. 
 
 
Figure 6.8.  Anti-CD90.2 treatment augments disease severity in DSS-induced colitis.  
Clinical parameters after an acute 7-day course of DSS administration in mice treated with 
anti-CD90.2 or control IgG.  P values were calculated using the nonparametric Mann-Whitney 
test.  * P < 0.05; ** P < 0.01. 
 
Following anti-CD90.2 IgG treatment, Rag2 KO mice exhibited worsening clinical features of 
inflammation, including reduced colon length and enhanced stool score, with pronounced 
gastrointestinal bleeding (Fig. 6.8).  Curiously, however, colon weight was significantly reduced 
in the absence of ILCs, a clinical feature generally used to demonstrate reduced disease 
severity.  Therefore, while gastrointestinal bleeding was more severe, local tissue inflammation 
may be reduced in the absence of ILCs, reflecting perhaps the differing roles played by ILC-





































































































Once again, ILC depletion was confirmed by flow cytometry (Fig. 6.9).  We sought to profile 
GM-CSF-producing cells by flow cytometry.  CD90.2+ SCA-1+ ILCs were identified as the major 
source of colonic IL-22 and GM-CSF (Fig. 6.9A).  Furthermore, anti-CD90.2 IgG treatment 
resulted in the reduction of total IL-22 and GM-CSF-producing cells (Fig. 6.9B), as well as IL-






Figure 6.9.  ILCs are the major source of IL-22 and GM-CSF and are depleted following 
anti-CD90.2 IgG treatment.  (A)  Intracellular cytokine staining for IL-22 and GM-CSF-
producing cells by flow cytometry at day 7 post-DSS.  (B) Depletion of total and CD90.2+ SCA-
1+ IL-22- and GM-CSF-producing cells following anti-CD90.2 IgG or control IgG administration 
at day 7 post-DSS.  Data are representative of three independent experiments.  P values were 





























































































































































Figure 6.10.  Reduced macrophage and neutrophil numbers in the absence of ILCs.  (A, 
B) Quantification of CX3CR1+ MNP subsets (A) and neutrophil (B) by flow cytometry in colons 
of mice after a 7-day course of DSS.  Data are representative of three independent 
experiments.  P values were calculated using the nonparametric Mann-Whitney test.  * P < 
0.05. 
 
Consistent with reduced immune infiltrate into the colonic LP, profiling of macrophage numbers 
by flow cytometry once again demonstrated reduction in these cells in the absence of ILCs 
(Fig. 6.10A).  ILC depletion once again primarily affected the macrophage subset of CX3CR1+ 
MNPs, with a less pronounced effect on monocytes.  While trending in Citrobacter rodentium 
infection, neutrophil numbers were significantly reduced in the colonic LP after DSS 
administration in the absence of ILCs (Fig. 6.10B). 
Pro-IL-1β production by CX3CR1+ MNPs was higher in DSS-induced colitis compared to C. 
rodentium infection, likely reflecting the broader inflammatory response induced by epithelial 
cell toxicity.  However, cytokine production was once again significantly reduced in the absence 
of ILCs, with an enhanced effect as Ly6Chi monocytes matured into Ly6Clo MHC-IIhi 
macrophages (Fig. 6.11A).  In addition to trends in the reduction of all CX3CR1+ MNP subsets 
(Fig. 6.10A), this resulted in significantly reduced numbers of all cytokine-producing CX3CR1+ 








































































Figure 6.11.  Defective macrophage IL-1β production in the absence of ILCs.  (A, B) 
Intracellular flow cytometry staining of pro-IL-1β-producing MNP subsets, showing 
representative plots (A) and quantification (B) at day 7 post DSS administration.  Data are 
representative of three independent experiments.  P values were calculated using the 
nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01. 
 
In summary, ILC depletion results in enhanced disease severity following acute DSS-induced 
colitis, with reduced colon length and worsening stool scores.  However, the reduction in 
intestinal ILCs also dampens the local inflammatory immune cell response, as highlighted by 
reduced intestinal macrophage and neutrophil numbers, dysfunctional IL-1β production, and a 
globally reduced inflammatory response following anti-CD90.2 IgG treatment versus mice 
receiving control IgG.  Therefore, enhanced disease severity is likely a combination of 
enhanced commensal infiltration and dissemination from the intestinal lumen into host tissues, 
as well as potentially differing roles of ILC-derived products in the coordination of tissue 
immunity and homeostasis, such as IL-22 in barrier function and GM-CSF in myeloid cell 
maturation.  These results support the observations made following CD90.2 depletion in C. 
rodentium infection, and suggest common immune-mediated inflammatory mechanisms 
regulated by ILCs. 
6.4. Potential mechanisms for macrophage regulation by ILCs 
We hypothesised that the observed defects in macrophage number and activation state in the 
absence of ILCs could have a number of explanations (Fig. 6.12).  (1) Defects in the 
recruitment of monocytes to the GI tract are consistent with the reduction in Ly6Chi cells 
observed within the LP in both models.  (2) Reduced macrophage MHC-II and CD45 






































































































maturation.  (3) ILC-derived mediators could directly prime macrophages for cytokine 
production.  (4) ILCs may be required for the survival of macrophages within the tissue.  
Alternatively, the observed macrophage phenotype could be due to a combination of these 




Figure 6.12.  Potential macrophage-immunomodulatory functions of ILC3s.  ILC3s may 
regulate macrophage recruitment and activation within the colonic lamina propria through a 
variety of contact-dependent and contact-independent mechanisms. 
 
6.5. Chemokine expression by intestinal ILCs 
Little is known about how ILCs may contribute to immune cell recruitment via the secretion of 
chemokines.  To address this question, we investigated chemokine gene expression in 
transcriptomics datasets of small intestinal ILC subsets from the Immgen consortium. 
Several chemokine transcripts were identified in SI ILC subsets.  Of note, Ccl3, Cxcl10, and 
Cx3cl1 were expressed by SI ILC3s (Fig. 6.13).  CX3CL1 is the ligand for CX3CR1 – the major 
MNP-associated chemokine receptor in the gut.  CX3CR1 is expressed by tissue-resident 
macrophages throughout the body, including microglia, and intestinal and pulmonary 
macrophages: tissues in which ILCs are known to reside.  This, therefore, raises the possibility 
that ILCs are required for maintenance of tissue-resident macrophages throughout the body.  
CXCL10 and CCL3 are also known to drive monocyte recruitment via binding to CXCR3 and 
CCR1/4/5, respectively.  Shown in Figure 6.13 are chemokines expressed at moderate levels 
in at least one ILC subset.  The classical monocyte-recruiting chemokine CCL2 is not included, 














Figure 6.13.  ILCs express macrophage-recruiting chemokines.  Heatmap showing 
transcriptomics analysis of chemokine expression by small intestinal ILC subsets (GSE37448). 
 
6.6. Cytokine analysis in ILC-depleted colons 
ILC3s are particularly abundant within the GI tract and important mediators of local immunity 
through the production of IL-22, IL-17A, and GM-CSF.   While an expanding body of literature 
has demonstrated the role of IL-22 in mediating intestinal barrier reinforcement in several 
models of intestinal inflammation and homeostasis [545], [573], [624], the study of how ILCs 
regulate proximal tissue-resident immune cells through the production of cytokines, such as 
GM-CSF and IL-17A, is still in its infancy.  We hypothesised that ILC3-derived IL-17A and GM-
CSF may play a role in the local activation of macrophages.  Therefore, we decided to profile 
changes in cytokine gene expression in whole colon tissue by qPCR following CD90.2 
depletion in C. rodentium infection and DSS-induced colitis. 
A significant reduction in global Csf2 levels was seen following CD90.2 depletion in C. 
rodentium infection (Fig. 6.14).  IL-17A expression was very lowly expressed within the colon 
and not detected by qPCR.  Curiously, Il6 expression was increased in the absence of ILCs.  
In DSS-induced colitis, the expression of several inflammatory cytokines was significantly 
reduced following anti-CD90.2 IgG treatment, including Il1b, Tnf, Il22, and a pronounced 
reduction in Csf2 (Fig. 6.15).  Therefore, CD90.2 depletion is consistently associated with a 
199 
reduction in intestinal GM-CSF expression levels, with GM-CSF being significantly more highly 





Figure 6.14.  ILC depletion reduces intestinal GM-CSF levels in C. rodentium infection.  
qPCR analysis of cytokine production in whole colon tissue at day 7 post-infection.  Il17a levels 
were too low and were not detected.  Data represent a single experiment.  P values were 






Figure 6.15.  Reduced inflammatory cytokine profile in the absence of ILCs during DSS-
induced colitis.  qPCR of whole colonic tissue from mice receiving anti-CD90.2 IgG or control 
IgG after a 7-day course of DSS.  Il17a levels were too low and not detected.  Data are 
representative of three independent experiments.  P values were calculated using the 












































































































































































































6.7. In vitro macrophage GM-CSF stimulation 
We hypothesised, given the phenotype of macrophages in the absence of ILCs, the 
pronounced depletion of colonic GM-CSF levels in the gut following ILC depletion, and the role 
of GM-CSF in regulating macrophage inflammatory responses, that intestinal ILC3s could 
coordinate local macrophage immune responses by production of GM-CSF.  This priming 
could enhance cytokine production, induce anti-microbial responses, such as ROS and NO 
production, and alter the metabolic profile of macrophages leading to enhanced anti-
commensal and anti-pathogen immunity. 
Of ILC3-derived cytokine receptors, intestinal macrophages express highest levels of GM-CSF 
receptors (Fig. 6.16A).  These are present in all CX3CR1+ MNP subsets, regardless of 
inflammation.  Macrophages also expressed significant levels of IL-17RA, although expression 
levels of other IL-17R-forming subunits were much lower.  IL-22R levels were very low, 
consistent with their expression predominantly on non-haematopoietic cells.  In keeping with 
an important role for GM-CSF, we found that priming of BMDMs with 20 ng/ml GM-CSF for 24 
h resulted in a significant increase in inflammatory cytokine production in response to LPS 
stimulation compared to unprimed BMDMs (Fig. 6.16B).  This effect was most pronounced for 
IL-1β and IL-23, with smaller yet significant effects also observed on CXCL chemokine 
production.  IL-1β production is classically thought to require two signals, a priming signal, 
such as LPS, that induces Il1b expression, and a second signal that results in inflammasome 
assembly.  These results demonstrate that LPS and GM-CSF in combination are sufficient for 
IL-1β expression, processing and secretion by macrophages.  Furthermore, the pronounced 
increase in IL-23 expression, a cytokine not thought to require such two-step signalling, 
suggests other priming mechanisms that may be contributing to macrophage responsiveness. 
GM-CSF priming also resulted in enhanced production of CXCL1 and CXCL2 by BMDMs 
stimulated with O-IC (Fig. 6.16C), but no IL-1β protein production was observed under these 
conditions.  Therefore, GM-CSF enhance cytokine production by macrophages in response to 












Figure 6.16.  GM-CSF promotes inflammatory cytokine production by macrophages.  (A) 
Heatmap showing transcriptomics analysis of ILC-derived cytokine receptors expressed by 
intestinal macrophage subsets (GSE42101).  (B) ELISA of cytokine and chemokine production 
by BMDMs primed for 24 h with 20 ng/ml GM-CSF prior to 16 h stimulation with LPS.  (C) 
Chemokine production by GM-CSF-primed BMDMs stimulated for 16 h with O or O-IC.  n  = 4 
per group.  Data are representative of three independent experiments.  P values were 
























































































































6.8. GM-CSF neutralisation in DSS-induced colitis 
Given the prominent effect of GM-CSF on macrophage cytokine production in vitro, we sought 
to determine whether GM-CSF neutralisation in vivo would have a similar effect to ILC anti-
CD90.2 depletion in the suppression of macrophage cytokine production and the clinical 
severity of DSS-induced colitis. 
Rag2 KO mice were administered with anti-CD90.2 IgG, anti-GM-CSF IgG or control IgG at 
days 0 and 3 on a 7-day DSS protocol.  At endpoint, ILC-depleted mice lost significantly less 
weight compared to mice receiving control IgG (Fig. 6.17A).  Anti-GM-CSF IgG administration 
resulted in reduced weight loss compared to control animals, although this reduction was not 
as large as CD90.2-depleted mice.  Furthermore, analysis of colon parameters demonstrated 
increased colon length and reduced colon weight in the absence of ILC3s (Fig. 6.17B).  
Curiously, increased colon length in the absence of ILCs is opposite to what was observed in 
Figure 6.9.  While not significant, there was a trend towards increased colon length and 
reduced weight following anti-GM-CSF administration.  Therefore, anti-GM-CSF IgG 




Figure 6.17.  Anti-GM-CSF IgG administration partially dampens colitis severity.  Final 
weight change (A) and colon clinical parameters (B) at day 7 post-DSS administration in Rag2 
KO mice receiving anti-CD90.2, anti-GM-CSF, or control IgG at days 0 and 3.  Data are 
representative of two independent experiments.  P values were calculated using the 
nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
Analysis of MNP and neutrophil numbers within the inflamed colonic LP by flow cytometry 
demonstrated a reduction in all MNP subsets with anti-CD90.2 IgG administration compared 
to controls, as previously observed (Fig. 6.18A).  Anti-GM-CSF IgG administration did not 






























































































































of monocytes appears to be GM-CSF-independent.  Consistent with previous data, ILC 
depletion once again resulted in a significant reduction of colonic neutrophils (Fig. 6.18B).  In 
this case, anti-GM-CSF IgG administration trended towards reduced neutrophil infiltration, 
consistent with the known roles of GM-CSF on granulopoiesis [415] and our data 
demonstrating effects of GM-CSF on macrophage chemokine production.  However, the 
variability of this group makes interpretation difficult.  
Next, we sought to investigate how GM-CSF depletion may alter the cytokine profile of 
macrophages.  Unlike monocyte recruitment, which is likely to occur secondarily to effects of 
GM-CSF on other cells, we have previously demonstrated that GM-CSF can directly influence 
LPS-induced inflammatory cytokine production by macrophages.  Once again, we observed a 
significant reduction in pro-IL-1β production by intestinal CX3CR1+ MNPs in the absence of 
ILCs, with the most profound effect on mature MHC-IIhi macrophages (Fig. 6.19).  Interestingly, 
anti-GM-CSF administration did not significantly reduce the percentage of pro-IL-1β-
expressing MNP subsets, although this was trending towards a reduction in MHC-IIhi 
macrophages.  In contrast, pro-IL-1β GMFI was significantly reduced in intestinal MHC-
IIhi macrophages.  Therefore, while the number of cytokine-producing cells did not change 




Figure 6.18.  GM-CSF neutralisation has no significant effects on neutrophil and 
monocyte recruitment.  Flow cytometric analysis of colonic CX3CR1+ MNP subsets (A) and 
neutrophils at day 7 post-DSS administration.  Data are representative of three independent 


























































































Figure 6.19.  GM-CSF neutralisation reduces intestinal macrophage IL-1β production.  
Analysis of pro-IL-1β production by CX3CR1+ MNP subsets at day 7 post-DSS administration 
by flow cytometry.  Data are representative of three independent experiments.  P values were 
calculated using the nonparametric Mann-Whitney test.  * P < 0.05; ** P < 0.01. 
 
In summary, GM-CSF neutralisation resulted in improved clinical disease progression and 
reduced macrophage IL-1β expression, although these effects were not as large as those 
induced by ILC depletion.  Furthermore, GM-CSF neutralisation did not affect macrophage 
numbers, although there was a trend towards a reduction in neutrophils.  Therefore, GM-CSF 
appears to contribute to several elements of the phenotype induced by pan-ILC depletion, 
including the activation of macrophages in situ.  Whether additional elements contribute to 
macrophage activation in addition to GM-CSF or whether an alternative anti-GM-CSF IgG 
dosing strategy is required to phenocopy pan-ILC depletion is not clear at present, but is an 
active area of investigation. 
6.9. Potential mechanisms for GM-CSF-mediated macrophage activation 
GM-CSF may contribute to macrophage cytokine production through several mechanisms: 
- Altered TLR and FcγR expression 
- Enhanced pro-IL-1β processing 
- Production of secondary mediators that induce macrophage activation 








































































To answer this, we performed GSEA on a transcriptomics dataset of M-CSF versus GM-CSF-
derived human MDMs (Fig. 6.20).  GM-CSF resulted in enrichment of 49 out of 50 Hallmarks 
pathways (data not shown), with notable examples including Glycolysis, Hypoxia, ROS 
pathway, and Inflammatory response (Fig. 6.20A).  This is consistent with an altered metabolic 
profile and enhanced anti-microbial immune response in GM-CSF-primed cells.  Analysis of 
the core enrichment of Glycolysis genes demonstrated an enrichment in several key glycolysis 
enzymes, including lactate dehydrogenase (LDHA) and hexokinase 2 (HK2) (Fig. 6.20B).  
While not included in the Glycolysis Hallmarks gene list, glucose transporters are also known 
to be key regulators of glycolysis, including GLUT1 (SLC2A1) [411].  We found that GM-CSF-
derived MDMs had enhanced expression of SLC2A1 and the related transporter SLC2A3 
compared to M-CSF-derived MDMs (Fig. 6.20C).  Therefore, as demonstrated by the 
schematic depicted in Figure 6.20D, GM-CSF induces the expression of several glycolysis-
associated enzymes and transporters, and supports the notion that enhanced inflammatory 
responses by these cells may be driven by an enhanced metabolic profile and switch to 
glycolysis.  This is of direct relevance to IL-1β production, as O’Neill and colleagues 
demonstrated that a glycolytic switch in macrophages drives HIF-1α-dependent IL-1β 
production [343]. 
A recent publication by Medzhitov and colleagues demonstrated that IL-10 stimulation of 
macrophages has a profound effect in suppressing immune responses by inhibiting glycolysis, 
GLUT-1 expression, and mitochondrial mass.  Indeed, they hypothesised that altered 
mitochondrial dynamics might be a principle mediator of these effects given the observation 
that IL-10 induced changes in the side scatter of these cells by flow cytometry, which correlated 
with their intracellular complexity.  Given the observed reduction in side-scatter of intestinal 
macrophages in the absence of ILCs, we hypothesised that GM-CSF may support an 
enhanced inflammatory profile and glycolysis in these cells by altering their mitochondrial 
fitness, either by inducing changes in mitochondrial fission/fusion or in mitochondrial 
maintenance within cells.  To address this, GM-CSF primed macrophages were stained for 
mitochondria using MG, a cell membrane-permeable dye that can be used on live cells.  
Encouragingly, we found that GM-CSF treatment enhanced total mitochondrial mass in 
BMDMs (Fig. 6.21), suggesting this may be a facet of intestinal macrophage biology regulated 





Figure 6.20.  GM-CSF induces glycolysis in macrophages.  (A) GSEA of inflammatory 
pathways in M-CSF and GM-CSF-derived human MDMs (GSE71253).  (B) Heatmap showing 
core enrichment glycolysis genes in GM-CSF-derived MDMs.  (C) Expression analysis of 
glucose transporters in M-CSF versus GM-CSF-derived MDMs.  (D) Schematic showing the 
glycolysis pathway, with enzymes in red, and boxes surrounding GM-CSF-induced genes.  P 






































































































































































































Figure 6.21.  GM-CSF priming increases macrophage mitochondrial mass.  Flow 
cytometric analysis of mitochondrial mass after 48 h stimulation of BMDMs with 20 ng/ml GM-
CSF using MG.  Data represent a single experiment.  n = 3 per group.  P values were calculated 
using the parametric Student’s t test.  ** P < 0.01.  
 
6.10. IL-1β-mediated cross-talk between macrophages and ILCs 
ILC3s are known to be regulated by macrophage-derived cytokines, most notably IL-23 and 
IL-1β.  Given the role of GM-CSF in directly promoting production of both cytokines by 
macrophages, we hypothesised that this cross-talk is essential in vivo for potentiating 
macrophage-mediated immunity. 
While analysis of GM-CSF expression by ILC subsets demonstrated high expression by both 
ILC3s and ILC2s within the SI (Fig. 6.22A), all of which are depleted with anti-CD90.2 IgG 
antibodies, IL-1R1 and IL-23R expression was predominantly restricted to ILC3 subsets (Fig. 
6.22B).  Therefore, IL-1β and IL-23-mediated cross-talk would only affect cytokine production 
by ILC3s.  Incubation of flow-sorted RORγt+ ILC3s with various ILC-activating cytokines 
demonstrated that only IL-1β stimulation, of those tested, induced GM-CSF expression by 
ILC3s (Fig. 6.22C), with negligible effect of IL-23A or IL-7.  In contrast, IL-22 production was 
induced by both IL-23 and IL-1β, although the effect was greatest for IL-1β.  Given the role of 
GM-CSF in promoting LPS-induced IL-1β and IL-23 production, this suggests that during a 
local inflammatory response, macrophage cytokine production in response to TLR stimulation 
would induce GM-CSF expression by ILCs, resulting in a positive feedback loop of enhanced 
macrophage activation, increased cytokine production and glycolysis, and greater ILC3-
derived GM-CSF.  Furthermore, this would support secondary induction of ILC3-derived IL-22 





































Figure 6.22.  IL-1β induces GM-CSF production by ILC3s.  (A) Analysis of Csf2 expression 
by ILC subsets.  (B) Analysis of inflammatory cytokine receptors by ILC subsets.  (C) ELISA 
showing GM-CSF and IL-22 production by flow-sorted small intestinal ILC3s in response to 
cytokine stimulation.    Data are representative of two independent experiments.  n = 3 per 












6.11.1. ILCs are essential for defence against Citrobacter rodentium infection and 
promote DSS-induced colitis 
ILC3s are enriched within the GI tract, where they have a major role in the regulation of function 
and tone of the epithelium.  This is primarily achieved through the production of IL-22, which 
has been shown to be protective in models of colitis and epithelial barrier disruption, including 
Graft-versus-host disease [361], [399]–[402], [544], [577], [594].  This is achieved via the 
induction of anti-microbial peptides, regulating epithelial cell glycosylation, and stem cell 
turnover, amongst others [397], [575], [576].  ILC3s are also critically implicated in the 
pathogenesis of colitis and colorectal cancer, however, both in mice and humans [292], [398].  
While IL-22 can promote tumorigenesis as well as induce pathogenic epithelial production of 
IL-18 [403], [404], [583], [625], [626], ILC3-derived IL-17A, and GM-CSF have been shown to 
support innate colitis and mucosal inflammation via the recruitment and activation of 
monocytes and granulocytes, respectively [297], [414], [415], [585].  In general, however, the 
mechanisms by which ILCs regulate proximal immune cells is poorly understood. 
Here, we have investigated the role of ILCs in two models of intestinal pathology via a depletion 
strategy in which Rag2-deficient mice were treated with an anti-CD90.2 IgG depleting antibody.  
Specifically, we have demonstrated that in the absence of ILCs, Rag2-deficient mice exhibit 
enhanced caecal CFUs and systemic dissemination in a model of C. rodentium infection.  
Despite enhanced bacterial burden, intestinal MHC-IIhi macrophages exhibited an 
unresponsive phenotype, with reduced total colonic macrophage numbers, reduced pro-IL-1β 
expression, and defective MHC-II upregulation following the maturation of monocytes.   
Strikingly, we observed a very similar macrophage phenotype in Rag2-deficient mice following 
an acute course of DSS-induced colitis.  ILC depletion resulted in reduced macrophage 
numbers, inhibited pro-IL-1β expression, and resulted in significantly diminished global levels 
of IL-1β, TNF, IL-22 and GM-CSF.  In this model, neutrophil recruitment to the inflamed colon 
was also significantly reduced, and may reflect the overwhelming inflammatory response 
induced by DSS: while trending towards a decreased in C. rodentium infection, DSS-induced 
inflammation may augment defects in the ability to recruit neutrophils. Curiously, the initial 
clinical phenotype of ILC-depleted mice was striking.  While colon length was shorter and stool 
score increased in the absence of ILCs, consistent with worse inflammation, colon weight was 
significantly reduced in the absence of ILCs.  This may reflect the differential effect of ILC-
derived mediators on different aspects of intestinal physiology.  For example, the enhanced 
rectal bleeding may result from impaired barrier repair in the absence of ILC-derived IL-22, 
amphiregulin, and IL-17A.  However, the absence of GM-CSF may lead to defective leukocyte 
recruitment and activation to the inflamed tissue, resulting in reduced abscess formation, and 
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tissue thickening and destruction.  Therefore, GM-CSF would be pathogenic in this instance, 
mirroring observations made by Powrie and colleagues in models of anti-CD40 and T cell 
transfer-driven colitis [297]. 
These results support a hypothesis that ILC-derived mediators are responsible for detrimental 
inflammation in DSS-induced acute inflammation but are required for the containment and 
possibly killing of C. rodentium, through the direct recruitment and regulation of tissue-resident 
macrophages.  Macrophage phenotype here was determined by flow cytometric analysis, 
limiting our investigation to relatively few key macrophage genes.  We would hypothesise that 
ILCs may regulate anti-microbial mechanisms in macrophages, such as ROS production that 
contribute to bacterial clearance.  From these results, however, we cannot determine whether 
this is the case, or identify the molecules involved in regulating macrophage phenotype.  
Finally, it would be of interest to determine whether exogenous administration of depleted 
macrophage cytokines, such as IL-1β, is sufficient to restore the inflammatory response in anti-
CD90.2 IgG-treated mice. 
Rag2-deficient mice are an excellent tool to study the role of ILCs in vivo, given the absence 
of confounding adaptive T helper cell subsets and the greater contribution of ILC-derived 
cytokines to the local milieu.  Furthermore, the use of C. rodentium, which is known to induce 
type 17 responses, also contributes to the specific investigation of ILC3-mediated immunity.  
However, these mice are a tool, and whether or not these results translate to 
immunocompetent mice with adaptive immune cells is not clear.  However, mechanisms to 
specifically deplete ILC3s in WT mice are not readily available.  It should be noted that GM-
CSF is known to be expressed by Th17 cells and, under certain conditions, B cells [367], [406].  
Therefore, it is likely that GM-CSF secretion would be compensated to a certain extent, 
although the contribution of different cell types in WT mice to colonic GM-CSF secretion has 
not been investigated here.  In this study, we demonstrated a reduction in MHC-II expression 
by macrophages, which is not possible to study in Rag2-deficient mice given the absence of T 
cells.  However, these mice would allow for elegant experiments involving the transfer of 
commensal-specific T cells without the confounding effects of local T cell responses. 
6.11.2. GM-CSF depletion improves DSS-induced colitis severity and dampens 
macrophage cytokine production 
Macrophages fail to develop appropriately within the colon in the absence of ILCs, suggesting 
that ILC-derived factors are required for adequate macrophage recruitment, maintenance and 
activation locally.  Given the pan-ILC depletion strategy, several candidate cytokines exist with 
known roles in the regulation of macrophage responses, including IL-17A, GM-CSF, and IFNγ.  
Furthermore, we demonstrated significant expression of monocyte-recruiting chemokines by 
ILC3s, including CX3CL1, CCL3 and CXCL10.  Whether ILCs are a major source of 
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chemokines within the intestine has not been investigated, with studies largely focusing on 
cytokine production.  Therefore, it is intriguing whether this facet of ILC biology contributes to 
the coordination of immune cells during inflammation. 
Of those cytokines investigated, GM-CSF was most notably diminished following anti-CD90.2 
IgG administration in both models of colitis.  Intestinal macrophages express high levels of 
GM-CSF receptor subunits, with lower expression of IL-17R and IL-22R, while in vitro GM-
CSF priming of BMDMs greatly augmented IL-1β secretion in response to LPS.  C. rodentium 
is a Gram-negative bacterium, so LPS was used as a reasonable model of the TLR 
engagement elicited by this bacterium.  However, it would be of interest to use heat-killed C. 
rodentium in future to see if these effects are synonymous.  Therefore, the macrophage 
phenotype observed here suggested a central role for this cytokine.  Of interest would be the 
role of GM-CSF on the generation of ROS.  ROS are required for the anti-microbial activity of 
macrophages, and may support clearance appropriate C. rodentium clearance in the presence 
of ILCs.  Furthermore, ROS is involved in the activation of the inflammasome, raising the 
possibility that GM-CSF-primed macrophages secrete mature IL-1β through a ROS-dependent 
mechanism [342]. 
GM-CSF depletion in DSS-induced colitis phenocopied certain features of pan-ILC depletion, 
including improved disease progression, reduced neutrophil recruitment, and impaired 
macrophage cytokine production.  However, these effects were not as striking as pan-ILC 
depletion.  This may be expected given the pleiotropic roles played by several ILC subsets in 
the GI tract.  GM-CSF may cooperate with ILC3-derived IL-17A or ILC1-derived IFNγ, both of 
which are known to promote macrophage anti-microbial activity and cytokine production in vivo 
[585], [597].  Alternatively, the GM-CSF dosing strategy used here may not be optimal.  Two 
doses of 0.125 mg anti-GM-CSF IgG as used here was employed by Powrie and colleagues 
in murine models of anti-CD40 colitis [297].  However, studies investigating the role of GM-
CSF in DSS-induced colitis and C. rodentium infection used a double concentration [416].  The 
higher dosing strategy remains to be repeated, and should help resolve whether GM-CSF-
independent mechanisms contribute to ILC-mediated intestinal inflammation and macrophage 
activation. 
It is noteworthy that monocyte recruitment was completely unaffected by GM-CSF depletion, 
and supports an GM-CSF-independent role for ILCs in the recruitment of these cells to 
inflamed tissues.  As well as chemokine production, ILCs could function indirectly via other 
local haematopoietic or non-haematopoietic cells.  For example, IL-22 signalling in epithelial 
cells can drive the production on inflammatory mediators, such as IL-18 [583].  It is possible 
that epithelial activation may also drive the production of chemokines, such as CCL2, that 
contribute to immune cell recruitment.   
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6.11.3. GM-CSF regulates macrophages metabolism and inflammatory cytokine 
production 
Several studies have highlighted a role for GM-CSF in the priming of monocyte inflammatory 
responses in vivo, and the activation of BMDMs in vitro.  GM-CSF drives a switch to glycolysis 
and the expression of GTPases that support inflammatory cytokine production [410], [411].  
The latter mechanism is not sufficient to explain differences in pro-IL-1β expression in vivo, 
however.  It is possible that GM-CSF drives transcriptional expression of IL-1β, as well as 
promoting its cleavage.  In support of this, we also observed a striking induction of LPS-induced 
IL-23 expression by BMDMs in vitro following GM-CSF priming.  As its production is 
fundamentally different to IL-1β, this cannot be explained by differences in assembly of the 
inflammasome.  This is in agreement with a study by O’Neill and colleagues demonstrating 
that macrophage IL-1β production upon LPS challenge was dependent on a glycolytic switch 
and the succinate-mediated stabilisation of the TF HIF-1α [343].  Indeed, GSEA of human 
MDMs stimulated with GM-CSF demonstrated enrichment of the glycolysis pathway, with 
increased expression of several key glycolysis genes, including LDHA, HK2, and the glucose 
transporter GLUT1 (SLC2A1).  Analysis of these genes in macrophages from ILC-depleted 
mice or anti-GM-CSF IgG-treated mice would help to decipher the contribution of this pathway 
to macrophage fitness in vivo.  However, previous studies have demonstrated that in vitro GM-
CSF-driven IL-1β production is HIF-1α-independent [411].  Furthermore, why the induction of 
chemokine expression was less pronounced is unclear, but this may reflect a diminished 
requirement for metabolic reprogramming for these cytokines, similar to TNF.  Therefore, the 
complete mechanistic underpinning of GM-CSF-driven inflammatory responses are not clear. 
Medzhitov and colleagues recently demonstrated that regulation of macrophage fitness, 
metabolism and cytokine production is mediated by intrinsic IL-10 signalling [425].  In the 
absence of this signalling, macrophages accumulate damaged mitochondrial through the 
suppression of mitophagy, resulting in elevated inflammatory responses driven by IL-1β.  The 
similarities with the observed phenotype presented here have led us to speculate that GM-
CSF may play a role in regulating mitochondrial fitness.  One might postulate that GM-CSF 
promotes a switch to glycolysis and the accumulation of mitochondria, resulting in an elevated 
capacity for cytokine production.  In line with this, we demonstrated increased mitochondrial 
mass in GM-CSF-primed macrophages.   
The mechanism for this accumulation, however, is not clear.  It may be that GM-CSF regulates 
the clearance of mitochondria through a similar suppression of mitophagy.  The use of a 
membrane potential-sensitive mitochondrial dye would help to determine whether this is the 
case.  Alternatively, GM-CSF may regulate the fusion and fission of mitochondria.  
Furthermore, we hypothesised that GM-CSF may regulate the production of ROS that 
contribute to bacterial killing in models of C. rodentium infection.  ROS is also implicated in the 
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regulation of the inflammasome, promoting mature IL-1β secretion, as observed by Medzhitov 
and colleagues [342], [425].  Therefore, GM-CSF-induced ROS production could have a 
central dual role in microbial killing and inflammatory cytokine production. 
6.11.4. IL-1β-mediated cross-talk between macrophages and ILCs 
Whether or not the above in vitro observations can be recapitulated by co-culture of ILC3s and 
macrophages remains an ongoing area of investigation.  Notably, GM-CSF is expressed by 
several ILC subsets, including ILC2s and ILC3s.  Therefore, pan-ILC depletion using anti-
CD90.2 IgG antibodies is likely to prevent designation of phenotype to particular cell types.  
However, we demonstrated that IL-1R1 and IL-23R expression is largely confined to ILC3s.  
Furthermore, culture of ILC3s with IL-1β significantly induced GM-CSF production, 
demonstrating that not only can GM-CSF priming promote IL-1β production, but that IL-1β is 
essential for ILC3-driven GM-CSF production.  Intriguingly, IL-22 production could be induced 
by both IL-1β and IL-23, both of which are regulated by GM-CSF.  This raises the possibility 
that GM-CSF activation of macrophages has secondary effects of the epithelial barrier via the 
induction of both IL-23 and IL-1β by macrophages following antigen encounter.  To this end, 
the investigation of IL-22 mediated mechanisms, such as anti-microbial peptide production, 
epithelial cell turnover and STAT3 signalling in epithelial cells, in the absence of ILC3-derived 
GM-CSF would be of interest.  Therefore, ILC3-macrophage cross-talk is essential for the 
functionality of both cell types, and drives a positive feedback loop with potential secondary 
effects on surrounding cells.   
In vivo studies investigating the IL-1β dependence on GM-CSF are lacking, but these results 
suggest that IL-1β blockade should suppress its own production in these circumstances via a 
block on GM-CSF secretion.  This could be investigated in vitro through ILC3-macrophage co-
cultures in the presence of blocking anti-IL-1R1 IgG and anti-GM-CSF IgG antibodies. 
Finally, a consistent feature of DSS-induced colitis and C. rodentium infection in the absence 
of ILCs is the reduction in local macrophage numbers.  We have already speculated that this 
may be due to an impairment in monocyte maturation and survival of cells within the LP.  
However, it is also possible that ILC-derived chemokines are required for the maintenance of 
these cells within tissues.  Strikingly, we observed significant expression of Cx3cl1, the 
chemokine that binds to CX3CR1.  As such, ILCs-derived CX3CL1 may contribute to the 
maintenance of CX3CR1+ MNPs within the colon.  How chemokine production by ILCs is 
regulated is largely unknown, but this may also participate in the ILC-macrophage cross-talk: 
ILCs promote the maintenance and activation of macrophages within the LP, which in turn 
reinforce GM-CSF and chemokine production by ILCs via IL-1β for their own survival. 
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6.11.5. Summary 
In conclusion, we have demonstrated that ILC depletion significantly alters the activation state 
of intestinal macrophages in separate models of colitis (Fig. 6.23).  This results in detrimental 
bacterial outgrowth in a model of C. rodentium infection but protection from overwhelming 
inflammation in DSS-induced colitis.  These effects are in part mediated by the absence of 
GM-CSF, which primes macrophages for glycolysis and inflammatory cytokine production in 
response to microbial stimulation.  ILC-macrophage cross-talk underlies these observations, 
as GM-CSF promotes macrophage IL-1β and IL-23 production, while these cytokines are 
essential for ILC3-derived GM-CSF and IL-22 secretion in vitro, respectively.  Furthermore, 
ILC3s may potentially promote macrophage maintenance within the LP via secretion of 
chemokines, including CCL3, CXCL10, and CX3CL1.  A significant number of additional 
experiments will be required to clarify the cellular mechanisms at play here, as will be 
discussed in the final chapter. 
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Figure 6.23.  Chapter 6 graphical summary. ILCs regulate intestinal macrophage activation, 
mediated through production of GM-CSF.  GM-CSF induces macrophage mTORC1 activation 
and glycolysis, resulting in enhanced cytokine production.  GM-CSF may potentially contribute 
to cytokine production through the suppression of autophagy and the subsequent 
accumulation of pro-IL-1β and mitochondria.  GM-CSF-induced cytokines support ILC3 
activation via ILC-macrophage cross-talk, with subsequent implications for the activation of the 
intestinal epithelium via production of IL-22.  Whether ILC3s contribute directly to the 
recruitment of monocytes to the inflamed mucosa is not clear, but is supported by observations 
that ILC3s express high levels of the chemokines CCL3, CXCL10, and CX3CL1, all associated 

































7. Conclusion and future directions 
7.1. IgG and FcγR signalling in intestinal inflammation 
Despite the observation that mucosal anti-commensal and auto-antibodies are frequently 
identified in patients with IBD [241], [429], [430], there has been little widespread acceptance 
that IgG ICs might play a pathogenic role in UC.  The dogma that mucosal humoral immunity 
is purely dominated by IgA, however, is changing, with the observation that homeostatic anti-
commensal IgG generation has important implications for intestinal immune development, 
vertically-transmissible immunity to neonates, and defence against infection [284], [477], [479].  
The association of the FcγRIIA-R/H131 variant (rs1801274) as the most significant non-HLA 
genetic variant with UC in a Japanese GWA study [156] supports a pathogenic role for IgG in 
this disease, driven by engagement of FcγRs.  FcγRIIA-R131 profoundly reduces affinity for 
IgG and confers protection against UC, a finding confirmed in a subsequent meta-analysis of 
IBD GWA studies [154].   
Attempts to mechanistically link intestinal IgG and FcγR function have focused on in vitro 
stimulation assays that interrogate the generic production of pro-inflammatory cytokines [430], 
with limited effort to ensure relevance to in vivo findings in UC.  Our results highlighted a strong 
association between FcγRIIA and IL-1β in UC colonic biopsies, which was subsequently borne 
out by in vitro stimulations with IgG IC.  Furthermore, global and macrophage FcγR A/I ratios 
were significantly skewed towards activation during inflammation, lowering the cellular 
activation threshold and allowing macrophages to be more readily activated by IgG IC.  Most 
importantly, in vivo manipulation of macrophage A/I ratios was sufficient to dictate the severity 
of IL-1β-driven intestinal inflammation via the activation of mucosal Th17 immune responses.  
Blocking this pathway proved beneficial in Fcgr2b-deficient mice, and adds to the growing 
literature into the role of IL-1β in mediating detrimental intestinal inflammation [279], [296].  
Therefore, our data implicate anti-commensal IgG and FcγR signalling as a previously 
unappreciated driver of this pathway in vivo.  
Our data have therapeutic implications, identifying antibody and activating FcγR receptor 
signalling as potential therapeutic targets in UC.  Previously, we discussed the limited number 
of studies targeting IgG and B cell responses in IBD, with reports of clinical improvement 
following IVIG [437]–[439] and acute responses to rituximab administration [440].  
Furthermore, small molecule SYK inhibitors used to block FcγR signalling have demonstrated 
significant benefit in the treatment of autoimmune diseases, such as RA [226].  However, such 
broad approaches have significant off-target effects, and more targeted therapeutics are 
required.  Here, we have demonstrated that manipulation of FcγRIIB expression on 
macrophages is sufficient to modulate disease severity in colitis.  Therapeutic strategies 
targeting FcγRIIB function have been suggested, and is indeed one of the major modes of 
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action of IVIG [227].  As well as its role in the suppression of activating FcγR signalling, an 
FcγRIIB agonist could influence B cell activation and drives plasma cell apoptosis, regulating 
both the generation and effector functions of anti-commensal IgG [106], [107].  It is possible 
that these therapies could supplement novel drugs targeting Th17 immunity, including IL-23 
and IL-1β blockade, to improve clinical remission rates.  Recently, modification of the IgG 
glycome has been attempted to drive pro-inflammatory IgG to an anti-inflammatory state.  IgG 
sialylation is essential for the function of IVIG [137], and enforced sialylation converts 
arthritogenic IgG into inhibitors of CIA [223].  Whether this is possible in vivo for the 
manipulation of human disease is not known, but opens the way for a personalised approach 
to redirect host detrimental mechanisms to a beneficial endpoint. 
We observed significant variability in the IgG anti-commensal response in UC patients, which 
correlated with disease activity.  As we enter the era of personalised medicine, it may be that 
UC patients could be stratified by FcγRIIA genotype and anti-commensal IgG response to tailor 
FcγR-centric therapeutic strategies in a targeted manner.  Due to CNV, FCGR genes are often 
excluded from GWA studies, and little literature exists as to how other FcγR SNPs may 
contribute to IBD susceptibility.  For example, the high-affinity FcγRIIIA-V158 variant is 
associated with susceptibility to RA and ITP [165]–[167] and may contribute to IBD 
susceptibility in a manner analogous to FcγRIIA-H131.  Alternatively, FcγRIIB dysfunction 
arising from the T232 polymorphism could similarly promote chronic IgG-driven intestinal 
inflammation [145], [161], as we demonstrated in Fcgr2b-deficient mice.  Indeed, it is possible 
that IBD susceptibility in FcγRIIB-T232 homozygous individuals would be driven by 
exacerbated myeloid responses to IgG, as well as elevated anti-commensal IgG responses as 
a result of B cell dysregulation and plasma cell survival.  Other than IBD susceptibility, IgG 
responses may contribute significantly to prognosis: exacerbated IgG responses may well 
arise secondarily to the onset of inflammation in IBD, but subsequently drive a therapeutically 
refractive state through the perpetuation of inflammation.  In this case, how FcγR variants 
contribute to IBD prognosis would be of great interest.  Our results here suggest that following 
the onset of inflammation, perhaps through barrier defects in UC, IL-1β-driven inflammation 
could be enhanced by local IgG.  Subsequently, inflammatory alterations in the IgG glycome, 
such as desialylation, could be driven by IL-1β-mediated Th17 responses [178], resulting in 
the positive reinforcement of inflammatory networks. 
While also associated with anti-commensal IgG, the association of FcγR variants with CD 
susceptibility is much less robust that that observed in UC [154], [263]. CD susceptibility is 
centred on defects in pathogen recognition and clearance, with notable genetic associations 
with NOD2 and ATG16L1 [234], [247]–[250].  Reduced NOD2 function, an intracellular 
receptor for peptidoglycan, results in bacterial outgrowth, dysbiosis, and the loss of host-
commensal mutualism [252], [253].  Mutations in ATG16L1, an autophagy gene, promote its 
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degradation and reduce autophagy, resulting in ER stress, epithelial dysfunction, and aberrant 
cytokine production [249], [254]–[258].  It is notable, therefore, that FcγRs are required for 
mucosal bacterial clearance in mice and humans [78], [283], [523] and FcγRIIA-R/R131 
homozygosity is associated with invasive pneumococcal disease [627].  Therefore, defective 
activating FcγR signalling may contribute to defective invasive microbial clearance in patients 
with CD. 
Secondary considerations regarding this differential association arise from the inflammatory 
networks contributing to CD and UC pathogenesis [318].  IFNγ is associated with CD [319], 
[320], but FcγR-TLR co-stimulation of M1 macrophages does not have a significant effect on 
the augmentation of inflammatory responses [74], [75].  In contrast, IL-4-primed human 
macrophages respond potently to FcγR-TLR co-stimulation by the production of Th17-inducing 
cytokines, including IL-1β.  IL-4 is associated with UC pathogenesis, and may contribute to the 
robust association with FcγRIIA. 
In summary, our study reveals the mechanisms by which anti-commensal IgG, acting via 
activating FcγRs cross-linking on intestinal macrophages, augments inflammation by inducing 
Th17 immunity via IL-1β.  This sheds light on the observed genetic association of FcγRIIA 
polymorphisms with UC and identifies novel therapeutic targets. 
7.2. The function of FcγRs on ILC3s 
ILCs are a newly identified group of lymphocytes that are specialised for the rapid production 
of T cell-associated cytokines prior to the induction of adaptive immunity [12].  These cells are 
enriched at mucosal sites, with a growing body of literature demonstrating that ILC3s have 
important roles in regulating epithelial cell function via the production of IL-22, and the 
coordination of local immune responses through GM-CSF and IL-17A secretion [285], [297], 
[396], [544], [575], [577], [583], [585].  Given the rapid kinetics of ILC activation, studies have 
largely focused on the role of PRR-induced cytokines derived from macrophages, DCs, and 
epithelial cells in the activation of these cells.  However, cross-talk with adaptive immunity is 
important in certain circumstances, with ILC-mediated antigen presentation demonstrated to 
suppress T cell activation within GALT and induce T cell responses in the spleen and lung 
[543], [554], [587], [589].  Furthermore, ILC3s have also been implicated in the activation of B 
cell responses via production of BAFF and expression of CD40L within the spleen [51]. 
The results presented in chapter 5 demonstrate that ILC3s and ILC1s are also capable of 
responding to IgG via their expression of FcγRIII, the canonical low affinity activating FcγR in 
mice.  This presents a novel paradigm for ILC function, demonstrating that ILCs can integrate 
signals from adaptive immunity to regulate their activation state.  The investigation of FcγR 
function on the closely related NK cell has had widespread implications for our understanding 
of anti-tumour and anti-viral immunity.  FcγRIII cross-linking induces ADCC and IFNγ secretion 
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that contribute to target cell death and a potent anti-viral response [102], [104], [105].  Whether 
the investigation of FcγR signalling in helper ILCs will result in similar advances remains to be 
seen.  We have demonstrated here that FcγR signalling on ILC3s induces the expression of 
several transcriptional regulators and chemokine receptors that promote ILC3 phenotype and 
function, e.g. AHR.  Furthermore, we observed an increase in MHC-II expression.  However, 
whether FcγR signalling has similar roles on ILC1s remains to be deduced.  Given their 
similarity to NK cells, FcγRIII cross-linking on ILC1s may well induce IFNγ secretion, with 
implications for disorders in which ILC1s accumulate, such as colitis [597].  In future, it would 
be of interest to flow-sort intestinal ILC1s, ILC3s and NK cells from uninflamed and DSS-
inflamed mice and perform transcriptomics analysis.  This would give us a widespread 
understanding of inter-ILC variation in cellular responses to FcγR cross-linking and also how 
inflammation alters this response.  This may be of particular importance given the upregulation 
of FcγRIIB during colitis.   
Whether human helper ILC subsets express FcγRs is not clear.  Several studies have 
suggested that FcγRIII expression in humans is confined to NK cells, and is absent from ILC 
subsets [597], [628].  However, a widespread characterisation of FcγR genes across ILC 
subsets is lacking, while this repertoire may potentially change during inflammatory conditions.  
We are currently in the process of flow-sorting human ILC3s to profile FcγR expression 
ourselves by qPCR. 
At present, the functional consequences of ILC3-intrinsic FcγR signalling in vivo are still to be 
characterised in great detail.  A recent study demonstrated that maternal IgG was required for 
the appropriate development of ILC3s within the neonatal GI tract [479].  The reason for this 
requirement was not clear.  We would hypothesise that ILC3-intrinsic FcγR signalling mediated 
by maternal IgG may induce a transcriptional programme in this cells that promotes their 
survival locally, mediated by induction of key ILC3-associated TFs and chemokine and 
cytokine receptors.  As such, IgG is not only relevant during chronic inflammatory conditions, 
but also in early life prior to the development of a fully-fledged intestinal humoral response.  In 
future, we hope to resolve whether FcγR signalling on ILC3s can indeed support ILC3 function 
in vivo in colitis models and during development.  To this end, we are currently in the process 
of generating RORγt-Cre FcγRIIB-floxed mice.  It may be hypothesised that FcγRIIB 
suppresses the pro-ILC3 phenotype induced by activating FcγR signalling, promoting the 
transition to the inflammatory ILC1 subset.  If this were the case, these mice may display 
elevated numbers of ILC3s during colitis and improved clinical disease via IL-22-dependent 
barrier reinforcement and the attenuation of IFNγ-dominated responses. 
Furthermore, we hope to determine how AHR-mediated mechanisms may promote IC-induced 
IL-22.  For example, do FcγRIIB-deficient ILC3s express higher levels of AHR and AHR-target 
genes associated with their elevated production of IL-22?  These studies are currently 
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underway, and we hope will help to discern the functional importance of ILC3 FcγR signalling 
in vivo.  
7.3. ILC-macrophage crosstalk mediates intestinal immune defence 
In the final chapter of this thesis, we have attempted to elucidate the mechanisms by which 
ILC3s may regulate other tissue-resident immune cells in two separate models of intestinal 
inflammation.  We have demonstrated that in the absence of ILCs, via a CD90.2 depletion 
strategy, mice are susceptible to C. rodentium infection, with greater CFUs at day 7 post-
infection, but significantly protected from detrimental inflammation in an acute model of DSS-
induced inflammation. 
Mechanistically, we have focused on the role of GM-CSF in the coordination of macrophages, 
as in the absence of ILCs, these cells exhibit an unresponsive phenotype, with reduced 
cytokine production and total numbers, correlating with the absence of this cytokine in vivo.  
GM-CSF has previously been shown to mediate accumulation of monocytes and granulocytes 
within the inflamed colon and regulate DC maintenance [297], [414]–[416], [506].  However, 
the mechanistic underpinning of these observations was not addressed.  GM-CSF is known to 
promote an M1-like phenotype in macrophages in vitro, with enhanced glycolysis and boosted 
IL-1β production [72], [410], [411].  However, we suspect that these mechanistic insights do 
not entirely account for the mechanism of GM-CSF function.  A recent study demonstrated that 
IL-10 suppresses macrophage function by the suppression of MTORC1, resulting in an 
increase in autophagy, mitochondrial clearance, and a reduction in IL-1β expression [425].  
The GM-CSF-mediated glycolytic switch was also dependent on MTORC1.  Therefore, we 
hypothesise that ILC3-derived GM-CSF induces the activation of MTORC1 and the 
subsequent suppression of autophagy.  Not only would this support a higher mitochondrial 
capacity, but also inhibit the clearance of pro-IL-1β, which has been shown to be regulated by 
autophagy [629].  Therefore, the observed reduction in pro-IL-1β expression by ILC-depleted 
macrophages in vivo could be due to a reduction in Il1b expression and an increase in 
engulfment of pro-IL-1β.  Furthermore, the observed increase in CFUs in vivo in the absence 
of ILCs could result from impaired anti-microbial capacity by macrophages, with defective ROS 
production.  As ROS production can also mediate inflammasome activation, we hypothesise 
that GM-CSF priming may induce ROS to induce bacterial killing and pro-IL-1β cleavage. 
In future, we hope to carry out mechanistic studies in vitro into the role of GM-CSF on 
macrophage function.  Specifically, does GM-CSF induce MTORC1 activation, the 
suppression of autophagy, and the accumulation of mitochondria and pro-IL-1β transcripts?  
Furthermore, can GM-CSF promote ROS production that could both contribute to bacterial 
killing and induce activation of the inflammasome?  These studies would help to further our 
understanding of the mechanistic roles played by GM-CSF in the immune response other than 
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in haematopoiesis.  In addition, we hope to carry out co-cultures between ILC3s and 
macrophages to determine whether a GM-CSF-IL-1β cross-talk circuit can promote similar 
observations in the absence of exogenous cytokines.  This would be the first demonstration, 
as far as we are aware, that ILC3s can directly regulate the metabolic state and inflammasome 
activation of macrophages.  Finally, we would like to translate these observations to our models 
of intestinal inflammation.  We have already demonstrated that GM-CSF depletion suppresses 
IL-1β expression by macrophages in vivo, but is this related to a wider phenotype of 
macrophage dysfunction and does this have implication for defence against C. rodentium 
infection?  Furthermore, we previously hypothesised that IL-22 may be diminished by GM-CSF 
blockade as a result of decreased IL-1β and IL-23 responses by macrophages in vivo.  Could 
IL-22-mediated mechanisms, particularly on the epithelial barrier, be similarly defective in the 
absence of GM-CSF that contribute to defective bacterial clearance?  These outstanding 
experiments are currently in progress, and will hopefully shed some light on the complex ILC-
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